Forest Laboratories, Inc.
909 Third Avenue
New York, New York 10022

STUDY Report for
Protocol No. CIT-MD-18

Title: A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Citalopram in Children and Adolescents with Depression

Abbreviated Title: *Citalopram Pediatric Depression*

Name of Study Drug: Citalopram
Indication: *Major Depressive Disorder*
Study Phase: III
Initiation Date: 31 Jan 2000
Completion Date: 10 Apr 2001

The study was carried out in compliance with the International Conference on Harmonization (ICH)-E6 Good Clinical Practice Guideline.

Report Date: April 8, 2002

1.0 ETHICAL CONSIDERATIONS

1.1 INSTITUTIONAL REVIEW BOARD (IRB)

The study protocol, the informed consent form, and information sheet advertisements were approved by Institutional Review Boards (IRBs) at each study center in conformance with 21 Code of Federal Regulations (CFR), Part 56.

A list of IRBs for this study is provided in Appendix I.3

1.2 ETHICAL CONDUCT OF THE STUDY

The study was conducted in full compliance with Food and Drug Administration (FDA) guidelines for Good Clinical Practices (GCP) and in accordance with the ethical principles that have their origins in the Declaration of Helsinki and 21 CFR, Part 56.

1.3 PATIENT INFORMATION AND CONSENT

Patients and their parent or guardian, after having the study explained to them, gave voluntary assent before participating in any study-related procedures. Each parent or guardian was provided with a written informed consent statement that complied with 21 CFR, Parts 50 and 312. Each parent or guardian read, assented understanding, and signed an instrument of informed consent having had an opportunity to discuss it with the clinical investigator before signing, and was made aware that the patient could withdraw from the study at any time.

2.0 INVESTIGATORS

This study was performed at 21 study centers located in the United States. At each center, the Principal Investigator was responsible for ensuring that the investigation was conducted according to the signed Investigator Agreement, the protocol, and Good Clinical Practice guidelines.

A list of investigators, including their affiliations and curricula vitae, are included in Appendix II. Full financial disclosure was obtained from all investigators and subinvestigators.

3.0 INTRODUCTION

Citalopram is a highly selective serotonin reuptake inhibitor that has minimal or no effect upon the reuptake of other biogenic amines such as norepinephrine and dopamine[1]. Furthermore, citalopram has little effect on cholinergic and histaminergic receptors, and as a result, anticholinergic and anti-histaminergic side effects are far less common with citalopram than with tricyclic antidepressants[1].

Human pharmacological studies indicate that citalopram has a bioavailability of approximately 80% and is eliminated with a half-life of 35 hours, consistent with a once daily dosing regimen. With repeated daily administration, citalopram plasma levels achieve steady-state in one week and show a linear relationship to the dose administered. Citalopram pharmacokinetics are not influenced by food intake.

The safety and efficacy of citalopram in adults has been established in clinical trials including over 20,000 citalopram-treated patients. Citalopram is approved for the treatment of depression in more than 70 countries, and has been prescribed for more than 35 million patients in clinical practice.

The antidepressant efficacy of citalopram in adults has been clearly demonstrated in placebo-controlled double-blind trials. The consistent antidepressant effect of citalopram in placebo-controlled studies was also seen in subpopulation analyses of patients categorized by race, gender, age, and depression characteristics at baseline. In addition, two 6-month, placebo-controlled continuation studies have shown citalopram to be significantly more effective than placebo in the prevention of depression relapse.

Our knowledge about depression in children and adolescents has increased considerably during the past 20 years, and it has now been demonstrated that depression in childhood occurs with the same characteristics as in adults[2, 3]. During puberty, the frequency of depression increases markedly[4]. Furthermore, the ratio between the sexes with respect to the incidence of depression is similar in the pediatric population to the ratio observed in adults[5]. Increasing numbers of children and adolescents with depression have been observed both in family studies and in epidemiological studies[6, 7]. In addition, the cumulative risk of experiencing depression by a given age has increased successively in younger cohorts[8, 9].

Numerous tricyclic antidepressants, including amitriptyline[10], imipramine[11], desipramine[12] and nortriptyline[13] have been studied in double-blind trials of depressed patients under 21 years of age, and none have been found to produce significantly greater improvement than placebo. In contrast to these trials, a placebo-controlled study of the selective serotonin uptake inhibitor (SSRI) fluoxetine in the treatment of pediatric depression[14] demonstrated a significantly greater improvement in fluoxetine-treated patients compared with placebo-treated patients. More recently, similar results were obtained with paroxetine in a randomized controlled trial in adolescent depression [15].

The present study was designed to evaluate the safety and efficacy of citalopram in child and adolescent outpatients diagnosed with major depressive disorder (MDD).

4.0 STUDY OBJECTIVES

The objective of this study was to evaluate the safety and efficacy of citalopram (20-40 mg/day) compared with placebo in children (7-11 years) and adolescent (12-17 years) outpatients with MDD.

5.0 INVESTIGATIONAL PLAN

5.1 STUDY DESIGN AND RATIONALE

Given the established efficacy and tolerability of citalopram in the treatment of adult depressed patients, citalopram is likely to be used in the treatment of depressed patients under 18 years of age. It is therefore important that the safety and efficacy of citalopram be systematically evaluated in this population. The current study was conducted to assess the safety and efficacy of citalopram in the treatment of pediatric depression.

The clinical trial was conducted as a randomized, double-blind, placebo-controlled, multicenter, parallel-group, 2-arm, flexible dose study comparing citalopram (20-40 mg/day) with placebo in pediatric outpatients diagnosed with MDD (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV] criteria). The study population was to be equally stratified between children (ages 7 to 11) and adolescents (ages 12 to 17). A total of 160 patients were to be randomized in a 1:1 ratio to double-blind treatment. The study consisted of a 1-week, single-blind placebo lead-in period followed by an 8-week double-blind treatment period, for a total study duration of 9 weeks.

The study involved a total of seven clinic visits: screening, baseline, and at the end of weeks 1, 2, 4, 6 and 8 of double-blind treatment. The diagnosis of MDD was based on the Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime (K-SADS-PL) administered at screening. The primary efficacy evaluation (Children's Depression Rating Scale-Revised) was conducted at each clinic visit. Patients who completed the study were eligible to participate in a separate 24-week open-label extension study.

Detailed descriptions of each study visit and the schedule of evaluations can be found in Section 5.5. The protocol for this study is provided in Appendix I.1, and a sample case report form (CRF) is provided in Appendix I.2.

5.2 SELECTION OF STUDY POPULATION

5.2.1 Inclusion Criteria

To be included in the study, patients had to satisfy all of the following criteria:

1. Male or female outpatient between 7 and 17 years of age;

2. The patient must have met DSM-IV diagnostic criteria for MDD. The duration of the current major depressive episode must have been at least 4 weeks at the baseline visit;

3. Patient must have had a Children's Depression Rating Scale-Revised (CDRS-R) score of 40 or greater at both the screening and baseline visits;

4. Physical examination, laboratory tests and electrocardiogram (ECG) results must have been normal at screening, or if abnormal, must have been deemed clinically insignificant by the investigator and documented in the CRF as such;

5. Female patients of childbearing potential must have had negative serum human chorionic gonadotropin (β–HCG) test results at screening;

6. Prior to the conduct of any study-specific procedures, the patient must have provided assent to participate and the parent or legal guardian must have provided written informed consent;

7. Patients must have been able to speak, read, and understand English sufficiently to understand the nature of the study and to allow completion of all study assessments;

8. A parent or caregiver capable of providing information about the patient's condition must have agreed to accompany the patient to all clinic visits.

5.2.2 Exclusion Criteria

Patients who met any of the following criteria were disqualified from participation in the study:

1. Patients with any primary psychiatric diagnosis other than MDD;

2. Patients who met DSM-IV criteria for attention deficit-hyperactivity disorder, posttraumatic stress disorder, bipolar disorder, pervasive developmental disorder, mental retardation, conduct disorder, or oppositional defiant disorder;

3. Patients with any psychotic features;

4. Patients with any personality disorder of sufficient severity to interfere with participation in the study;

5. A history of substance abuse, including alcohol, within the past year;

6. Patients who tested positive for alcohol or any other prohibited medication on the urine drug screen collected at the screening visit;

7. A history of anorexia nervosa or bulimia within the past year;

8. Females who were pregnant or breast feeding;

9. Females of childbearing potential who were not practicing, or not willing to practice, a reliable method of birth control;

10. Patients with a medical condition that might have interfered with the conduct of the study, confounded interpretation of the study results, or endangered the patient's well-being. Patients with evidence or history of malignancy (other than excised basal cell carcinoma) or any significant hematological, endocrine, cardiovascular (including any rhythm disorder), neurological, respiratory, renal, hepatic, or gastrointestinal disease. (If there was a history of such disease, but the condition had been stable for more than 1 year and was judged by the investigator not to interfere with the patient's participation in the study, the patient may have been included, with the documented approval of the Medical Monitor);

11. Patients with a history of seizure;

12. Patients who had been treated with any antidepressant or anxiolytic medication within 2 weeks of the baseline visit (4 weeks for fluoxetine);

13. Patients who had been treated with any neuroleptic or stimulant (e.g., methylphenidate) within 6 months prior to the screening visit;

14. Patients who required concomitant treatment with any psychotropic drug (except zolpidem for sleep), or any drug with a psychotropic component;

15. Patients who required concomitant treatment with any prescription or over-the-counter medications that were prohibited by the protocol (see Appendix I.1);

16. Patients who had been in a previous investigational study of citalopram;

17. Patients who had received treatment with any investigational drug within 30 days or 5 half lives (whichever was longer), prior to study entry;

18. Patients with a history of hypersensitivity reaction to citalopram or other SSRIs;

19. Patients who had previously failed to respond to an adequate trial of citalopram or to adequate trials of two other SSRIs;

20. Patients who had initiated psychotherapy or behavior therapy within 3 months prior to the screening visit, or who planned to inititate or change such therapies during the course of the study;

21. Patients who were unable to swallow tablets;

22. Patients who were considered a suicide risk (active suicidal ideations), who had made a serious suicide attempt within the past year, or who had ever been hospitalized because of a suicide attempt;

23. Patients who, in the investigator's opinion, might not have been suitable for the study.

5.3 TREATMENTS

5.3.1 Identity of Investigational Products

Citalopram (20 mg) and placebo medication were supplied by Forest Laboratories, Inc. as film-coated, white tablets of identical appearance. For the single-blind lead-in period, patients were to be supplied with placebo tablets only. For the double-blind treatment period, identically appearing tablets contained either 20 mg of citalopram or placebo. Medication was supplied in bottles containing either 10 tablets or 40 tablets.

All study medication bottles were labeled with the protocol number, visit number, instructions to take tablets as directed, and storage and warning information. Additionally, bottles of double-blind medication were labeled with a patient number.

Prior to dispensing the medication, the investigator wrote the patient's initials, the center number, and the date on the label. Study medication was kept in an appropriate, secure area. All drug supplies were stored at controlled room temperature, 59 F – 86 F (15 C - 30 C), and protected from heat and moisture.

The lot numbers of the citalopram and placebo tablets used in this trial are shown in Panel 1.

Panel 1. Study Drug Lot Numbers

Study Medication	Lot No.
Citalopram 20 mg	P01102 P01165 P02161
Placebo	P01164

5.3.2 Method of Assigning Patients to Treatment Groups

Each study site was provided with double-blind drug supplies corresponding to two different sequences of patient numbers. Patients between 7 and 11 years of age were sequentially assigned numbers between 101 and 299. Patients between 12 and 17 years of age were sequentially assigned numbers between 501 and 699. The randomized study population was to be equally stratified between children (ages 7 to 11) and adolescents (ages 12 to 17).

Appendix IV provides the randomization scheme and codes.

5.3.3 Dosing Regimen

The dosing regimen is presented in Panel 2. Patients who met all of the eligibility criteria at screening were dispensed one bottle containing 10 placebo tablets prior to departing from the clinic. Patients were instructed to take one tablet each evening until they returned 1 week later for the baseline visit.

Patients who met all of the eligibility criteria at the end of the single-blind lead-in period (baseline visit) were assigned a randomization number and dispensed the corresponding bottle containing 10 tablets of study medication for week 1 of double-blind treatment. Patients were instructed to take one tablet each evening, beginning on the day that the study medication was dispensed. Dosing could be switched to the morning if preferred. In accordance with their assigned treatment, patients received either one placebo tablet or one tablet of 20 mg citalopram daily through the end of Week 4.

At the end of the Week 4 and Week 6 visits, patients were dispensed one bottle containing 40 tablets of either placebo or active (20 mg citalopram) medication. Patients who exhibited a satisfactory therapeutic response by the end of Week 4 visit were instructed to continue taking one tablet of medication daily. However, if at the end of Week 4 visit (or any time thereafter), the clinician determined that the therapeutic response was not satisfactory and the patient was not experiencing dose-limiting AEs, the dose could be increased and the patient instructed to take two tablets daily (placebo or 40 mg citalopram). All study medication still was to be taken as a single daily dose.

The dose of medication could have been decreased at any time because of AEs. However, the daily dose for this study was never to be less than one tablet or greater than two tablets.

Panel 2. Dosing Regimen

		Citalopram		***Placebo***	
Study Week	*Blinding*	*Minimum Dose*	*Maximum Dose*	*Minimum Dose*	*Maximum Dose*
Screening	single-blind	1 placebo tablet	1 placebo tablet	1 placebo tablet	1 placebo tablet
Week 1-4	double-blind	1 citalopram 20 mg tablet	1 citalopram 20 mg tablet	1 placebo tablet	1 placebo tablet
Week 5-8	double-blind	1 citalopram 20 mg tablet	2 citalopram 20 mg tablets	1 placebo tablet	2 placebo tablets

5.3.4 Blinding

A list of patient randomization numbers and the corresponding assigned treatment was generated by Forest Laboratories, Department of Biostatistics, and retained in electronic format. A hard copy was retained by the Department of Drug Safety Surveillance in a secure, locked area.

Double-blind medication was labeled with a tear-off panel that, once opened, revealed the treatment corresponding to the patient randomization number. The tear-off panel for the double-blind medication was placed, unopened, in the patient's CRF. In case of emergency, the tear-off panel could be opened to reveal the study medication assignment of any patient.

No double-blind treatment assignment was unblinded by this procedure before database lock. Because of a drug packaging error, the citalopram or placebo tablets initially dispensed to 9 patients at 3 study centers were distinguishable in color, although otherwise blinded (see Section 7.0). When this error was identified at the beginning of the study period, all study medication shipments were replaced in full with tablets of identical color to remove any potential for unblinding.

5.4 PRIOR AND CONCOMITANT THERAPY

A medication history, including psychotropic medication during the previous 5 years and any other medication during the previous 3 months, was to be obtained from the patient at the time of screening. In addition, any subsequent changes in these medications or their doses, or any new medications introduced during the course of the study, was to be recorded in the CRF. A history of non-drug treatments was also recorded during the screening visit. The study protocol (Appendix I.1) provides a list of drugs that were allowed and not allowed as concomitant medications. No concomitant psychotropic medication or medication with a psychotropic component was permitted during the study except zolpidem as a sleep aid, at a maximum dose of 10 mg/day, up to three times per week. In addition, the use of any neuroleptic or stimulant (e.g., methylphenidate) within 6 months prior to study entry precluded study participation. The use of any investigational drug within 30 days or 5 half-lives prior to study entry was also not allowed. The initiation of psychotherapy or behavior therapy within 3 months prior to the screening visit, or the initiation or change of such therapies during the course of the study, was not permitted. In addition, patients were instructed to abstain from alcohol during the study.

5.5 STUDY PROCEDURES

Panel 3 presents the study procedures conducted at the screening and baseline visits and throughout the double-blind treatment period. A copy of the CRF is provided in Appendix I.2.

Panel 3. Study Flow Chart of Procedures and Determinations

			Double-Blind Treatment: End of Week				
Visit Name	**Screen**	**Baseline**	**1**	**2**	**4**	**6**	**8**
Visit Number	*1*	*2*	*3*	*4*	*5*	*6*	*7*
ASSESSMENT							
Informed Consent	X						
Inclusion/Exclusion Criteria	X	X					
Medical History — Psychiatric History	X						
Physical Exam (with ECG)	X						X
Laboratory Evaluations	X						X
Analytical Sample							X
Pregnancy Test	X						
Urine Drug Screen	X						
Vital Signs	X	X	X	X	X	X	X
Diagnostic Evaluation (K-SADS-PL)	X						
Primary Efficacy Evaluation: CDRS-R	X	X	X	X	X	X	X
CGI-S		X	X	X	X	X	X
CGI-I			X	X	X	X	X
CGAS		X			X		X
K-SADS-P (depression module)		X					X
Drug Dispensed	X	X	X	X	X	X	
Concomitant Medications	X	X	X	X	X	X	X
Adverse Events		X	X	X	X	X	X
Final Evaluation*							X

* The final evaluation, including all procedures scheduled for the end of Week 8, was to be conducted at the end of Week 8 for patients who completed the study or at the time a patient discontinued from the study.

5.5.1 Screening Visit (Visit 1)

The placebo screening phase was used for evaluation of potential study patients for inclusion in the study. At the screening visit, study procedures were reviewed with the patient and guardian and documentation of informed consent was obtained. The following data were collected and procedures performed at the screening visit. See efficacy and safety measurements in Sections 5.5.6 and 5.5.7 for detailed descriptions of each parameter.

a. Psychiatric and medical history;

b. Physical examination (including ECG, height and vital signs);

c. Laboratory determinations (including β-HCG, if applicable, and urine drug screen);

d. Concomitant medications;

e. Diagnostic interview (K-SADS-PL);

f. CDRS-R;

g. Review of inclusion/exclusion criteria.

Eligible patients were dispensed single-blind placebo tablets. Results from the laboratory and ECG evaluations were reviewed during the 1-week single-blind placebo lead-in phase.

5.5.2 Baseline Visit (Visit 2)

At the baseline visit it was determined whether patients were eligible to continue into the double-blind treatment phase of the study. Baseline efficacy assessments were obtained for the CDRS-R, Clinical Global Impressions — Severity (CGI-S), Kiddie Schedule for Affective Disorders and Schizophrenia — Present (K-SADS-P) depression module, and Children's Global Assessment Scale (CGAS). Drug accountability was conducted on the returned single-blind medication. Vital signs were measured and AEs and concomitant medication use were recorded.

If patients were determined to be eligible to continue into the double-blind phase, they were assigned the next available randomization number, in ascending sequential order, and were dispensed the corresponding double-blind study medication for the first week of double-blind treatment.

5.5.3 Double-Blind Study Visits (Visits 3 to 7)

After the baseline visit at the end of the placebo lead-in, study visits were conducted after 1, 2, 4, 6, and 8 weeks of double-blind treatment. The following procedures were performed at each visit:

a. Vital signs;
b. Review of concomitant medications;
c. Review of AEs;
d. Drug accountability;
e. CDRS-R, CGI-S, and CGI-I.

Additionally, at the end of Week 4 (Visit 5) the CGAS was assessed. Patients returned previously dispensed bottles of double-blind study medication and, except at the final visit, were dispensed new bottles of double-blind study medication. The following additional assessments were made at the final visit (end of Week 8):

a. Physical examination including ECG and height;
b. Laboratory determinations;
c. Plasma sample for determination of citalopram concentrations;
d. CGAS and K-SADS-P depression module.

5.5.4 Premature Discontinuation

Any enrolled patient who ceased participation in the study, regardless of circumstances, before completion of the protocol (prior to the Week 8 visit) was considered prematurely discontinued. For each discontinued patient, the investigator identified one of the following as the primary reason for discontinuation:

a. An AE;
b. An insufficient therapeutic response;
c. A protocol violation, including lack of compliance;
d. Patient withdrawal of consent;
e. The patient was "lost to follow-up";
f. Other reasons, such as administrative reasons.

Upon discontinuation, patients were administered all assessments scheduled for the end of Week 8 visit.

5.5.5 Diagnostic Assessment

The K-SADS-PL is a semi-structured diagnostic interview that assesses the major diagnostic criteria relevant to psychiatric disorders in children and adolescents, including depression. It evaluates both past and current episodes and was used in this study to

establish that patients met DSM-IV criteria for MDD, and to rule out other psychiatric diagnoses. The full K-SADS-PL was administered at the screening visit only.

5.5.6 Efficacy Measurements

The following instruments were used to assess efficacy (see Panel 3). To ensure the sensitivity and reliability of the assessments, the same Investigator (clinician) was to assess a particular patient at each evaluation. Efficacy ratings were not to be administered if the patient was not accompanied by the identified parent or caregiver.

5.5.6.1 Primary Efficacy Measure

The primary efficacy measure in this study was the CDRS-R. The CDRS-R is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6-17 years. It contains 17 ordinally scaled items that evaluate the presence and severity of symptoms commonly associated with depression in childhood. A total CDRS-R score ≥ 40 is consistent with a diagnosis of MDD. The CDRS-R was administered at all clinic visits, including screening, and was administered separately to both the patient and the identified parent or caregiver.

5.5.6.2 Secondary Efficacy Measures

5.5.6.2.1 Clinical Global Impressions (CGI)

The CGI Severity (CGI-S) scale was administered at all visits, except the screening visit. This scale rated the severity of the patient's MDD based on the investigator's clinical opinion. The patient was rated on a scale from 1 to 7, with 1 being normal and 7 being a patient who was among the most extremely ill.

The CGI Improvement (CGI-I) scale was administered at all visits after the baseline visit. Based on the investigator's clinical opinion, this scale rated the total improvement or worsening in the patient's mental illness relative to baseline, regardless of whether the investigator considered it due to drug treatment. The patient was rated on a scale from 1 to 7 with 1 being very much improved and 7 being very much worse.

5.5.6.2.2 Kiddie Schedule for Affective Disorders and Schizophrenia-Present (depression module)

The K-SADS-P depression module, a component of the full K-SADS-PL administered at screening for diagnostic purposes, was completed at baseline and at study termination to evaluate response to treatment. Patients were rated in the following nine areas: mood/irritability/dysphoria; guilt; anhedonia; fatigue; ability to concentrate; psychomotor

agitation/retardation; sleep; appetite; and suicidal ideation. The time frame for the assessment was the previous seven days.

5.5.6.2.3 Children's Global Assessment Scale

The CGAS was completed at baseline, at the end of Week 4, and at study termination to evaluate overall functioning. Patients were rated on a scale of 1–100 on the basis of their general level of functioning over the previous 14 days.

5.5.7 Safety Measurements

Patients were seen by a physician at every visit and the evaluation documented. The following safety evaluations were performed during the study at the designated visits (see Panel 3 and Sections 5.5.1, 5.5.2, and 5.5.3 for a detailed description of when each measurement was performed).

5.5.7.1 Adverse Events

Reports of AEs were collected at all study visits, or during any contact with a patient or patient representative, subsequent to the first administration of single-blind study medication. An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study medication, whether or not considered related to study medication.

Adverse events included:

a. Changes in the general condition of the patient;

b. Subjective symptoms offered by or elicited from the patient;

c. Objective signs observed by the investigator or study personnel;

d. All concurrent diseases that occured after the start of the trial, including any change in severity or frequency of pre-existing diseases;

e. All investigator identified clinically relevant laboratory abnormalities or physical findings that occured during the trial.

For each AE, the investigator provided an assessment of the seriousness, severity, timing, and causal relationship to study drug of the event. All actions taken with regard to study drug and any other treatment measures were documented and detailed.

For all AEs judged to be serious, the investigator or other study personnel were required to inform Forest Laboratories, Inc. immediately (within 24 hours). A serious adverse event (SAE) was one that:

a. Resulted in death;

b. Was an immediate threat to life;

c. Required inpatient hospitalization, or prolongation of existing hospitalization;

d. Resulted in persistent or significant disability/incapacity;

e. Was a congenital abnormality or birth defect.

In addition to the above, important medical events that did not result in death, were not life-threatening, or did not require hospitalization were considered SAEs if, based upon appropriate medical judgment, they were considered to have jeopardized the patient and may have required medical or surgical intervention to prevent one of the outcomes listed above.

When assessing the causality and the severity of the AE, investigators assessed the events as related, possibly related, or not related to study drug administration and as mild, moderate, or severe.

The investigator was required to follow up any clinical findings occurring at the final examination, or at premature discontinuation for any reason, including clinically significant laboratory abnormalities, until the condition returned to pretrial status or could be explained as being unrelated to study drug. A follow-up visit was to be conducted 28 days after termination, if necessary.

5.5.7.2 Vital Signs and Body Weight

Vital signs, including body weight, systolic and diastolic blood pressure, and radial pulse rate, were recorded at every visit. Blood pressure and pulse determinations were recorded after the patient had been seated for 5 minutes. Height was recorded at the screening visit and at the end of Week 8 visit (or early termination).

5.5.7.3 Laboratory Evaluations

Blood and urine samples for laboratory tests were collected at the screening and at the final visit (end of Week 8 or upon early termination). Values obtained at screening were used to determine whether a patient could be included in the study. The investigator assessed the clinical significance of any values outside the reference range and patients with abnormalities judged to be clinically significant were excluded. All reference

ranges are presented in Listing 15 of Appendix IX. The following laboratory tests were conducted on the samples obtained:

1. Hematology: Hematology included red blood cell (RBC) count, white blood cell (WBC) count with differential, hemoglobin, hematocrit, and platelet count;

2. Chemistry: Blood chemistry screen included sodium, potassium, calcium, chloride, glucose, blood urea nitrogen (BUN), creatinine, total protein, alkaline phosphatase, albumin, total bilirubin, aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT), cholesterol, and uric acid;

3. Urinalysis: Urinalysis included specific gravity, pH, acetone, albumin, glucose, WBC/hpf, RBC/hpf, casts/lpf, protein, and ketones;

4. Urine drug screen, thyroid function test, and serum β-HCG pregnancy test (for women of childbearing potential only), were conducted at screening only; positive results on the urine drug screen or pregnancy test excluded patients from participating in the study.

A central laboratory was also used to evaluate all urine and blood samples, which were collected, processed, and stored according to the instructions provided by the laboratory. The contact address for this laboratory is:

Covance Central Laboratory Services, Inc.
8211 SciCor Dr.
Indianapolis, IN 46214-2985

5.5.7.4 Electrocardiogram

A 12-lead ECG was performed at screening and the end of Week 8 or upon early termination. The overall interpretation was categorized as normal, abnormal but not clinically significant, or clinically significantly abnormal. Patients with a clinically significant ECG abnormality at screening were excluded from participating in the study.

5.5.7.5 Physical Examination

A complete physical examination was performed at the screening visit and at the end of the Week 8 evaluation (or upon early termination). General physical well-being was to be assessed by evaluating the head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, peripheral pulses, skin, and other physical conditions of note.

5.6 PHARMACOKINETICS

A blood sample for the measurement of citalopram steady-state concentrations in plasma was collected at the end of Week 8 (or early termination) visit along with the blood samples for laboratory determinations. If possible, the sample was to be collected between 8-14 hours after the last dose of study medication was taken. Blood samples were collected in 10 mL Vacutainers and separated by refrigerated centrifuge at 4°C at 1500G for 5 minutes. At least 2 mL of plasma was transferred to a polypropylene tube, immediately frozen, and stored at -70°C. The concentration of citalopram, escitalopram, R-citalopram, and metabolites was determined on the basis of a validated LC/MS/MS assay with a lower limit of quantification of 1 ng/mL.

5.7 DATA QUALITY ASSURANCE

5.7.1 Investigator Site Training and Monitoring

Before study site initiation, representatives of Forest Laboratories, Inc. conducted an investigator's meeting with the investigators and site personnel to review the protocol, CRFs, and study procedures, including procedures for proper source documentation. During this meeting, raters received training on the administration of the assessment instruments. A representative of Forest Laboratories, Inc. met with each investigator and his/her staff during an initiation visit conducted prior to the enrollment of the first patient. At the initiation visit, the study drug inventory was reviewed, as well as the procedures to be followed in conducting the study and recording the findings on the CRFs. At site monitoring visits, CRFs were reviewed by clinical monitors for validity, accuracy, and completeness; all source documents were verified, and drug accountability was performed.

5.7.2 Data Entry

Case report form data were double-entered into a validated database system. A combination of manual and programmatic edit checks were used to review the data for completeness, logic, and adherence to study protocol. Any resulting queries were addressed by the study site and returned to Forest Laboratories, Inc. for review. If necessary, the database was updated to reflect the new or changed information. A complete audit trail recorded the date, time, and reason for all changes made to the database. Treatment codes were unblinded only after all issues had been resolved and the database was locked.

6.0 STATISTICAL METHODS

The complete statistical analysis plan is presented in Appendix V.

6.1 STATISTICAL OBJECTIVES

6.1.1 Primary Statistical Objective

The primary objective of this study was to compare the efficacy of citalopram (20-40 mg/day) to placebo in children (7-11 years) and adolescents (12-17 years) with MDD. The primary efficacy parameter was the change from baseline in the CDRS-R score at Week 8.

6.1.2 Secondary Statistical Objectives

The secondary statistical objectives of this study were:

a. To further compare the efficacy of citalopram to placebo in children and adolescents with MDD using:

b. the change from baseline in CGI-S;

c. the CGI-I;

d. the change from baseline in K-SADS-P;

e. the change from baseline in CGAS.

9. To evaluate the safety of 20 – 40 mg/day citalopram in children and adolescents.

6.2 PATIENT DISPOSITION

6.2.1 Patient Populations

Patient populations were defined as follows:

- Randomized population — The randomized population consisted of all patients randomized in the study.

- Safety population — The safety population consisted of all randomized patients who received at least one dose of the double-blind study medication, ie, all treated patients.

- Intent-to-treat (ITT) Population — The ITT population consisted of all patients in the safety population with at least one post-baseline efficacy assessment of the primary efficacy variable (CDRS-R score).

The number of patients in each patient population was summarized by treatment group, age group, and study center.

6.2.2 Premature Discontinuation

The number (percentage) of patients in the safety population who prematurely discontinued from the study was summarized by treatment group, age group, and reason for discontinuation as recorded in the termination page of the CRF.

6.3 DEMOGRAPHICS AND OTHER BASELINE CHARACTERISTICS

Demographic parameters (age, gender, and race) and other baseline characteristics (weight and height) were summarized for the safety and ITT populations. Depression history was summarized for the safety population, including the following items: disease course, duration of MDD, duration of current episode, age at onset of MDD, previous antidepressant treatment, and response to and tolerance of previous antidepressant treatments. The incidence of ongoing secondary psychiatric disorders and the incidence of previous or ongoing secondary psychiatric disorders were summarized. The baseline scores of the efficacy parameters were summarized for the ITT population.

Descriptive statistics, including the number (N), mean and standard deviation (SD), median, and range were presented for continuous variables and frequency distributions (count and percent) were presented for categorical variables.

Comparability between treatment groups was tested using a three-way analysis of variance (ANOVA) model with age group, treatment, and study center as factors for continuous variables. Cohran-Mantel-Haenszel (CMH) tests controlling for age group and study center were used for categorical variables.

6.4 EFFICACY

Efficacy analyses were based on the ITT population. All tests were two-sided with 5% significance level for main effects and 10% significance level for interaction terms.

The analyses were carried out using the LOCF approach. In addition to LOCF, an OC approach was used, in which only observed values were analyzed.

6.4.1 Primary Efficacy Parameter

The primary efficacy parameter was the change from baseline to Week 8 in the CDRS-R score. Comparison between citalopram and placebo was performed using an analysis of covariance (ANCOVA) model with treatment, study center, and age group as factors, and the baseline score as covariate.

6.4.2 Secondary Efficacy Parameters

To further test the efficacy of citalopram relative to placebo, the secondary parameters listed in Section 6.1.2 were analyzed. An ANCOVA model, as described for the primary efficacy parameter, was used to analyze the change from baseline in these parameters except for the CGI-I. A three-way ANOVA model was used for the CGI-I score, since this parameter, by definition, records improvement relative to baseline and is not measured at baseline. The numbers of CGI-I responders (CGI-I = 1 or 2) and CDRS-R responders (CDRS-R 28) in the citalopram group relative to the placebo group were compared using the CMH test controlling for center and age group.

By-visit analyses (LOCF and OC) were conducted for all efficacy parameters using additive ANCOVA or ANOVA models for continuous parameters and the CMH test for categorical parameters.

6.4.3 Examination of Treatment-By-Age Group Interaction

The consistency in treatment effect across age groups was examined using an ANCOVA or ANOVA model with treatment, study center, age group, and the interaction between treatment and age group as factors and (in the ANCOVA model) baseline score as covariate. These analyses were carried out using the LOCF approach at Week 8 for all continuous efficacy parameters.

6.4.4 Examination of Treatment-By-Center Interaction

The consistency in treatment effect across centers was examined through graphical presentations using the LOCF approach at Week 8. Small centers, i.e., centers with 0 or 1 patient in at least one treatment group in the ITT population were not included.

6.4.5 Examination of Treatment-By-Baseline Interaction

The significance of the treatment-by-baseline score interaction was tested at the 10% level using an ANCOVA model with treatment, study center, age group, and the interaction between treatment and baseline score as factors, and baseline score as covariate. These analyses were carried out using the LOCF approach at Week 8 for all continuous efficacy parameters administered at baseline.

If the treatment-by-baseline score interaction had been significant, the results from an ANOVA model with treatment, study center, and age group as factors were to be used instead.

6.4.6 Missing Data

Missing values were imputed using the LOCF approach. Missing assessments at post-baseline visits were imputed by the last observed non-missing value immediately prior to the missing value. If the missing value occurred at Week 1, the baseline value was carried forward for Week 1, provided at least one subsequent post-baseline assessment was available. For each efficacy parameter, only the total score, not individual items, was carried forward.

6.4.7 Visit Windows

Panel 4 presents the visits assigned for efficacy and safety analyses corresponding to the range of treatment days (window) over which an actual study visit may have occurred. Days on drug (double-blind study medication) were calculated as visit date - first date on double-blind study medication +1. If there was more than one visit within a visit window, the one closer to the scheduled date was used for that visit. If there were two visits with equal distance from the scheduled visit date within a visit window, the later one was used.

Panel 4. Visit Time Windows

Visit	*Scheduled Visit Day*[*]	*Window*
Week 1	Day 7	Days 1 – 10
Week 2	Day 14	Days 11 – 21
Week 4	Day 28	Days 22 – 35
Week 6	Day 42	Days 36 – 48
Week 8	Day 56	Days 49 – 77

[*] Day 1 is the first day of double-blind study medication.

6.5 SAFETY

Safety analyses were performed on the safety population (i.e., all patients who received study drug).

6.5.1 Extent of Exposure

The duration of exposure to double-blind study medication and mean daily dose (or number of tablets taken) were summarized by treatment group and age group for the safety population.

6.5.2 Adverse Events

All AEs were coded using the World Health Organization Adverse Reaction Terminology (WHOART) Dictionary, version 1998/04. An AE that occurred during the double-blind study medication period was defined as a "treatment emergent" adverse event (TEAE) if either it was not present at baseline or it was present at baseline but increased in severity during the double-blind treatment period. If the severity assessment for an AE was missing pre-baseline, then "mild" was assigned. If the severity assessment was missing post-baseline, "severe" was assigned.

The number and percentage of patients with at least one TEAE during the double-blind treatment period were summarized by system organ class (body system), preferred term, gender, treatment group, age group, and investigator's assessment of the severity and relationship to the double-blind study medication. The incidence of treatment-limiting AEs (events contributing to premature discontinuation) were also tabulated. Individual patient listings were compiled for all patients who discontinued the study due to AEs or experienced an SAE and included study center, gender, age, and days to onset of the event. Individual patient narratives were generated for all SAEs or discontinuations because of an AE.

6.5.3 Vital Signs

Sitting pulse, systolic and diastolic blood pressure, and body weight were assessed at every visit in this study. Height was measured at the screening and final study visits. The criteria listed in Panel 5 were used to identify potentially clinically significant (PCS) vital signs. A post-baseline value was regarded as a PCS value if it met both the criterion value and the change relative to baseline. The criteria used for the adolescent age group were the same as those used for adult outpatients, whereas the criteria for the patients between 7 and 11 years of age were adjusted in accordance with the normative vital sign values for this age group. A secondary analysis was conducted in which the criteria for the adolescent patients were applied to all patients. For each parameter, the number (percentage) of patients with any PCS values were tabulated for each treatment group, along with supportive listings.

Panel 5. Criteria for Potentially Clinically Significant Vital Signs

Variable	*Criterion Value*	*Change Relative to Baseline*
Age 12 - 17		
Systolic Blood Pressure	≥ 180 mmHg	Increase of ≥ 20
	≤ 90 mmHg	Decrease of ≥ 20
Diastolic Blood Pressure	≥ 105 mmHg	Increase of ≥ 15
	≤ 50 mmHg	Decrease of ≥ 15
Pulse	≥ 120 bpm	Increase of ≥ 15
	≤ 50 bpm	Decrease of ≥ 15
Weight	Not applicable	Change of ≥ 7%
Age 7 - 11		
Systolic Blood Pressure	≥ 130 mmHg	Increase of ≥ 20
	≤ 75 mmHg	Decrease of ≥ 20
Diastolic Blood Pressure	≥100 mmHg	Increase of ≥ 15
	≤ 40 mmHg	Decrease of ≥ 15
Pulse	≥ 130 bpm	Increase of ≥ 15
	≤ 55 bpm	Decrease of ≥ 15
Weight	Not applicable	Not applicable

Note: A post-baseline value was regarded as a PCS value if it met both the criterion value and the change relative to baseline.

Descriptive statistics were presented for each parameter by visit including the final visit for each treatment group and age group. Changes from baseline were also summarized. Only patients with a baseline assessment and at least one post-baseline assessment were included in the summary. Results from the screening visit were used if the baseline assessment was missing.

6.5.4 Laboratory Parameters

The number (percentage) of patients with post-baseline PCS values was tabulated for each parameter by treatment group and age group using the criteria presented in Panel 6. All results were presented in System International (SI) units. Listings were prepared for patients with post-baseline PCS values.

Panel 6. Criteria for Potentially Clinically Significant Laboratory Values

Laboratory Parameter	*SI Units*	*PCS Criteria Low Values*	*PCS Criteria High Values*
Hematology			
Hemoglobin	g/dL	≤ 0.9*LNL	--
Hematocrit	%	≤ 0.9*LNL	--
Eosinophils	%	--	≥ 10
Neutrophils Segs	%	≤ 15	--
Platelet Count	10^9/L	≤ 75	≥ 700
White Cell Count	10^9/L	≤ 2.8	≥ 16
Chemistry			
Alkaline Phosphatase	IU/L	--	≥ 3*UNL
ALT (SGPT)	IU/L	--	≥ 3*UNL
AST (SGOT)	IU/L	--	≥ 3*UNL
Blood Urea Nitrogen	mmol/L	--	≥ 10.7
Calcium	mmol/L	≤ 1.75	≥ 3.0
Cholesterol	mmol/L	--	≥ 7.8
Creatinine	mmol/L	--	≥ 175
Potassium	mmol/L	≤ 3.0	≥ 5.5
Sodium	mmol/L	≤ 125	≥ 155
Total Bilirubin	mmol/L	--	≥ 34.2
Urinalysis			
Protein		--	Increase of ≥ 2
Glucose		--	Increase of ≥ 2

LNL= Lower normal limit of laboratory reference range.
UNL= Upper normal limit of laboratory reference range.

Descriptive statistics were presented by treatment group and age group for each parameter at the screening visit, final visit, and the change from screening at the final visit. Only patients with a screening assessment and at least one post-baseline assessment were included in the summary.

6.5.5 Electrocardiogram

For each ECG parameter, the number (percentage) of patients with PCS values was tabulated by age group and treatment group based on the criteria presented in Panel 7. Listings were prepared for patients with PCS values.

Panel 7. Criteria for Potentially Clinically Significant ECG Values

ECG Variable	*Units*	*PCS Criteria*
PR Interval	msec	≥ 250
QT_C Interval	msec	>500

Descriptive statistics were presented by treatment group and age group for each parameter at the screening visit, the final visit, and the change from screening at the final visit. Only patients with a screening assessment and at least one post-baseline assessment were included in the summary. The incidence of ECG abnormalities at the screening visit and the final visit, regardless of clinical significance, was also summarized.

6.5.6 Physical Examination

For each organ class, the number (percentage) of patients with an abnormal finding at the final visit was tabulated by treatment group and age group. Only patients with a normal or missing value (not done) at screening were included in the summary.

6.5.7 Concomitant Medications

Concomitant medications were coded using the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) Dictionary, Version 1998/04. The number (percentage) of patients who took concomitant medications was summarized by drug class (based on the ATC codes), age group, and treatment group.

Medications taken during the screening period up to and including the baseline day, and all medications taken during the double-blind treatment period including drugs started prior to the start of double-blind study medication and continued during the treatment period were tabulated by treatment group and age group. Drugs started after the stop of double-blind study medication were not summarized.

6.6 PHARMACOKINETICS

Plasma concentrations for citalopram and its active enantiomer escitalopram, and for their metabolites demethylcitalopram (DCT), didemethylcitalopram (DDCT), S-demethylcitalopram (S-DCT) and S-didemethylcitalopram (S-DDCT), were summarized by dose, by age group, and overall. Correlation analyses were conducted to examine the relationship between both citalopram plasma concentration and escitalopram plasma concentration and patient age, body weight, and change from baseline in CDRS-R score.

6.7 SAMPLE SIZE CONSIDERATIONS

The primary efficacy parameter was the change from baseline in CDRS-R score at Week 8. Assuming an effect size (treatment group difference relative to pooled standard deviation) of 0.5, a sample size of 80 patients in each treatment group was used to provide 85% power using a two-sided t-test with alpha level of 0.05.

6.8 COMPUTER METHODS

Statistical analyses were performed using SAS (version 6.12) under a UNIX operating system. PROC Univariate was used for descriptive statistics and PROC FREQ was used for frequency distribution and CMH test with centers as strata. PROC MIXED was used for analysis of covariance and analysis of variance with the options DIFF and CI to compute the difference of least squares means (LSM) and 95% confidence interval, respectively.

7.0 CHANGES IN THE CONDUCT OF THE STUDY AND PLANNED ANALYSES

In the protocol it was specified that a three-way additive ANCOVA model, without the treatment-by-baseline score interaction, was to be used for the analysis of the primary efficacy parameter. In response to comments on the protocol from the FDA (dated February 14, 2000), Forest Laboratories, Inc. modified the statistical analysis plan such that initially an ANCOVA with treatment, study center, age group, and the interaction between treatment and baseline score as factors and baseline score as covariate was conducted. The planned ANCOVA without the treatment-by-baseline score interaction was to be used as the primary statistical analysis only if the interaction was not significant. If the interaction was significant at the 10% level, an ANOVA with treatment, study center, and age group as factors was to be used instead as the primary statistical analysis.

Nine patients (Patients 105, 113, 114, 505, 506, 507, 509, 513, and 514) were mistakenly dispensed 1 week of medication with potentially unblinding information (tablets had an incorrect color coating). Therefore, in addition to the analysis specified in Section 6.4.1 for the primary efficacy parameter, a post-hoc analysis was performed on an ITT subpopulation that excluded these 9 patients.

8.0 PATIENT DISPOSITION

Patient disposition data are summarized by treatment group and center in Tables 1.1 and 1.2, Appendix IX Listing 1, and Panel 8. Appendix Table 1A provides the distribution of individual randomized patients by center. A total of 174 patients received double-blind study drug, of whom 89 received citalopram and 85 received placebo. These patients were included in all safety and efficacy analyses, and so the safety population and ITT population were identical. Among the 89 patients treated with citalopram, 45 were between 7 and 11 years of age and 44 were between 12 and 17 years of age. Among the 85 patients treated with placebo, 38 were between 7 and 11 years of age and 47 were between 12 and 17 years of age. A total of four additional patients were randomized to citalopram but were lost to follow-up and never received study drug (Appendix Table 1B).

Panel 8 presents the number of patients who discontinued prematurely by treatment group and reason, using the safety population as the total sample. A total of 138 (79%) patients completed the study, 80% of patients in the citalopram group and 79% of patients in the placebo group. There was no significant difference between treatment groups or age groups in the overall percentage of patients who discontinued from the study prematurely. The rates of discontinuation by individual reason were also similar between treatment groups, the most frequent being adverse event and lost to follow-up, each of which occurred in 5.6% of citalopram treated patients and 5.9% of placebo treated patients.

Panel 8. Reasons for Patient Discontinuation: Number (%)

	Placebo			***Citalopram***		
	Children (N=38)	*Adolescents (N=47)*	*Total (N=85)*	*Children (N=45)*	*Adolescents (N=44)*	*Total (N=89)*
Total Completers	30 (78.9)	37 (78.7)	67 (78.8)	36 (80.0)	35 (79.5)	71 (79.8)
Total Withdrawn For Any Reason	8 (21.1)	10 (21.3)	18 (21.2)	9 (20.0)	9 (20.5)	18 (20.2)
Adverse Event	1 (2.6)	4 (8.5)	5 (5.9)	3 (6.7)	2 (4.5)	5 (5.6)
Insufficient Therapeutic Response	0	1 (2.1)	1 (1.2)	2 (4.4)	0	2 (2.2)
Protocol Violation	2 (5.3)	1 (2.1)	3 (3.5)	0	2 (4.5)	2 (2.2)
Withdrawal of Consent	0	2 (4.3)	2 (2.4)	0	2 (4.5)	2 (2.2)
Lost to Follow-Up	4 (10.5)	1 (2.1)	5 (5.9)	2 (4.4)	3 (6.8)	5 (5.6)
Other	1 (2.6)	1 (2.1)	2 (2.4)	2 (4.4)	0	2 (2.2)

Note: Percentages are relative to number of patients (N) in safety population.
Cross-reference: Table 1.2, Table 1.3, and Appendix IX, Listing 1.

Table 1.3 lists the patients who discontinued prematurely by treatment group, reason for discontinuation, number of days on drug, and day of last visit.

Section 12.2.3 provides detailed information on patients who prematurely withdrew from the study due to AEs. Narratives for each of these patients can be found in the Patient Narrative Section at the end of this report.

9.0 DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS

9.1 DEMOGRAPHICS

Demographic data for the safety population are summarized by treatment and age groups in Tables 2.1 and 2.2, Appendix IX Listing 2, and Panel 9. Subgroup analyses of demographic data by treatment for the safety population are summarized in Appendix Table 2A for children and in Appendix Table 2B for adolescents. A patient listing of demographic and baseline data for all randomized patients is provided in Appendix IX, Listing 2. Demographic characteristics were similar between the treatment groups. The majority of subjects in both treatment groups were female (53% for citalopram and 54% for placebo) and Caucasian (81% and 73%, respectively). However, patients between 7 and 11 years of age were predominantly male (58%), whereas the adolescent patients were predominantly female (64%). Mean age in both treatment groups was 12 years. Among the children, the mean age in the citalopram group was 9.3 years and the mean age in the placebo group was 9.6 years. Among the adolescents, the mean age in the citalopram group was 14.9 years and the mean age in the placebo group was 14.1 years.

Panel 9. Demographic Characteristics

Characteristic		*Placebo*			*Citalopram*		
		Children (N=38)	*Adolescents (N=47)*	*Total (N=85)*	*Children (N=45)*	*Adolescents (N=44)*	*Total (N=89)*
Age, years	Mean (SD)	9.6 (1.3)	14.1 (1.8)	12.1 (2.8)	9.3 (1.1)	14.9 (1.7)	12.1 (3.1)
	Min, Max	7, 11	12, 17	7, 17	7, 11	12, 17	7, 17
Sex, %	Female	42.1%	63.8%	54.1%	42.2%	63.6%	52.8%
	Male	57.9%	36.2%	45.9%	57.8%	36.4%	47.2%
Race, %	Caucasian	81.6%	66.0%	72.9%	80.0%	81.8%	80.9%
	Non-Caucasian	18.4%	34.0%	27.1%	20.0%	18.2%	19.1%
Weight, lbs	Mean (SD)	97.6 (38.0)	148.2 (60.3)	125.6 (57.2)	98.9 (43.0)	149.1 (46.2)	123.7 (51.0)
	Min, Max	48, 219	72, 396	48, 396	50, 247	75, 280	50, 280

Note: Percentages are relative to number of patients (N) in safety population.
Cross-reference: Table 2.1, Table 2.2, and Appendix IX, Listing 2.

9.2 PATIENT HISTORY

Table 2.3 presents the depression history of the safety population by treatment group and age group. Subgroup analyses of the depression history by treatment for the safety population are summarized in Appendix Table 3A for children and in Appendix Table 3B for adolescents.

There were no apparent differences between treatment groups. The percentage of patients who were experiencing their first episode of depression was 78.7% in the citalopram group and 82.4% in the placebo group. The mean duration of MDD was approximately 2 years and the average age of onset was 10 years for both treatment groups. Among the children, the onset of MDD had occurred while they were 7 years of age, on average, and the onset of MDD among the adolescents was at a mean age of approximately 12 years. Twenty percent of patients in the citalopram group and 18% of patients in the placebo group had previously received antidepressant treatment, and approximately 15% of patients in the citalopram group and 16% of patients in the placebo group had a history of treatment nonresponse.

The incidence of ongoing secondary psychiatric disorders and of previous or ongoing secondary psychiatric disorders is presented by treatment group and age group in Appendix Tables 9A and 9B. The overall incidence of ongoing psychiatric comorbidity was 16.9% in the citalopram group and 9.4% in the placebo group; the overall incidence of psychiatric comorbidity at present or by history was 25.8% in the citalopram group and 15.3% in the placebo group. The most frequent ongoing secondary psychiatric disorders were enuresis (7 patients) and dysthymia (6 patients). Encopresis, social anxiety disorder, anxiety, and specific phobia were also present in more than one patient.

Overall, the psychiatric, medical, and psychotropic drug treatment histories of patients in the safety population were similar between treatment groups.

Individual patient listings of psychiatric history, suicide history, medical history, psychotropic drug treatment, and nondrug psychiatric treatment histories can be found in Appendix IX, Listings 3, 4, 5, 6, and 7, respectively.

9.3 EFFICACY VARIABLES AT BASELINE

Efficacy variables for the ITT population at baseline are presented in Table 2.4, Appendix IX Listing 8, and Panel 10. The mean baseline scores in each treatment group are indicative of moderate to severe depressive symptomatology producing significant functional impairment, consistent with a diagnosis of major depressive disorder. No statistically significant differences between groups were observed for any efficacy parameter at baseline.

Panel 10. Efficacy Variables at Baseline (Mean [SD])

Efficacy Parameter	*Placebo (N=85)*	*Citalopram (N=89)*	*p-value*
CDRS-R	57.8 (11.1)	58.8 (10.9)	0.653
CGI-S	4.3 (0.5)	4.4 (0.6)	0.721
CGAS	51.8 (7.0)	51.3 (7.7)	0.579
K-SADS-P Depression Module	28.7 (5.0)	28.9 (5.3)	0.977

ITT population
p-values for between-treatment comparisons are from three-way ANOVA with factors of treatment, age group, and center.
Cross-reference: Table 2.4 and Appendix IX, Listing 8.

10.0 EFFICACY EVALUATION

All efficacy analyses are based on the ITT population. Tables 3.1 through 3.5, 4.1 through 4.5, and 5.1 through 5.5 present the results of the primary (CDRS-R) and secondary (CGI-I, CGI-S, CGAS, and K-SADS-P Depression Module) efficacy analyses as means, medians, SD, and SEM; the p-value for the overall treatment effect; and the difference of the LSM with 95% CIs.

10.1 CHILDREN'S DEPRESSION RATING SCALE — REVISED

The primary efficacy parameter was the change from baseline in the CDRS-R score after 8 weeks of double-blind treatment. Table 3.1 and Panel 11 present the results from the LOCF analysis for the change from baseline to Week 8. The p-value for the treatment by baseline score interaction is presented in Table 3.8. The LOCF analysis by visit is presented in Table 4.1A. The OC analysis by visit is presented in Table 4.1B. Descriptive statistics by visit are presented in Tables 5.1A (LOCF) and 5.1B (OC).

At Week 8, the LOCF analysis comparing the mean change from baseline in CDRS-R in the citalopram and placebo groups demonstrated a statistically significant treatment effect in favor of citalopram (p=0.038; see Panel 11). This treatment effect was already apparent at Week 1 and was observed at all subsequent clinic visits (see Panel 12 and Table 4.1A). Similar effects were seen in the children and adolescent subgroups, as evidenced by the lack of a treatment-by-age group interaction (p=0.136, Appendix Table 5). The treatment effect was also independent of baseline severity of depression, as indicated by the lack of a treatment-by-baseline score interaction (p=0.116; Table 3.8).

Analyses using the OC approach likewise demonstrated significantly greater improvement in the citalopram group compared to the placebo group, with significant citalopram-placebo differences (p0.05) observed at Weeks 1, 4, and 6 (Table 4.1B).

The response rate at Week 8 (with response defined as CDRS-R 28) was significantly higher in the citalopram group (36.0%) than the placebo group (23.5%) in the LOCF analysis (p=0.041; Table 3.7). The CDRS-R responder rate by visit is shown in Table 4.7A (LOCF) and 4.7B (OC). The number and percent of patients with a ≥50% decrease in CDRS-R scores from baseline at each week of treatment is summarized in Appendix Table 7A (LOCF) and Appendix Table 7B (OC).

Panel 11. Change from Baseline to Week 8 in CDRS-R (Mean ± SEM)

	Placebo (N=85)	*Citalopram (N=89)*	*p-value*
Mean ± SEM	-16.5 ± 1.6	-21.7 ± 1.6	0.038

ITT population
p-value is based on a three-way ANCOVA model with treatment, age group, and center as factors and baseline score as covariate.
Cross-reference: Tables 3.1, 4.1A, and Appendix IX, Listing 8.

Panel 12. CDRS-R Change from Baseline Over Time



* p<0.05 compared to placebo
** p<0.01 compared to placebo

Appendix Table 6 presents the results from the LOCF analysis for the change from baseline to Week 8 excluding data from the 9 patients for whom the study blind was potentially compromised (see Section 5.3.4). The results from the Week 8 LOCF analysis comparing the mean change from baseline in CDRS-R in the citalopram and placebo groups was not substantially affected by the exclusion of those patients; the LSM difference decreased from 4.6 to 4.3 and the p-value increased from 0.038 to 0.052.

The SAS outputs for the analysis of change from baseline in CDRS-R by visit are provided in Appendix Tables 15 and 16 for the LOCF analysis and OC analysis, respectively.

10.2 SECONDARY PARAMETERS

10.2.1 Clinical Global Impressions

The LOCF analysis of the CGI-I at Week 8 and the change from baseline in CGI-S at Week 8 are presented in Table 3.2 and 3.3, respectively. By visit LOCF analyses for the CGI-I and the CGI-S are presented in Table 4.2A and 4.3A, respectively. OC analyses for the CGI-I and CGI-S are presented in Table 4.2B and 4.3B, respectively. Descriptive statistics by visit for LOCF and OC analyses of the CGI-I are presented in Table 5.2A and 5.2B, respectively, and descriptive statistics for LOCF and OC analyses of the CGI-S are presented in Table 5.3A and 5.3B, respectively. Individual patient data are provided in Appendix IX, Listing 8.

On the CGI-S, significant improvement in the citalopram group relative to the placebo group (p0.05) was observed in the LOCF analysis at the end of Weeks 1, 2, 4, and 6 of double-blind treatment, but not the end of Week 8 (Table 4.3A). Similar results were obtained in the OC analyses (Table 4.3B). On the CGI-I, numerically greater improvement was observed at every visit in the citalopram group relative to the placebo group, but these differences achieved statistical signficance ($p<0.01$) at the end of Week 6 only, in both the LOCF and OC analysis (Tables 4.2A and 4.2B).

The response rate at Week 8, with response defined as a CGI-I of 1 (very much improved) or 2 (much improved) was 47% in the citalopram group and 45% in the placebo group (Table 3.6). The CGI-I responder rate by visit is shown in Table 4.6A (LOCF) and 4.6B (OC).

10.2.2 Children's Global Assessment Scale

Table 3.4 presents the results from the LOCF analysis of the CGAS rating at Week 8. Table 4.4A presents the results of the LOCF analysis by visit, and Table 4.4B presents the results of the OC analysis. Descriptive statistics by visit for CGAS are presented in Tables 5.4A (LOCF) and 5.4B (OC), respectively. Individual patient data are provided in Appendix IX, Listing 8.

The CGAS was administered at baseline, the end of Week 4, and the end of Week 8. Significant improvement (p0.05) was observed in the citalopram group relative to the placebo group at the end of Week 4 in both the LOCF and OC analyses and nonsignificantly greater mean improvement was observed in the citalopram group relative to the placebo group at the end of Week 8.

10.2.3 K-SADS-P Depression Module

The K-SADS-P depression module was administered at screening, baseline, and the end of Week 8. Results from the LOCF analysis are presented in Table 3.5 and 4.5A.

Results from the OC analysis are presented in Table 4.5B. Descriptive statistics are presented in Table 5.5A (LOCF) and Table 5.5B (OC). K-SADS-P responder analyses are presented in Appendix Tables 8A (LOCF) and 8B (OC). Individual patient data are provided in Appendix IX, Listing 8. On the K-SADS-P depression module, numerically greater improvement was observed in the citalopram group relative to the placebo group in both the LOCF and OC analysis, but the difference did not reach statistical significance.

10.3 TREATMENT-BY-BASELINE SCORE INTERACTION

The effect of baseline severity on the observed treatment-group differences was evaluated by examining the treatment-by-baseline score interaction from the Week 8 ANCOVA using the LOCF approach for each efficacy variable (Table 3.8). No signficant treatment-by-baseline score interactions were found on the CDRS-R, CGI-S, CGAS, or K-SADS-P.

10.4 TREATMENT-BY-AGE GROUP INTERACTION

The significance of the treatment-by-age group interaction from the Week 8 ANCOVA using the LOCF approach for each efficacy variable is summarized in Appendix Table 5. No significant treatment-by-age group interaction was found on the CDRS-R, CGI-I, CGI-S, CGAS, or K-SADS-P

10.5 EFFICACY CONCLUSIONS

On the primary efficacy parameter, the change from baseline in CDRS-R at Week 8, citalopram produced significantly greater improvement than placebo ($p=0.038$ in the LOCF analysis). The citalopram group exhibited significantly greater improvement than the placebo group at Week 1 and all subsequent clinic visits. Analysis of the response rate on the CDRS-R also revealed a significantly higher percentage of responders (CDRS-R $\leq$ 28 at study endpoint) in the citalopram group as compared to the placebo group ($p=0.041$).

Significant differences ($p<0.05$), indicative of greater improvement in citalopram patients than placebo patients, were also observed on the CGI-I, CGI-S, and CGAS. Statistically significant effects were not found as consistently across study timepoints for the secondary efficacy parameters as for the primary efficacy parameter, but numerically greater improvement in the citalopram group was observed on every efficacy parameter at every clinic visit in both the LOCF and OC analyses. Results from the LOCF and OC analyses were similar.

No treatment-by-age group interaction was observed, indicating that the magnitude of the treatment effect was similar in the child and adolescent subgroups. In patients between 7

and 11 years of age, mean CDRS-R scores worsened from Week 6 to Week 8 in both the citalopram and placebo groups. This finding may have been related to the duration of the Week 8 visit, which included, in addition to all of the efficacy ratings, plasma samples, urine samples, a physical examination, ECG, and informed consent procedures for the extension study, in no protocol-stipulated order.

No treatment-by-baseline score interaction was observed, indicating that the magnitude of the treatment effect was not related to the patients' baseline symptom severity.

11.0 PHARMACOKINETICS AND PHARMACODYNAMICS

Descriptive statistics for plasma concentrations of citalopram and its metabolites, by previous dose, are summarized in Appendix Table 13A. Summaries of the mean plasma concentrations of escitalopram and its metabolites are provided in Appendix Table 13B. Results from analyses of the correlation between citalopram or escitalopram plasma concentration and patient age, patient weight, and the change from baseline to endpoint in CDRS-R, are provided in Appendix Table 14. Scattergrams depicting the relationship between patient age and citalopram concentration, patient age and escitalopram concentration, patient weight and citalopram concentration, and patient weight and escitalopram concentration, are provided in Appendix Figure 3.1, 3.2, 3.3, and 3.4, respectively. A listing of citalopram, escitalopram, and metabolite plasma concentrations at the final visit is provided in Appendix IX, Listings 24A and 24B.

The concentration of citalopram was approximately 13% higher in the children as compared to the adolescents (Appendix Table 13A). However, the correlation analyses revealed no significant correlation between age and citalopram concentration ($r=-0.059$; $p=0.650$) or escitalopram concentration ($r=0.048$; $p=0.714$). Body weight also appeared to be uncorrelated with either citalopram concentration ($r=-0.218$; $p=0.089$) or escitalopram concentration ($r=-0.119$; $p=0.357$). Improvement on the CDRS-R also showed no significant relationship to plasma levels of either citalopram ($r=0.123$; $p=0.341$) or its active enantiomer escitalopram ($r=0.104$; $p=0.422$).

12.0 SAFETY EVALUATION

12.1 EXTENT OF EXPOSURE

The mean duration of treatment and mean daily dose (or number of tablets) for patients in each treatment group are presented in Table 6.1. Appendix Table 4A summarizes the distribution of final dose by treatment group, and Appendix Table 4B summarizes the modal daily dose by visit and treatment group. The average duration of treatment was 53 and 51 days for patients in the citalopram and placebo groups, respectively. The mean daily citalopram dose was 23.8 mg/day and the mean daily placebo dose was 1.21 tablets/day. The mean citalopram dose was 24.4 mg/day in the adolescent patients and 23.3 mg/day in the child patients. The majority of patients in both groups were eventually titrated up to 2 tablets or 40 mg per day.

12.2 DEATHS, SERIOUS ADVERSE EVENTS, AND DISCONTINUATIONS DUE TO ADVERSE EVENTS

12.2.1 Deaths

No deaths occurred during the conduct of this study.

12.2.2 Serious Adverse Events

One patient experienced an SAE during the study. The patient is listed in Table 7.1. A brief discussion of the SAE for this patient is presented below. A narrative describing the SAE is provided in the Patient Narratives Section of this report. The CRF for this patient is located in Appendix X.

Patient 137, a 10-year-old male who had been discontinued from double-blind placebo because of the adverse event of personality disorder, showed serious impulsive behavior 24 days after discontinuation. The event was considered by the investigator to be moderate in severity and not related to study drug treatment. The impulsive behavior resolved spontaneously after seven days.

12.2.3 Discontinuations Due to Adverse Events

The incidence of discontinuations due to AEs is presented in Tables 1.2 and 7.2. A listing of patients who discontinued due to AEs is presented in Panel 13. Ten patients experienced 15 AEs that resulted in discontinuation from the study: 5 (5.6%) patients in the citalopram group and 5 (5.9%) patients in the placebo group. The most common AEs leading to discontinuation were aggravated depression, which occurred in 2 (2.4%) adolescents treated with placebo, and agitation, which occurred in 2 (2.2%) children in the citalopram group.

Panel 13. List of Patients who Discontinued due to Adverse Events

Treatment Group/ Patient Number	*Age (yrs)*	*Sex*	*AE Start Day**	*AE (Preferred Term)*
PLACEBO				
137	10	Male	31	Personality Disorder
507	13	Female	30	Rash
519	12	Female	41	Suicidal Tendency
550	13	Male	29	Depression Aggravated
574	15	Female	5	Depression Aggravated
CITALOPRAM				
144	10	Male	47	Hypomania
			53	Headache
			53	Abdominal Pain
193	9	Male	36	Agitation
229	7	Male	15	Agitation
			15	Concentration Impaired
534	16	Female	24	Akathisia
561	16	Female	8	Fatigue
			8	Appetite Decreased
			8	Weight Decreased

* AE Start Day = AE Start Date – Date of First Dose +1.

Cross-reference: Table 7.3.

Individual narratives for the patients listed in Panel 13 are provided in the Patient Narratives Section at the end of this report; the corresponding CRFs are located in Appendix X.

12.3 ADVERSE EVENTS

The following sections present the incidence of TEAEs for the safety population by treatment and age groups, by body system, preferred term, severity, relationship to study drug, and sex.

12.3.1 Incidence of Treatment-Emergent Adverse Events

The number and percentage of patients who experienced a TEAE are presented by treatment group, age group, body system, and preferred term in Table 7.4. Panel 14 presents the number and percentage of patients who experienced a TEAE with an incidence of at least 5.0% in any treatment group; TEAEs are presented in order of decreasing frequency in the citalopram group.

The overall incidence of TEAEs was 84.3% in the citalopram group and 69.4% in the placebo group. Other than headache (19.1% citalopram, 20.0% placebo), the most frequent TEAEs in both treatment groups were gastrointestinal and respiratory disorders. The TEAEs that occurred with an incidence greater than 5% in the citalopram group and at least twice the incidence in the placebo group were rhinitis (13.5% citalopram, 5.9% placebo), nausea (13.5% citalopram, 3.5% placebo), influenza-like symptoms (6.7% citalopram, 0% placebo), fatigue (5.6% citalopram, 1.2% placebo), and diarrhea (5.6% citalopram, 1.2% placebo). The most frequent psychiatric side effects in the citalopram group were insomnia (4.5%), agitation (3.4%), and irritability (3.4%). No sexual dysfunction was reported.

The overall incidence of TEAEs was 82.2% in citalopram-treated children and 86.4% in citalopram-treated adolescents. In the citalopram group, the only individual TEAEs that differed in incidence between age groups by at least 10% (i.e., 5 patients) were fever (11.1% in children, 0% in adolescents) and nausea (2.2% in children, 25.0% in adolescents).

Panel 14. Most Frequent Treatment Emergent Adverse Events (≥5.0%)

Preferred Term	*Number (%) of Patients*	
	Placebo	*Citalopram*
	Total (N=85)	Total (N=89)
Patients with at least 1 TEAE	59 (69.4)	75 (84.3)
Headache	17 (20.0)	17 (19.1)
Rhinitis	5 (5.9)	12 (13.5)
Nausea	3 (3.5)	12 (13.5)
Abdominal Pain	6 (7.1)	10 (11.2)
Influenza-Like Symptoms	0	6 (6.7)
Pharyngitis	7 (8.2)	6 (6.7)
Fever	5 (5.9)	5 (5.6)
Fatigue	1 (1.2)	5 (5.6)
Vomiting	5 (5.9)	5 (5.6)
Diarrhea	1 (1.2)	5 (5.6)
Back Pain	3 (3.5)	5 (5.6)
Coughing	6 (7.1)	4 (4.5)
Upper Respiratory Tract Infection	6 (7.1)	4 (4.5)

Note: Percentages are relative to number of patients (N) in safety population.
Cross-reference: Table 7.4, Appendix Table 10A, and Appendix IX, Listings 11, 12 and 13.

Listings of AEs for individual patients for the placebo lead-in and double-blind treatment periods are presented in Appendix IX, Listings 11 and 12, respectively. Appendix IX, Listing 13 presents TEAEs by treatment group, body system, and preferred term.

12.3.2 Treatment-Emergent Adverse Events by Severity and Causality

The number of patients with TEAEs by severity, treatment group, and age group are shown in Table 7.5, and the total number of AEs by severity, treatment group, and age group is shown in Appendix Table 10A. Most adverse events in both the citalopram and placebo groups were mild in intensity and more than 98% in both groups were mild or moderate in intensity.

The number and percentage of patients with TEAEs by causality, age, and treatment group is presented in Table 7.6, and the total number of AEs by causality, treatment

group, and age group is shown in Appendix Table 10B. Most adverse events were judged to be unrelated to the study medication.

12.3.3 Treatment-Emergent Adverse Events by Sex

The number and percentage of patients with TEAEs are shown by sex and treatment group in Table 7.7. Appendix Tables 11A and 11B present the number and percentage of patients by sex for children and adolescents, respectively. The overall number of patients with TEAEs within each treatment group was similar between male and female patients.

Overall, the type and frequency of TEAEs reported for male and female patients were similar to those reported for the treatment group as a whole. Among patients treated with citalopram, the largest male-female difference in the incidence of an individual TEAE was observed for headache, which was reported for 26.2% of male versus 12.8% of female patients. Among patients treated with placebo, headache was more frequently reported among females (21.7%) than among males (17.9%). Abdominal pain tended to be more common among citalopram-treated males than females, whereas nausea, appetite decreased, insomnia, and coughing tended to be more frequent among citalopram-treated females than males. Overall, no clinically important differences in the TEAE profile of citalopram were observed between male and female patients.

12.4 VITAL SIGNS AND BODY WEIGHT

Table 8.1 presents the incidence of all vital sign values by treatment group and age group that were identified as PCS on the basis of criteria in Panel 5. Table 8.2 lists the baseline value, the PCS value, and the final value for all patients with PCS values. Tables 8.3 through 8.7 present summary statistics of the actual value and the change from baseline for systolic blood pressure, diastolic blood pressure, pulse rate, body weight, and height, respectively. Data are presented by treatment group, age group, and by visit, including endpoint. Individual patient data listings of all recorded vital sign values are provided in Appendix IX, Listing 14.

There were few cases of PCS values for blood pressure or pulse rate, and none of them continued to meet PCS criteria at the final visit. Two (2.2%) children in the citalopram group and 1 (1.2%) child in the placebo group had a PCS increase in systolic blood pressure. PCS decreases in systolic blood pressure occurred in 2 (2.2%) patients (1 child and 1 adolescent) in the citalopram group and in 1 (1.2%) adolescent in the placebo group. The mean change in systolic blood pressure at endpoint was -0.6 mmHg in the citalopram group and +2.2 mmHg in the placebo group. No patient in either treatment group had a PCS increase in diastolic blood pressure. One (1.1%) adolescent in the citalopram group and 2 (2.4%) adolescents in the placebo group had PCS decreases in diastolic blood pressure. The mean change in diastolic blood pressure at endpoint was -1.4 mmHg in the citalopram group and -0.8 mmHg in the placebo group. No patient had

a PCS increase in pulse rate and 1 (1.1%) child in the citalopram group had a PCS decrease in pulse rate. The mean change in pulse rate from baseline to endpoint was an increase of 1.4 bpm for both treatment groups.

None of the PCS values for vital signs were classified as AEs and no patient discontinued study drug due to PCS values. Only 1 adolescent in the citalopram group experienced a mild cardiovascular TEAE (flushing) that was considered by the investigator to be possibly related to study drug treatment.

Potentially clinically significant increases in body weight ≥7% in adolescents were infrequent, occurring in 2 (4.5%) adolescents in the citalopram group and 2 (4.3%) adolescents in the placebo group. Potentially clinically significant decreases ≥7% in body weight occurred only in 1 (2.3%) adolescent in the citalopram group. Overall, there was no mean change in body weight for patients in the citalopram group at endpoint; the mean change in the placebo group was an increase of 1.4 lb.

Appendix Table 12A presents the incidence of all vital sign values by treatment and age group that were identified as PCS on the basis of the adolescent criteria in Panel 5. Appendix Table 12B lists all patients with PCS vital sign values based on the adolescent criteria. One child in the placebo group and 2 children in the citalopram group had post-baseline systolic blood pressure readings between 75 and 90 mmHg that met the adolescent PCS criteria. Two children in the placebo group and 6 children in the citalopram group had post-baseline diastolic blood pressure readings between 40 and 50 mmHg that met the adolescent PCS criteria. One child in the citalopram group exhibited a weight increase ≥7% and two children in the citalopram group exhibited weight decreases ≥7%.

12.5 CLINICAL LABORATORY EVALUATION

Table 9.1 presents the incidence of all laboratory test results that were identified as PCS based on the criteria in Panel 6. Table 9.2 presents the screening value, the PCS value, and the final value for each patient who had a post-baseline laboratory test result that was considered PCS. Descriptive statistics for all laboratory parameters are presented, in SI units, in Table 9.3. For each treatment group, mean values and standard deviations are given at screening, at the final visit, and for the change from screening to the final visit. Individual patient data listings of screening and follow-up laboratory results and any investigator's comments are provided in Appendix IX, Listings 15 and 16.

Four patients in the citalopram group and 2 patients in the placebo group had PCS clinical laboratory values. One adolescent patient receiving citalopram exhibited elevations of ALT and AST to 117 IU/L and 197 IU/L, respectively. These values had returned to normal after 13 days of continued citalopram treatment in the extension study. The mean change from screening to endpoint in ALT was -1.1 IU/L in the placebo group and 0.6 IU/L in the citalopram group; the mean change in AST was -0.4 IU/L in the placebo group and 1.6 IU/L in the citalopram group. No patient was discontinued from the study because of a laboratory abnormality, and no AEs related to laboratory abnormalities were reported. The magnitude of the observed mean changes from screening to final value was not clinically noteworthy for any laboratory tests.

12.6 ELECTROCARDIOGRAMS

ECGs were evaluated on the basis of criteria in Panel 7. As shown in Tables 10.1 and 10.2, no PCS values were found. In addition, no ECG test results were considered to be AEs.

The emergence of any ECG abnormalities, regardless of clinical importance, is summarized by treatment group in Table 10.3. The percentage of patients with an ECG abnormality at screening was 27.5% (22/80) in the citalopram group and 23.7% (18/76) in the placebo group. The percentage of patients who had a normal ECG at screening and an ECG assessed as abnormal at endpoint was 13.8% (11/80) in the citalopram group and 11.8% (9/76) in the placebo group. Only one patient had a clinically significant ECG abnormality, a child (Patient 203) treated with placebo who had a normal ECG at screening (PR=172 msec, QT=388 msec, and QTc=445 msec) and an ECG judged by the investigator as abnormal clinically significant at the end of Week 8 visit (PR=144 msec, QT=412 msec, QTc=467 msec). An ECG recorded one day later was judged abnormal not clinically significant (PR=118 msec, QT=428 msec, QTc=488 msec).

Individual patient data listings of baseline and post-baseline ECG evaluation results are provided in Appendix IX, Listing 17. Individual patient data listings of ECG abnormalities are provided in Appendix IX, Listing 18.

Descriptive statistics for ECG parameters are presented in Table 10.4 for each treatment group; mean values and standard deviations are given at screening, at the final visit (endpoint), and for the change from screening to the final visit. The mean changes in ventricular heart rate, QRS interval, PR interval, QT interval, and QTc interval from screening to the final visit were small and clinically unimportant.

12.7 PHYSICAL EXAMINATION

Table 11.1 presents the number and percentage of patients with an abnormal value at the final visit by treatment group for patients with a normal or missing value (not done) at screening. The incidence of abnormal physical findings was low and similar among treatment groups.

Individual patient data are provided in Appendix IX, Listings 19 and 20.

12.8 CONCOMITANT MEDICATION

Table 12.1 shows the concomitant medications received by patients in each treatment and age group after the screening visit and before randomization. A total of 43 (48.3%) patients in the citalopram group and 44 (51.8%) patients in the placebo group received concomitant medications between screening and randomization. The most commonly used concomitant medications during this period were analgesics, anti-inflammatory drugs, and vitamins.

Table 12.2 shows the concomitant medications received by patients in each treatment and age group after randomization. A total of 70 (78.7%) patients in the citalopram group and 63 (74.1%) patients in the placebo group received concomitant medications during the double-blind treatment period. Overall, the use of concomitant medications was similar between treatment groups during the double-blind treatment period and comparable to that during the baseline period. The most commonly used concomitant medications were analgesics, anti-inflammatory drugs, antibiotics, antihistamines, and vitamins.

Individual patient data are provided in Appendix IX, Listings 21 through 23.

12.9 SAFETY CONCLUSIONS

No deaths occurred during the conduct of the study. There was one serious adverse event, in a placebo treated patient, and one clinically significant ECG abnormality, also in a placebo treated patient. The rate of discontinuation for adverse events was 5.6% in the citalopram group and 5.9% in the placebo group. Treatment emergent adverse events with a higher incidence in the citalopram group than the placebo group were typically either gastrointestinal symptoms (nausea and diarrhea) or respiratory disorders. Few psychiatric adverse events were reported, with little sign of CNS stimulation or depression. More than 98% of adverse events in each treatment group were mild or moderate in intensity. Citalopram's adverse event profile was generally similar in child and adolescent patients and in male and female patients. Analysis of laboratory, vital sign, body weight, and ECG parameters revealed a low incidence of PCS values in both treatment groups; the mean changes from baseline were clinically unremarkable.

13.0 DISCUSSION AND OVERALL CONCLUSIONS

Present results versus previous studies

The positive results obtained in the present study contradict the high failure rate found in antidepressant trials in patients under 18 years of age. Several factors may have contributed to the outcome of this study. First, citalopram treatment was tolerated by more than 94% of the patients treated, and 80% of the citalopram patients completed the full 8-week study. Good tolerability for the adult starting dose (20 mg/day) also allowed for flexible upward titration (to 40 mg/day), improving the opportunity to achieve effective citalopram plasma concentrations. Finally, the CDRS-R, which was employed in this study, is a sensitive and reliable efficacy instrument for depressed children and adolescents that utilizes convergent information from the child and parent/caregiver.

Time course of effect and dosing

The primary efficacy measure, the CDRS-R, revealed significantly greater improvement in the citalopram group relative to the placebo group at every clinic visit during double-blind treatment. Consistent citalopram-placebo differences were observed at the end of Week 4, before patients could be titrated above 20 mg/day, suggesting that 20 mg/day is an effective antidepressant dose in children and adolescents. Less consistent effects on secondary efficacy measures were observed at the end of Week 8. However, less robust treatment effects at the end of Week 8 are probably not attributable to upward titration to 40 mg/day citalopram. Worsened scores from the end of Week 6 to the end of Week 8 in children receiving either citalopram or placebo may have been due to the extensive set of procedures administered at the final visit.

Validity

The study was designed to provide a valid, prospectively randomized, double-blind comparison of the treatment effects of citalopram and placebo. A medication packaging error partially compromised the study blind for 9 of the 174 patients. Post-hoc analysis excluding these patients supported the results from the intent-to-treat analysis. It is concluded that the study results are valid and interpretable.

Age effects

The safety profile of citalopram was generally similar in the children and adolescents, even though nausea occurred as a treatment emergent adverse event in only one of 45 citalopram-treated children. The magnitude of the mean citalopram-placebo differences on the efficacy ratings was numerically higher in the adolescents than in the children, but no significant treatment-by-age group interactions were observed, indicating that the citalopram treatment effect was not age dependent. Plasma concentrations of citalopram were 13% higher in the children as compared to the adolescents, but no significant correlation was found between plasma concentrations and age or body weight.

Safety versus adults
The safety profile of citalopram in depressed children and adolescents in the present study was generally similar to the one described for depressed adults in citalopram NDA 20-822 and the citalopram package insert. No new medical issues were identified in this study. The incidence of psychiatric adverse events, such as somnolence and insomnia, and the incidence of sexual dysfunction was lower in citalopram-treated children and adolescents than citalopram-treated adults, but these differences may be attributable to the reporting characteristics of the two populations.

Overall conclusion
The results of this study support the conclusion that citalopram, 20–40 mg/day, is safe and efficacious in the treatment of major depressive disorder in children and adolescents.

Forest Laboratories, Inc.
Protocol CIT-MD-18

Citalopram
10/30/2001 (Page 1 of 1)

Table 3.1

Primary Efficacy
Change from Baseline in CDRS-R after 8 Weeks
ITT Population - LOCF

	Placebo			Citalopram					
	Children (N=38)	Adolescents (N=47)	Total (N=85)	Children (N=45)	Adolescents (N=44)	Total (N=89)	LSMD	95% CI	p-value
Baseline									
Mean	56.8	58.6	57.8	60.0	57.5	58.8			
N	38	47	85	45	44	89			
SD	10.31	11.75	11.10	10.90	10.93	10.93			
SEM	1.67	1.71	1.20	1.63	1.65	1.16			
Median	56.5	56.0	56.0	58.0	56.0	57.0			
Range	40, 92	40, 92	40, 92	40, 95	41, 79	40, 95			
Week 8									
Mean	39.1	43.2	41.4	39.2	34.9	37.0			
N	38	47	85	45	44	89			
SD	14.22	17.55	16.19	15.19	13.67	14.53			
SEM	2.31	2.56	1.76	2.26	2.06	1.54			
Median	37.0	40.0	38.0	43.0	30.0	34.0			
Range	18, 67	17, 82	17, 82	17, 74	17, 84	17, 84			
Week 8 - Baseline									
Mean	-17.8	-15.4	-16.5	-20.9	-22.6	-21.7	4.6	[0.3, 9.0]	0.038
N	38	47	85	45	44	89			
SD	14.71	15.24	14.96	15.25	14.46	14.81			
SEM	2.39	2.22	1.62	2.27	2.18	1.57			
Median	-20.0	-15.0	-17.0	-20.0	-19.5	-20.0			
Range	-46, 12	-55, 14	-55, 14	-67, 7	-58, 5	-67, 7			

Note: Statistical inferences are from three-way ANCOVA model with treatment, age group and center as factors and baseline score as covariate. LSMD indicates the difference of least-squares means between treatments; CI = Confidence Interval for the LSMD. P-value is for the between-treatment comparison.

Report Generated by Program: /sasprog/cit/citmd18/programs/tables/teff8bs.sas

Forest Laboratories, Inc.
Protocol CIT-MD-18

Citalopram
10/30/2001 (Page 1 of 1)

Table 3.2

Secondary Efficacy
CGI Improvement after 8 Weeks
ITT Population - LOCF

	Placebo			Citalopram					
	Children (N=38)	Adolescents (N=47)	Total (N=85)	Children (N=45)	Adolescents (N=44)	Total (N=89)	LSMD	95% CI	p-value
Week 8									
Mean	2.68	2.89	2.80	2.73	2.36	2.55	0.2	[-0.2, 0.6]	0.257
N	38	47	85	45	44	89			
SD	1.118		1.289	1.213	1.232	1.036		1.148	
SEM	0.181	0.188	0.132	0.184	0.156	0.122			
Median	3.00	3.00	3.00	3.00	2.00	3.00			
Range	1, 5	1, 6	1, 6	1, 5	1, 4	1, 5			

Note: Statistical inferences are from three-way ANOVA model with treatment, age group and center as factors.
LSMD indicates the difference of least-squares means between treatments; CI = Confidence Interval for the LSMD. P-value is for the between-treatment comparison.

Report Generated by Program: /sasprog/cit/citmd18/programs/tables/teff8bs.sas

Table 3.3

Secondary Efficacy
Change from Baseline in CGI Severity after 8 Weeks
ITT Population - LOCF

	Placebo			Citalopram					
	Children (N=38)	Adolescents (N=47)	Total (N=85)	Children (N=45)	Adolescents (N=44)	Total (N=89)	LSMD	95% CI	p-value
Baseline									
Mean	4.29	4.36	4.33	4.38	4.34	4.36			
N	38	47	85	45	44	89			
SD	0.460	0.568	0.521	0.650	0.479	0.569			
SEM	0.075	0.083	0.056	0.097	0.072	0.060			
Median	4.00	4.00	4.00	4.00	4.00	4.00			
Range	4, 5	4, 6	4, 6	3, 6	4, 5	3, 6			
Week 8									
Mean	3.24	3.30	3.27	3.20	2.91	3.06			
N	38	47	85	45	44	89			
SD	1.101	1.301	1.209	1.325	1.217	1.274			
SEM	0.179	0.190	0.131	0.197	0.183	0.135			
Median	3.50	3.00	3.00	4.00	3.00	3.00			
Range	1, 5	1, 6	1, 6	1, 6	1, 5	1, 6			
Week 8 - Baseline									
Mean	-1.05	-1.06	-1.06	-1.18	-1.43	-1.30	0.2	[-0.2, 0.6]	0.266
N	38	47	85	45	44	89			
SD	1.138	1.358	1.257	1.319	1.149	1.238			
SEM	0.185	0.198	0.136	0.197	0.173	0.131			
Median	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00			
Range	-4, 0	-4, 1	-4, 1	-5, 1	-4, 0	-5, 1			

Note: Statistical inferences are from three-way ANCOVA model with treatment, age group and center as factors and baseline score as covariate.
LSMD indicates the difference of least-squares means between treatments; CI = Confidence Interval for the LSMD. P-value is for the between-treatment comparison.

Report Generated by Program: /sasprog/cit/citmd18/programs/tables/teff8bs.sas

Table 3.4

Secondary Efficacy
Change from Baseline in CGAS after 8 Weeks
ITT Population - LOCF

	Placebo			Citalopram					
	Children (N=38)	Adolescents (N=47)	Total (N=85)	Children (N=45)	Adolescents (N=44)	Total (N=89)	LSMD	95% CI	p-value
Baseline									
Mean	52.2	51.5	51.8	50.6	51.4	51.0			
N	35	46	81	45	42	87			
SD	5.79	7.90	7.04	7.42	7.56	7.46			
SEM	0.98	1.16	0.78	1.11	1.17	0.80			
Median	51.0	51.5	51.0	50.0	50.0	50.0			
Range	41, 65	35, 65	35, 65	40, 70	30, 75	30, 75			
Week 8									
Mean	62.9	64.1	63.6	62.4	68.3	65.2			
N	35	46	81	45	42	87			
SD	12.45	13.94	13.25	15.85	13.94	15.16			
SEM	2.10	2.06	1.47	2.36	2.15	1.63			
Median	60.0	60.0	60.0	60.0	71.0	65.0			
Range	42, 86	40, 95	40, 95	40, 91	40, 95	40, 95			
Week 8 - Baseline									
Mean	10.7	12.6	11.8	11.8	16.9	14.3	-2.0	[-6.0, 1.9]	0.309
N	35	46	81	45	42	87			
SD	11.34	13.93	12.84	15.36	12.89	14.37			
SEM	1.92	2.05	1.43	2.29	1.99	1.54			
Median	6.0	10.0	10.0	5.0	16.5	10.0			
Range	-3, 39	-10, 45	-10, 45	-8, 50	-5, 45	-8, 50			

Note: Statistical inferences are from three-way ANCOVA model with treatment, age group and center as factors and baseline score as covariate.
LSMD indicates the difference of least-squares means between treatments; CI = Confidence Interval for the LSMD. P-value is for the between-treatment comparison.
Only patients with baseline and at least one post-baseline assessment are included.

Report Generated by Program: /sasprog/cit/citmd18/programs/tables/teff8bs.sas

Table 3.5

Secondary Efficacy
Change from Baseline in K-SADS-P Depression Module after 8 Weeks
ITT Population - LOCF

	Placebo			Citalopram					
	Children (N=38)	Adolescents (N=47)	Total (N=85)	Children (N=45)	Adolescents (N=44)	Total (N=89)	LSMD	95% CI	p-value
Baseline									
Mean	28.0	29.1	28.6	28.4	29.2	28.8			
N	33	44	77	42	40	82			
SD	3.46	6.01	5.08	5.55	5.29	5.41			
SEM	0.60	0.91	0.58	0.86	0.84	0.60			
Median	28.0	29.5	29.0	28.0	30.0	28.0			
Range	20, 37	17, 43	17, 43	18, 43	21, 40	18, 43			
Week 8									
Mean	20.4	22.3	21.5	20.8	18.5	19.6			
N	33	44	77	42	40	82			
SD	6.35	8.14	7.44	8.00	6.66	7.42			
SEM	1.11	1.23	0.85	1.23	1.05	0.82			
Median	20.0	22.0	21.0	22.5	17.0	18.0			
Range	9, 32	9, 44	9, 44	9, 36	9, 35	9, 36			
Week 8 - Baseline									
Mean	-7.6	-6.8	-7.2	-7.6	-10.7	-9.1	1.9	[-0.4, 4.2]	0.105
N	33	44	77	42	40	82			
SD	7.31	8.30	7.85	8.82	6.04	7.70			
SEM	1.27	1.25	0.89	1.36	0.96	0.85			
Median	-9.0	-7.0	-7.0	-6.0	-10.0	-8.0			
Range	-26, 7	-23, 12	-26, 12	-32, 10	-26, 0	-32, 10			

Note: Statistical inferences are from three-way ANCOVA model with treatment, age group and center as factors and baseline score as covariate.
LSMD indicates the difference of least-squares means between treatments; CI = Confidence Interval for the LSMD. P-value is for the between-treatment comparison.
Only patients with baseline and at least one post-baseline assessment are included.

Report Generated by Program: /sasprog/cit/citmd18/programs/tables/teff8bs.sas

Table 4.1A

Change from Baseline by Visit for CDRS-R
ITT Population - LOCF

	Placebo			Citalopram					
	Children (N=38)	Adolescents (N=47)	Total (N=85)	Children (N=45)	Adolescents (N=44)	Total (N=89)	LSMD	95% CI	p-value
Baseline									
Mean	56.8	58.6	57.8	60.0	57.5	58.8			
N	38	47	85	45	44	89			
SD	10.31	11.75	11.10	10.90	10.93	10.93			
SEM	1.67	1.71	1.20	1.63	1.65	1.16			
Median	56.5	56.0	56.0	58.0	56.0	57.0			
Range	40, 92	40, 92	40, 92	40, 95	41, 79	40, 95			
Week 1 - Baseline									
Mean	-9.1	-5.0	-6.9	-11.0	-9.6	-10.3	3.2	[0.7, 5.8]	0.011
N	38	47	85	45	44	89			
SD	9.99	7.40	8.84	9.00	9.30	9.12			
SEM	1.62	1.08	0.96	1.34	1.40	0.97			
Median	-6.0	-5.0	-6.0	-10.0	-9.0	-9.0			
Range	-38, 3	-25, 14	-38, 14	-41, 2	-30, 12	-41, 12			
Week 2 - Baseline									
Mean	-13.4	-11.3	-12.2	-16.7	-15.3	-16.0	3.7	[0.6, 6.7]	0.020
N	38	47	85	45	44	89			
SD	12.05	10.08	10.99	11.43	9.48	10.48			
SEM	1.96	1.47	1.19	1.70	1.43	1.11			
Median	-10.5	-10.0	-10.0	-15.0	-15.0	-15.0			
Range	-47, 12	-39, 14	-47, 14	-52, 1	-32, 5	-52, 5			

Note: Statistical inferences are from three-way ANCOVA model with treatment, age group and center as factors and baseline score as covariate. LSMD indicates the difference of least-squares means between treatments; CI = Confidence Interval for the LSMD. p-values are for between-treatment comparisons.

Report Generated by Program: /sasprog/cit/citmd18/programs/tables/teffvisa.sas

Table 4.1A
Change from Baseline by Visit for CDRS-R
ITT Population - LOCF

	Placebo			Citalopram					
	Children (N=38)	Adolescents (N=47)	Total (N=85)	Children (N=45)	Adolescents (N=44)	Total (N=89)	LSMD	95% CI	p-value
Week 4 - Baseline									
Mean	-17.0	-10.9	-13.7	-20.9	-17.0	-19.0	4.4	[1.0, 7.8]	0.012
N	38	47	85	45	44	89			
SD	13.47	11.71	12.82	13.42	11.67	12.66			
SEM	2.19	1.71	1.39	2.00	1.76	1.34			
Median	-16.0	-10.0	-13.0	-21.0	-15.5	-17.0			
Range	-63, 12	-39, 14	-63, 14	-58, 7	-44, 7	-58, 7			
Week 6 - Baseline									
Mean	-19.2	-13.3	-16.0	-22.6	-21.8	-22.2	5.5	[1.8, 9.3]	0.004
N	38	47	85	45	44	89			
SD	14.47	14.13	14.50	14.23	11.88	13.05			
SEM	2.35	2.06	1.57	2.12	1.79	1.38			
Median	-18.0	-13.0	-15.0	-21.0	-19.0	-19.0			
Range	-52, 12	-36, 14	-52, 14	-66, 7	-50, -2	-66, 7			
Week 8 - Baseline									
Mean	-17.8	-15.4	-16.5	-20.9	-22.6	-21.7	4.6	[0.3, 9.0]	0.038
N	38	47	85	45	44	89			
SD	14.71	15.24	14.96	15.25	14.46	14.81			
SEM	2.39	2.22	1.62	2.27	2.18	1.57			
Median	-20.0	-15.0	-17.0	-20.0	-19.5	-20.0			
Range	-46, 12	-55, 14	-55, 14	-67, 7	-58, 5	-67, 7			

Note: Statistical inferences are from three-way ANCOVA model with treatment, age group and center as factors and baseline score as covariate. LSMD indicates the difference of least-squares means between treatments; CI = Confidence Interval for the LSMD. p-values are for between-treatment comparisons.

Report Generated by Program: /sasprog/cit/citmd18/programs/tables/teffvisa.sas

Table 4.1B

Change from Baseline by Visit for CDRS-R
ITT Population - Observed Cases

	Placebo			Citalopram					
	Children (N=38)	Adolescents (N=47)	Total (N=85)	Children (N=45)	Adolescents (N=44)	Total (N=89)	LSMD	95% CI	p-value
Baseline									
Mean	56.8	58.6	57.8	60.0	57.5	58.8			
N	38	47	85	45	44	89			
SD	10.31	11.75	11.10	10.90	10.93	10.93			
SEM	1.67	1.71	1.20	1.63	1.65	1.16			
Median	56.5	56.0	56.0	58.0	56.0	57.0			
Range	40, 92	40, 92	40, 92	40, 95	41, 79	40, 95			
Week 1 - Baseline									
Mean	-9.3	-5.3	-7.1	-11.2	-10.3	-10.8	3.1	[0.6, 5.7]	0.017
N	37	45	82	44	41	85			
SD	10.01	7.49	8.90	8.94	9.25	9.05			
SEM	1.65	1.12	0.98	1.35	1.44	0.98			
Median	-6.0	-6.0	-6.0	-10.0	-9.0	-10.0			
Range	-38, 3	-25, 14	-38, 14	-41, 2	-30, 12	-41, 12			
Week 2 - Baseline									
Mean	-13.8	-12.3	-13.0	-16.7	-15.4	-16.1	2.9	[-0.1, 6.0]	0.060
N	37	44	81	45	43	88			
SD	11.98	9.28	10.55	11.43	9.57	10.52			
SEM	1.97	1.40	1.17	1.70	1.46	1.12			
Median	-11.0	-11.5	-11.0	-15.0	-15.0	-15.0			
Range	-47, 12	-39, 6	-47, 12	-52, 1	-32, 5	-52, 5			

Note: Statistical inferences are from three-way ANCOVA model with treatment, age group and center as factors and baseline score as covariate. LSMD indicates the difference of least-squares means between treatments; CI = Confidence Interval for the LSMD. p-values are for between-treatment comparisons.

Report Generated by Program: /sasprog/cit/citmd18/programs/tables/teffvisa.sas

Table 4.1B
Change from Baseline by Visit for CDRS-R
ITT Population - Observed Cases

	Placebo			Citalopram					
	Children (N=38)	Adolescents (N=47)	Total (N=85)	Children (N=45)	Adolescents (N=44)	Total (N=89)	LSMD	95% CI	p-value
Week 4 - Baseline									
Mean	-17.5	-11.4	-14.0	-21.5	-17.8	-19.7	4.1	[0.6, 7.6]	0.021
N	33	45	78	43	40	83			
SD	13.21	11.35	12.46	13.39	11.96	12.78			
SEM	2.30	1.69	1.41	2.04	1.89	1.40			
Median	-16.0	-10.0	-12.5	-21.0	-16.0	-19.0			
Range	-63, -3	-39, 11	-63, 11	-58, 7	-44, 7	-58, 7			
Week 6 - Baseline									
Mean	-19.9	-14.6	-16.9	-25.2	-23.4	-24.3	5.4	[1.5, 9.4]	0.007
N	32	41	73	33	36	69			
SD	13.99	13.58	13.92	13.77	11.83	12.73			
SEM	2.47	2.12	1.63	2.40	1.97	1.53			
Median	-18.0	-14.0	-15.0	-23.0	-19.0	-21.0			
Range	-52, 10	-36, 10	-52, 10	-66, -6	-50, -2	-66, -2			
Week 8 - Baseline									
Mean	-18.9	-18.8	-18.9	-22.8	-22.9	-22.8	3.3	[-1.4, 7.9]	0.167
N	32	37	69	38	35	73			
SD	14.68	14.35	14.40	15.25	14.33	14.71			
SEM	2.59	2.36	1.73	2.47	2.42	1.72			
Median	-20.5	-18.0	-20.0	-21.0	-22.0	-21.0			
Range	-46, 12	-55, 7	-55, 12	-67, 1	-58, 5	-67, 5			

Note: Statistical inferences are from three-way ANCOVA model with treatment, age group and center as factors and baseline score as covariate. LSMD indicates the difference of least-squares means between treatments; CI = Confidence Interval for the LSMD. p-values are for between-treatment comparisons.

Report Generated by Program: /sasprog/cit/citmd18/programs/tables/teffvisa.sas

Forest Laboratories, Inc.
Protocol CIT-MD-18

Citalopram
09/05/2001 (Page 1 of 1)

Appendix Table 5
Treatment-by-Age Group Interaction
ITT Population - LOCF

Efficacy Parameter	Treatment by Age Group Interaction p-value
CDRS-R	0.136
CGI-I	0.142
CGI-Severity	0.446
CGAS	0.366
K-SADS-P Depression Module	0.124

Note: p-values are from three-way ANCOVA model with treatment, age group, center, treatment-by-age group interaction as factors and baseline score as covariate, and week 8 change from baseline as response variable.
For CGI-I, p-value is from three-way ANOVA model with treatment, age group, center, treatment-by-age group interaction as factors and Week 8 assessment as response variable

Report Generated by Program: /sasprog/cit/citmd18/programs/tables/apndx5.sas

Forest Laboratories, Inc.
Protocol CIT-MD-18

09/12/2001 Citalopram (Page 1 of 1)

Appendix Table 6
Change from Baseline in CDRS-R after 8 Weeks
ITT Sub-population - LOCF

	Placebo			Citalopram					
	Children (N=37)	Adolescents (N=44)	Total (N=81)	Children (N=43)	Adolescents (N=42)	Total (N=85)	LSMD	95% CI	p-value
Baseline									
Mean	55.9	57.8	56.9	59.2	56.9	58.1			
N	37	44	81	43	42	85			
SD	8.60	10.91	9.91	10.39	10.62	10.51			
SEM	1.41	1.65	1.10	1.58	1.64	1.14			
Median	56.0	56.0	56.0	58.0	56.0	57.0			
Range	40, 77	40, 79	40, 79	40, 95	41, 79	40, 95			
Week 8									
Mean	38.6	42.2	40.5	40.2	33.2	36.7			
N	37	44	81	43	42	85			
SD	14.13	17.33	15.96	14.77	11.16	13.49			
SEM	2.32	2.61	1.77	2.25	1.72	1.46			
Median	36.0	37.0	36.0	44.0	30.0	34.0			
Range	18, 67	17, 82	17, 82	17, 74	17, 57	17, 74			
Week 8 - Baseline									
Mean	-17.3	-15.6	-16.4	-19.1	-23.6	-21.3	4.3	[-0.0, 8.5]	0.052
N	37	44	81	43	42	85			
SD	14.59	15.69	15.13	12.91	13.95	13.55			
SEM	2.40	2.37	1.68	1.97	2.15	1.47			
Median	-20.0	-14.5	-17.0	-20.0	-21.0	-20.0			
Range	-46, 12	-55, 14	-55, 14	-49, 7	-58, -4	-58, 7			

Note: Patients (105, 113, 114, 505, 506, 507, 509, 513, 514) with drug dispensing error are excluded.
Statistical inferences are from three-way ANCOVA model with treatment, age group and center as factors and baseline score as covariate.
LSMD indicates the difference of least-squares means between treatments; CI = Confidence Interval for the LSMD. P-value is for the between-treatment comparison.

Report Generated by Program: /sasprog/cit/citmd18/programs/tables/apndx6.sas

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
101	14	Citalopram	Children	05/03/2000	04/27/2000		Screening		70.00						
				06/27/2000	05/03/2000		Baseline		45.00			4.00		60.00	30.00
					05/10/2000	8	Week 1	Week 1	41.00	No	4.00	4.00	No		
					05/17/2000	15	Week 2	Week 2	36.00	No	4.00	4.00	No		
					06/01/2000	30	Week 4	Week 4	31.00	No	3.00	3.00	No	80.00	
					06/14/2000	43	Week 6	Week 6	31.00	No	3.00	3.00	No		
					06/28/2000	57	Week 8	Week 8	27.00	Yes	1.00	2.00	Yes	85.00	12.00
102	14	Placebo	Children	06/22/2000	06/14/2000		Screening		48.00						
				08/20/2000	06/22/2000		Baseline		41.00			4.00		50.00	28.00
					06/29/2000	8	Week 1	Week 1	39.00	No	4.00	4.00	No		
					07/06/2000	15	Week 2	Week 2	43.00	No	4.00	4.00	No		
					07/20/2000	29	Week 4	Week 4	37.00	No	4.00	4.00	No	50.00	
					08/03/2000	43	Week 6	Week 6	36.00	No	4.00	4.00	No		
					08/23/2000	63	Week 8	Week 8	53.00	No	4.00	4.00	No	50.00	24.00
103	14	Placebo	Children	08/02/2000	07/27/2000		Screening		48.00						
				09/28/2000	08/02/2000		Baseline		40.00			4.00		60.00	26.00
					08/10/2000	9	Week 1	Week 1	43.00	No	4.00	4.00	No		
					08/15/2000	14	Week 2	Week 2	29.00	No	2.00	3.00	Yes		
					08/31/2000	30	Week 4	Week 4	30.00	No	2.00	3.00	Yes	75.00	
					09/14/2000	44	Week 6	Week 6	27.00	Yes	2.00	3.00	Yes		
					09/29/2000	59	Week 8	Week 8	27.00	Yes	2.00	3.00	Yes	75.00	15.00
104&	14	Citalopram	Children		11/06/2000		Screening		46.00						
					11/16/2000		Baseline		45.00			4.00		60.00	20.00
105	02	Citalopram	Children	02/07/2000	01/31/2000		Screening		88.00						
				04/02/2000	02/07/2000		Baseline		84.00			6.00		40.00	43.00
					02/14/2000	8	Week 1	Week 1	51.00	No	3.00	5.00	No		
					02/21/2000	15	Week 2	Week 2	32.00	No	2.00	3.00	Yes		

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
105	02	Citalopram	Children		03/06/2000	29	Week 4	Week 4	26.00	Yes	2.00	2.00	Yes	80.00	
					03/20/2000	43	Week 6	Week 6	18.00	Yes	1.00	1.00	Yes		
					04/03/2000	57	Week 8	Week 8	17.00	Yes	1.00	1.00	Yes	90.00	11.00
113	16	Placebo	Children	02/07/2000	01/31/2000		Screening		67.00						
				04/05/2000	02/07/2000		Baseline		92.00			5.00		55.00	30.00
					02/14/2000	8	Week 1	Week 1	59.00	No	3.00	4.00	No		
					02/23/2000	17	Week 2	Week 2	45.00	No	2.00	3.00	Yes		
					03/09/2000	32	Week 4	Week 4	29.00	No	2.00	3.00	Yes	60.00	
					03/24/2000	47	Week 6	Week 6	40.00	No	2.00	3.00	Yes		
					04/06/2000	60	Week 8	Week 8	56.00	No	3.00	4.00	No	60.00	25.00
114	16	Citalopram	Children	02/23/2000	02/16/2000		Screening		78.00						
				04/19/2000	02/23/2000		Baseline		70.00			4.00		55.00	30.00
					03/02/2000	9	Week 1	Week 1	47.00	No	3.00	4.00	No		
					03/08/2000	15	Week 2	Week 2	34.00	No	2.00	3.00	Yes		
					03/23/2000	30	Week 4	Week 4	17.00	Yes	1.00	2.00	Yes	75.00	
					04/05/2000	43	Week 6	Week 6	20.00	Yes	1.00	1.00	Yes		
					04/20/2000	58	Week 8	Week 8	18.00	Yes	1.00	1.00	Yes	80.00	9.00
115	16	Citalopram	Children	06/27/2000	06/23/2000		Screening		98.00						
				08/24/2000	06/27/2000		Baseline		95.00			6.00		45.00	39.00
					07/06/2000	10	Week 1	Week 1	79.00	No	4.00	6.00	No		
					07/14/2000	18	Week 2	Week 2	76.00	No	4.00	6.00	No		
					07/25/2000	29	Week 4	Week 4	68.00	No	3.00	4.00	No	50.00	
					08/08/2000	43	Week 6	Week 6	58.00	No	3.00	4.00	No		
					08/25/2000	60	Week 8	Week 8	74.00	No	5.00	6.00	No	45.00	36.00
116	16	Placebo	Children	12/04/2000	11/21/2000		Screening		58.00						
				01/29/2001	12/04/2000		Baseline		60.00			4.00		55.00	30.00
					12/08/2000	5	Week 1	Week 1	47.00	No	3.00	4.00	No		

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit CRF	Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
116	16	Placebo	Children		12/14/2000	11	Week 2	Week 2	35.00	No	3.00	4.00	No		
					12/28/2000	25	Week 4	Week 4	23.00	Yes	2.00	3.00	Yes	58.00	
					01/29/2001	57	Week 8	Week 8	33.00	No	2.00	3.00	Yes	58.00	20.00
117	13	Placebo	Children	03/20/2000	03/14/2000		Screening		50.00						
				05/14/2000	03/20/2000		Baseline		50.00			4.00		51.00	30.00
					03/27/2000	8	Week 1	Week 1	46.00	No	4.00	4.00	No		
					04/06/2000	18	Week 2	Week 2	33.00	No	2.00	3.00	Yes		
					04/17/2000	29	Week 4	Week 4	25.00	Yes	2.00	3.00	Yes	60.00	
					04/27/2000	39	Week 6	Week 6	29.00	No	2.00	3.00	Yes		
					05/15/2000	57	Week 8	Week 8	18.00	Yes	2.00	3.00	Yes	80.00	9.00
118	13	Citalopram	Children	03/30/2000	03/17/2000		Screening		53.00						
				05/03/2000	03/30/2000		Baseline		65.00			4.00		45.00	30.00
					04/06/2000	8	Week 1	Week 1	53.00	No	3.00	4.00	No		
					04/14/2000	16	Week 2	Week 2	52.00	No	3.00	4.00	No		
					05/04/2000	36	Week 4	Week 6	49.00	No	3.00	4.00	No	50.00	
119&	13	Citalopram	Children		11/21/2000		Screening		62.00						
					11/28/2000		Baseline		51.00			4.00		50.00	30.00
120	13	Placebo	Children	11/02/2000	10/27/2000		Screening		51.00						
				01/01/2001	11/02/2000		Baseline		52.00			4.00		53.00	26.00
					11/08/2000	7	Week 1	Week 1	32.00	No	2.00	3.00	Yes		
					11/15/2000	14	Week 2	Week 2	40.00	No	3.00	4.00	No		
					11/29/2000	28	Week 4	Week 4	47.00	No	4.00	4.00	No	55.00	
					12/18/2000	47	Week 6	Week 6	53.00	No	4.00	4.00	No		
					01/02/2001	62	Week 8	Week 8	52.00	No	3.00	4.00	No	55.00	22.00
121	09	Placebo	Children	03/29/2000	03/23/2000		Screening		55.00						
				05/25/2000	03/29/2000		Baseline		48.00			4.00		51.00	26.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	____Visit Name_____ CRF	DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
121	09	Placebo	Children		04/05/2000	8	Week 1	Week 1	42.00	No	3.00	4.00	No		
					04/12/2000	15	Week 2	Week 2	29.00	No	2.00	3.00	Yes		
					04/25/2000	28	Week 4	Week 4	43.56	No	3.00	4.00	No	55.00	
					05/10/2000	43	Week 6	Week 6	21.00	Yes	1.00	2.00	Yes		
					05/26/2000	59	Week 8	Week 8	19.00	Yes	1.00	1.00	Yes	61.00	13.00
125	01	Citalopram	Children	10/25/2000	10/19/2000		Screening		54.00						
				12/16/2000	10/25/2000		Baseline		50.00			4.00		70.00	24.00
					11/01/2000	8	Week 1	Week 1	40.00	No	3.00	4.00	No		
					11/08/2000	15	Week 2	Week 2	32.00	No	2.00	3.00	Yes		
					11/21/2000	28	Week 4	Week 4	37.00	No	2.00	3.00	Yes	72.00	
					12/05/2000	42	Week 6	Week 6	29.00	No	2.00	3.00	Yes		
					12/20/2000	57	Week 8	Week 8	30.00	No	2.00	2.00	Yes	75.00	20.00
133	06	Placebo	Children	08/04/2000	07/27/2000		Screening		58.00						
				09/26/2000	08/03/2000		Baseline		56.00			4.00		50.00	30.00
					08/09/2000	6	Week 1	Week 1	48.00	No	2.00	3.00	Yes		
					08/17/2000	14	Week 2	Week 2	39.00	No	2.00	3.00	Yes		
					08/30/2000	27	Week 4	Week 4	34.00	No	2.00	2.00	Yes	63.00	
					09/13/2000	41	Week 6	Week 6	31.00	No	2.00	2.00	Yes		
					09/27/2000	55	Week 8	Week 8	31.00	No	1.00	2.00	Yes	70.00	18.00
134	06	Citalopram	Children	12/06/2000	11/17/2000		Screening		57.00						
				01/29/2001	12/06/2000		Baseline		57.00			4.00		55.00	18.00
					12/13/2000	8	Week 1	Week 1	52.00	No	4.00	4.00	No		
					12/20/2000	15	Week 2	Week 2	53.00	No	3.00	4.00	No		
					01/05/2001	31	Week 4	Week 4	34.00	No	2.00	3.00	Yes	65.00	
					01/17/2001	43	Week 6	Week 6	48.00	No	3.00	4.00	No		
					01/30/2001	56	Week 8	Week 8	50.00	No	4.00	4.00	No	54.00	22.00
135	06	Citalopram	Children	01/19/2001	01/11/2001		Screening		70.00						

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
135	06	Citalopram	Children	03/15/2001	01/19/2001		Baseline		68.00			4.00		50.00	31.00
					01/26/2001	8	Week 1	Week 1	55.00	No	3.00	4.00	No		
					01/31/2001	13	Week 2	Week 2	53.00	No	3.00	4.00	No		
					02/16/2001	29	Week 4	Week 4	57.00	No	3.00	4.00	No	50.00	
					03/02/2001	43	Week 6	Week 6	52.00	No	3.00	4.00	No		
					03/16/2001	57	Week 8	Week 8	53.00	No	5.00	4.00	No	45.00	27.00
137	18	Placebo	Children	08/07/2000	07/25/2000		Screening		44.00						
				09/08/2000	08/07/2000		Baseline		40.00			4.00		56.00	23.00
					08/11/2000	5	Week 1	Week 1	41.00	No	3.00	4.00	No		
					08/28/2000	22	Week 4	Week 4	33.00	No	2.00	3.00	Yes	63.00	
					09/21/2000	46	Week 8	Week 6	35.00	No	4.00	4.00	No	53.00	19.00
138	18	Citalopram	Children	08/29/2000	08/18/2000		Screening		46.00						
				10/23/2000	08/28/2000		Baseline		40.00			4.00		63.00	18.00
					09/01/2000	4	Week 1	Week 1	25.00	Yes	2.00	3.00	Yes		
					09/08/2000	11	Week 2	Week 2	26.00	Yes	3.00	3.00	No		
					09/22/2000	25	Week 4	Week 4	34.00	No	3.00	3.00	No	65.00	
					10/10/2000	43	Week 6	Week 6	22.00	Yes	1.00	1.00	Yes		
					10/23/2000	56	Week 8	Week 8	20.00	Yes	1.00	1.00	Yes	68.00	12.00
141	12	Placebo	Children	04/04/2000	03/27/2000		Screening		77.00						
				05/31/2000	04/03/2000		Baseline		60.00			4.00		60.00	37.00
					04/13/2000	10	Week 1	Week 1	36.00	No	3.00	3.00	No		
					04/18/2000	15	Week 2	Week 2	25.00	Yes	2.00	2.00	Yes		
					05/02/2000	29	Week 4	Week 4	22.00	Yes	2.00	2.00	Yes	75.00	
					05/12/2000	39	Week 6	Week 6	22.00	Yes	2.00	2.00	Yes		
					06/01/2000	59	Week 8	Week 8	19.00	Yes	1.00	1.00	Yes	80.00	11.00
143	12	Citalopram	Children	08/18/2000	08/10/2000		Screening		50.00						
				10/19/2000	08/17/2000		Baseline		57.00			4.00		55.00	23.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	____Visit Name_____ CRF	DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
143	12	Citalopram	Children		08/24/2000	7	Week 1	Week 1	47.00	No	3.00	4.00	No		
					09/06/2000	20	Week 2	Week 2	37.00	No	2.00	4.00	Yes		
					09/21/2000	35	Week 4	Week 4	43.00	No	3.00	4.00	No	55.00	
					10/05/2000	49	Week 6	Week 8	43.00	No	3.00	4.00	No		
					10/19/2000	63	Week 8	Week 8	42.00	No	3.00	4.00	No	60.00	18.00
144	12	Citalopram	Children	01/18/2001	01/05/2001		Screening		63.00						
				03/10/2001	01/17/2001		Baseline		49.00			4.00		50.00	23.00
					01/22/2001	5	Week 1	Week 1	46.00	No	4.00	4.00	No		
					01/29/2001	12	Week 2	Week 2	30.00	No	3.00	3.00	No		
					02/14/2001	28	Week 4	Week 4	22.00	Yes	2.00	2.00	Yes	70.00	
					02/26/2001	40	Week 6	Week 6	24.00	Yes	2.00	2.00	Yes		
					03/21/2001	63	Week 8	Week 8	50.00	No	4.00	5.00	No	50.00	33.00
145	10	Citalopram	Children	05/23/2000	05/16/2000		Screening		71.00						
				07/27/2000	05/23/2000		Baseline		46.00			3.00		55.00	18.00
					05/30/2000	8	Week 1	Week 1	34.00	No	2.00	2.00	Yes		
					06/06/2000	15	Week 2	Week 2	22.31	Yes	2.00	1.00	Yes		
					06/20/2000	29	Week 4	Week 4	19.00	Yes	1.00	1.00	Yes	70.00	
					07/18/2000	57	Week 6	Week 8	19.13	Yes	1.00	1.00	Yes		
					07/28/2000	67	Week 8	Week 8	19.13	Yes	1.00	1.00	Yes	70.00	12.00
146	10	Placebo	Children	12/27/2000	12/18/2000		Screening		53.00						
				02/18/2001	12/27/2000		Baseline		56.00			4.00		50.00	24.00
					01/02/2001	7	Week 1	Week 1	41.44	No	3.00	4.00	No		
					01/08/2001	13	Week 2	Week 2	42.00	No	2.00	3.00	Yes		
					01/23/2001	28	Week 4	Week 4	40.00	No	2.00	3.00	Yes	53.00	
					02/05/2001	41	Week 6	Week 6	42.00	No	3.00	4.00	No		
					02/19/2001	55	Week 8	Week 8	50.00	No	3.00	4.00	No	50.00	25.00
149	03	Citalopram	Children	10/27/2000	10/20/2000		Screening		69.00						

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit CRF	Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
149	03	Citalopram	Children	12/27/2000	10/26/2000		Baseline		71.00			4.00		55.00	33.00
					11/02/2000	7	Week 1	Week 1	69.00	No	4.00	4.00	No		
					11/10/2000	15	Week 2	Week 2	70.00	No	4.00	5.00	No		
					11/21/2000	26	Week 4	Week 4	50.00	No	3.00	3.00	No	61.00	
					12/07/2000	42	Week 6	Week 6	35.00	No	2.00	4.00	Yes		
					12/27/2000	62	Week 8	Week 8	36.00	No	3.00	4.00	No	61.00	30.00
153	08	Citalopram	Children	09/19/2000	09/11/2000		Screening		70.00						
				11/14/2000	09/18/2000		Baseline		64.00			6.00		40.00	38.00
					09/25/2000	7	Week 1	Week 1	49.00	No	3.00	5.00	No		
					10/03/2000	15	Week 2	Week 2	58.00	No	3.00	5.00	No		
					10/17/2000	29	Week 4	Week 4	56.00	No	3.00	5.00	No	40.00	
					11/01/2000	44	Week 6	Week 6	52.00	No	3.00	5.00	No		
					11/15/2000	58	Week 8	Week 8	58.00	No	4.00	5.00	No	40.00	30.00
157	19	Placebo	Children	06/13/2000	06/06/2000		Screening		59.00						
				08/06/2000	06/13/2000		Baseline		59.00			4.00		55.00	25.00
					06/20/2000	8	Week 1	Week 1	27.00	Yes	3.00	3.00	No		
					06/27/2000	15	Week 2	Week 2	22.00	Yes	2.00	2.00	Yes		
					07/11/2000	29	Week 4	Week 4	20.00	Yes	2.00	2.00	Yes	85.00	
					07/24/2000	42	Week 6	Week 6	17.00	Yes	1.00	1.00	Yes		
					08/07/2000	56	Week 8	Week 8	22.00	Yes	1.00	1.00	Yes	85.00	13.00
158	19	Placebo	Children	10/19/2000	10/12/2000		Screening		61.00						
				11/29/2000	10/19/2000		Baseline		62.00			4.00		54.00	31.00
					10/24/2000	6	Week 1	Week 1	64.00	No	4.00	4.00	No		
					11/02/2000	15	Week 2	Week 2	66.00	No	4.00	4.00	No		
					11/16/2000	29	Week 4	Week 4	59.00	No	4.00	4.00	No	60.00	
					12/21/2000	64	Week 8	Week 8	65.00	No	4.00	4.00	No	54.00	31.00
159	19	Citalopram	Children	10/20/2000	10/13/2000		Screening		66.00						

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
159	19	Citalopram	Children	12/14/2000	10/20/2000		Baseline		67.00			5.00		55.00	33.00
					10/27/2000	8	Week 1	Week 1	64.00	No	4.00	5.00	No		
					11/03/2000	15	Week 2	Week 2	52.00	No	3.00	4.00	No		
					11/17/2000	29	Week 4	Week 4	32.00	No	3.00	3.00	No	61.00	
					12/01/2000	43	Week 6	Week 6	43.00	No	3.00	4.00	No		
					12/15/2000	57	Week 8	Week 8	36.00	No	3.00	4.00	No	55.00	19.00
160	19	Citalopram	Children	10/31/2000	10/23/2000		Screening		61.00						
				12/25/2000	10/31/2000		Baseline		61.00			4.00		41.00	28.00
					11/06/2000	7	Week 1	Week 1	60.00	No	4.00	4.00	No		
					11/13/2000	14	Week 2	Week 2	51.00	No	4.00	4.00	No		
					12/01/2000	32	Week 4	Week 4	47.00	No	3.00	4.00	No	60.00	
					12/20/2000	51	Week 6	Week 8	51.00	No	4.00	4.00	No		
					12/26/2000	57	Week 8	Week 8	49.00	No	4.00	4.00	No	50.00	22.00
161	05	Placebo	Children	05/16/2000	05/11/2000		Screening		61.00						
				06/09/2000	05/16/2000		Baseline		61.00			4.00		42.00	32.00
					05/23/2000	8	Week 1	Week 1	48.00	No	3.00	4.00	No		
					05/30/2000	15	Week 2	Week 2	41.00	No	3.00	4.00	No		
162	05	Citalopram	Children	10/18/2000	10/13/2000		Screening		63.00						
				10/29/2000	10/18/2000		Baseline		60.00			4.00		47.00	27.00
					10/23/2000	6	Week 1	Week 1	57.00	No	4.00	4.00	No		
					10/30/2000	13	Week 8	Week 2	57.00	No	4.00	4.00	No	42.00	32.00
163	05	Placebo	Children	10/23/2000	10/17/2000		Screening		55.00						
				12/17/2000	10/23/2000		Baseline		51.00			4.00		48.00	31.00
					10/30/2000	8	Week 1	Week 1	50.00	No	4.00	4.00	No		
					11/06/2000	15	Week 2	Week 2	45.00	No	3.00	4.00	No		
					11/20/2000	29	Week 4	Week 4	36.00	No	2.00	3.00	Yes	62.00	
					12/04/2000	43	Week 6	Week 6	33.00	No	3.00	3.00	No		

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit CRF	Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
163	05	Placebo	Children		12/18/2000	57	Week 8	Week 8	31.00	No	2.00	3.00	Yes	74.00	17.00
164	05	Citalopram	Children	11/13/2000	11/08/2000		Screening		51.00						
				01/07/2001	11/13/2000		Baseline		51.00			4.00		48.00	28.00
					11/20/2000	8	Week 1	Week 1	37.00	No	2.00	3.00	Yes		
					11/27/2000	15	Week 2	Week 2	37.00	No	3.00	3.00	No		
					12/11/2000	29	Week 4	Week 4	32.00	No	2.00	3.00	Yes	67.00	
					12/27/2000	45	Week 6	Week 6	28.00	Yes	2.00	2.00	Yes		
					01/08/2001	57	Week 8	Week 8	21.00	Yes	1.00	1.00	Yes	86.00	10.00
165	17	Citalopram	Children	11/17/2000	11/06/2000		Screening		71.00						
				01/21/2001	11/17/2000		Baseline		64.00			4.00		50.00	30.00
					11/27/2000	11	Week 1	Week 2	60.00	No	3.00	4.00	No		
					12/06/2000	20	Week 2	Week 2	51.00	No	3.00	4.00	No		
					12/21/2000	35	Week 4	Week 4	47.00	No	2.00	3.00	Yes	85.00	
					01/05/2001	50	Week 6	Week 8	43.00	No	2.00	3.00	Yes		
					01/22/2001	67	Week 8	Week 8	39.00	No	3.00	4.00	No	60.00	29.00
169	20	Citalopram	Children	06/21/2000	06/12/2000		Screening		49.00						
				08/15/2000	06/21/2000		Baseline		45.00			4.00		50.00	22.00
					06/26/2000	6	Week 1	Week 1	38.00	No	3.00	4.00	No		
					07/05/2000	15	Week 2	Week 2	36.00	No	3.00	3.00	No		
					07/19/2000	29	Week 4	Week 4	22.00	Yes	2.00	2.00	Yes	70.00	
					08/02/2000	43	Week 6	Week 6	20.00	Yes	1.00	2.00	Yes		
					08/16/2000	57	Week 8	Week 8	21.00	Yes	1.00	2.00	Yes	85.00	10.00
170	20	Citalopram	Children	06/27/2000	06/20/2000		Screening		68.00						
				08/20/2000	06/27/2000		Baseline		66.00			5.00		50.00	30.00
					07/05/2000	9	Week 1	Week 1	41.00	No	3.00	4.00	No		
					07/11/2000	15	Week 2	Week 2	35.00	No	2.00	3.00	Yes		
					07/25/2000	29	Week 4	Week 4	35.00	No	2.00	3.00	Yes	70.00	

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
170	20	Citalopram	Children		08/04/2000	39	Week 6	Week 6	24.00	Yes	2.00	2.00	Yes		
					08/21/2000	56	Week 8	Week 8	23.00	Yes	2.00	2.00	Yes	85.00	14.00
171	20	Placebo	Children	08/23/2000	08/16/2000		Screening		58.00						
				10/17/2000	08/23/2000		Baseline		60.00			5.00		50.00	30.00
					08/30/2000	8	Week 1	Week 1	55.00	No	4.00	5.00	No		
					09/06/2000	15	Week 2	Week 2	38.00	No	3.00	4.00	No		
					09/20/2000	29	Week 4	Week 4	38.00	No	3.00	4.00	No	65.00	
					10/04/2000	43	Week 6	Week 6	30.00	No	2.00	3.00	Yes		
					10/18/2000	57	Week 8	Week 8	30.00	No	2.00	3.00	Yes	65.00	16.00
172	20	Placebo	Children	09/27/2000	09/18/2000		Screening		57.00						
				11/19/2000	09/27/2000		Baseline		74.00			5.00		65.00	28.00
					10/05/2000	9	Week 1	Week 1	68.00	No	4.00	5.00	No		
					10/12/2000	16	Week 2	Week 2	60.00	No	4.00	5.00	No		
					10/23/2000	27	Week 4	Week 4	51.00	No	3.00	4.00	No	75.00	
					11/07/2000	42	Week 6	Week 6	49.00	No	3.00	4.00	No		
					11/20/2000	55	Week 8	Week 8	47.00	No	4.00	4.00	No	75.00	25.00
185	21	Citalopram	Children	07/25/2000	07/18/2000		Screening		64.00						
				09/18/2000	07/25/2000		Baseline		69.00			4.00		50.00	31.00
					08/03/2000	10	Week 1	Week 1	58.00	No	4.00	4.00	No		
					08/08/2000	15	Week 2	Week 2	45.00	No	3.00	4.00	No		
					08/22/2000	29	Week 4	Week 4	47.00	No	3.00	4.00	No	52.00	
					09/07/2000	45	Week 6	Week 6	48.00	No	3.00	4.00	No		
					09/19/2000	57	Week 8	Week 8	51.00	No	3.00	4.00	No	52.00	27.00
186	21	Placebo	Children	08/16/2000	08/09/2000		Screening		63.00						
				10/18/2000	08/16/2000		Baseline		69.00			5.00		50.00	29.00
					08/24/2000	9	Week 1	Week 1	68.00	No	4.00	5.00	No		
					08/31/2000	16	Week 2	Week 2	63.00	No	4.00	5.00	No		

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit CRF	Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
186	21	Placebo	Children		09/13/2000	29	Week 4	Week 4	38.00	No	2.00	4.00	Yes	60.00	
					09/30/2000	46	Week 6	Week 6	31.00	No	2.00	3.00	Yes		
					10/19/2000	65	Week 8	Week 8	38.00	No	2.00	3.00	Yes	55.00	20.00
187	21	Citalopram	Children	08/22/2000	08/15/2000		Screening		68.00						
				10/17/2000	08/22/2000		Baseline		72.00			5.00		50.00	34.00
					08/29/2000	8	Week 1	Week 1	62.00	No	4.00	4.00	No		
					09/07/2000	17	Week 2	Week 2	50.00	No	3.00	4.00	No		
					09/19/2000	29	Week 4	Week 4	51.00	No	3.00	4.00	No	55.00	
					10/03/2000	43	Week 6	Week 6	62.00	No	3.00	4.00	No		
					10/18/2000	58	Week 8	Week 8	53.00	No	3.00	4.00	No	55.00	28.00
188	21	Placebo	Children	09/21/2000	09/12/2000		Screening		59.00						
				10/30/2000	09/21/2000		Baseline		58.00			4.00		48.00	31.00
					09/28/2000	8	Week 1	Week 1	52.00	No	4.00	4.00	No		
					10/05/2000	15	Week 2	Week 2	51.00	No	4.00	4.00	No		
					10/17/2000	27	Week 4	Week 4	50.00	No	4.00	4.00	No	50.00	
					10/31/2000	41	Week 6	Week 6	50.00	No	4.00	4.00	No		
189	22	Citalopram	Children	09/13/2000	09/06/2000		Screening		67.00						
				11/07/2000	09/13/2000		Baseline		63.00			5.00		52.00	25.00
					09/20/2000	8	Week 1	Week 1	53.00	No	3.00	4.00	No		
					09/27/2000	15	Week 2	Week 2	30.00	No	2.00	3.00	Yes		
					10/11/2000	29	Week 4	Week 4	42.00	No	3.00	4.00	No	62.00	
					10/25/2000	43	Week 6	Week 6	18.00	Yes	1.00	1.00	Yes		
					11/08/2000	57	Week 8	Week 8	34.00	No	2.00	2.00	Yes	70.00	24.00
190	22	Citalopram	Children	09/18/2000	09/11/2000		Screening		61.00						
				11/12/2000	09/18/2000		Baseline		62.00			5.00		55.00	28.00
					09/25/2000	8	Week 1	Week 1	49.00	No	3.00	4.00	No		
					10/03/2000	16	Week 2	Week 2	53.00	No	3.00	4.00	No		

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
190	22	Citalopram	Children		10/16/2000	29	Week 4	Week 4	25.00	Yes	2.00	3.00	Yes	77.00	
					10/30/2000	43	Week 6	Week 6	34.00	No	2.00	3.00	Yes		
					11/13/2000	57	Week 8	Week 8	59.00	No	4.00	5.00	No	50.00	30.00
191	22	Placebo	Children	09/18/2000	09/12/2000		Screening		57.00						
				10/21/2000	09/18/2000		Baseline		55.00			5.00		50.00	26.00
					09/25/2000	8	Week 1	Week 1	40.00	No	3.00	4.00	No		
					10/02/2000	15	Week 2	Week 2	67.00	No	5.00	5.00	No		
192	22	Placebo	Children	09/21/2000	09/13/2000		Screening		50.00						
				11/13/2000	09/21/2000		Baseline		49.00			4.00		48.00	24.00
					09/29/2000	9	Week 1	Week 1	40.00	No	3.00	4.00	No		
					10/06/2000	16	Week 2	Week 2	32.00	No	2.00	3.00	Yes		
					10/19/2000	29	Week 4	Week 4	31.00	No	2.00	3.00	Yes	65.00	
					11/02/2000	43	Week 6	Week 6	59.00	No	3.00	4.00	No		
					11/14/2000	55	Week 8	Week 8	27.00	Yes	2.00	3.00	Yes	70.00	15.00
193	22	Citalopram	Children	10/03/2000	09/26/2000		Screening		66.00						
				11/11/2000	10/03/2000		Baseline		50.00			5.00		48.00	26.00
					10/11/2000	9	Week 1	Week 1	37.00	No	3.00	4.00	No		
					10/18/2000	16	Week 2	Week 2	27.00	Yes	3.00	3.00	No		
					11/06/2000	35	Week 4	Week 4	46.00	No	4.00	4.00	No	58.00	
					11/14/2000	43	Week 8	Week 6	44.00	No	4.00	4.00	No	48.00	24.00
194	22	Citalopram	Children	10/03/2000	09/26/2000		Screening		68.00						
				11/30/2000	10/03/2000		Baseline		65.00			5.00		44.00	31.00
					10/11/2000	9	Week 1	Week 1	55.00	No	3.00	5.00	No		
					10/18/2000	16	Week 2	Week 2	48.00	No	3.00	4.00	No		
					11/06/2000	35	Week 4	Week 4	38.00	No	2.00	4.00	Yes	62.00	
					11/14/2000	43	Week 6	Week 6	46.00	No	3.00	4.00	No		
					12/01/2000	60	Week 8	Week 8	44.00	No	3.00	4.00	No	51.00	27.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit CRF	Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
195	22	Placebo	Children	10/03/2000	09/26/2000		Screening		70.00						
				11/30/2000	10/03/2000		Baseline		56.00			5.00		48.00	25.00
					10/11/2000	9	Week 1	Week 1	50.00	No	3.00	4.00	No		
					10/18/2000	16	Week 2	Week 2	47.00	No	3.00	4.00	No		
					11/06/2000	35	Week 4	Week 4	51.00	No	4.00	4.00	No	50.00	
					11/14/2000	43	Week 6	Week 6	44.00	No	4.00	4.00	No		
					12/01/2000	60	Week 8	Week 8	67.00	No	4.00	5.00	No	45.00	32.00
196	22	Placebo	Children	10/09/2000	10/03/2000		Screening		55.00						
				10/22/2000	10/09/2000		Baseline		57.00			4.00		55.00	26.00
					10/16/2000	8	Week 1	Week 1	19.00	Yes	2.00	3.00	Yes		
					10/23/2000	15	Week 2	Week 2	28.00	Yes	3.00	4.00	No		
197	20	Citalopram	Children	10/17/2000	10/10/2000		Screening		73.00						
				11/13/2000	10/17/2000		Baseline		70.00			4.00		70.00	37.00
					10/24/2000	8	Week 1	Week 1	49.00	No	3.00	4.00	No		
					10/30/2000	14	Week 2	Week 2	37.00	No	3.00	3.00	No		
					11/13/2000	28	Week 4	Week 4	25.00	Yes	2.00	3.00	Yes	85.00	
					12/11/2000	56	Week 8	Week 8	21.00	Yes	3.00	3.00	No	85.00	15.00
201	21	Placebo	Children	10/03/2000	09/20/2000		Screening		52.00						
				11/27/2000	10/03/2000		Baseline		51.00			4.00		50.00	28.00
					10/12/2000	10	Week 1	Week 1	51.00	No	3.00	4.00	No		
					10/19/2000	17	Week 2	Week 2	44.00	No	3.00	4.00	No		
					10/31/2000	29	Week 4	Week 4	35.00	No	2.00	3.00	Yes	52.00	
					11/09/2000	38	Week 6	Week 6	33.00	No	2.00	3.00	Yes		
					11/28/2000	57	Week 8	Week 8	33.00	No	2.00	3.00	Yes	55.00	19.00
202	21	Citalopram	Children	10/26/2000	10/19/2000		Screening		60.00						
				01/10/2001	10/26/2000		Baseline		55.00			5.00		48.00	27.00
					11/02/2000	8	Week 1	Week 1	44.00	No	3.00	4.00	No		

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
202	21	Citalopram	Children		11/09/2000	15	Week 2	Week 2	41.00	No	2.00	4.00	Yes		
					11/22/2000	28	Week 4	Week 4	37.00	No	2.00	3.00	Yes	55.00	
					12/08/2000	44	Week 6	Week 6	18.00	Yes	2.00	3.00	Yes		
					01/11/2001	78	Week 8	Week 8	24.00	Yes	2.00	3.00	Yes	55.00	11.00
203	21	Placebo	Children	11/15/2000	11/08/2000		Screening		57.00						
				01/08/2001	11/15/2000		Baseline		55.00			4.00		45.00	26.00
					11/21/2000	7	Week 1	Week 1	49.00	No	4.00	4.00	No		
					11/28/2000	14	Week 2	Week 2	49.00	No	3.00	4.00	No		
					12/12/2000	28	Week 4	Week 4	49.00	No	4.00	4.00	No	45.00	
					12/26/2000	42	Week 6	Week 6	48.00	No	4.00	4.00	No		
					01/09/2001	56	Week 8	Week 8	48.00	No	4.00	4.00	No	45.00	26.00
204	21	Citalopram	Children	11/21/2000	11/14/2000		Screening		63.00						
				01/22/2001	11/21/2000		Baseline		52.00			4.00		45.00	28.00
					11/30/2000	10	Week 1	Week 1	48.00	No	4.00	4.00	No		
					12/05/2000	15	Week 2	Week 2	53.00	No	4.00	4.00	No		
					12/19/2000	29	Week 4	Week 4	43.00	No	4.00	4.00	No	45.00	
					01/09/2001	50	Week 6	Week 8	52.00	No	4.00	4.00	No		
					01/23/2001	64	Week 8	Week 8	50.00	No	4.00	4.00	No	45.00	26.00
205	21	Citalopram	Children	11/22/2000	11/15/2000		Screening		52.00						
				01/22/2001	11/22/2000		Baseline		56.00			4.00		45.00	26.00
					11/30/2000	9	Week 1	Week 1	54.00	No	4.00	4.00	No		
					12/06/2000	15	Week 2	Week 2	57.00	No	5.00	4.00	No		
					12/20/2000	29	Week 4	Week 4	51.00	No	4.00	4.00	No	45.00	
					01/09/2001	49	Week 6	Week 8	53.00	No	4.00	4.00	No		
					01/23/2001	63	Week 8	Week 8	53.00	No	4.00	4.00	No	45.00	26.00
206	21	Placebo	Children	01/11/2001	01/02/2001		Screening		50.00						
				03/06/2001	01/11/2001		Baseline		53.00			4.00		45.00	25.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
206	21	Placebo	Children		01/18/2001	8	Week 1	Week 1	48.00	No	4.00	4.00	No		
					01/26/2001	16	Week 2	Week 2	47.00	No	3.00	4.00	No		
					02/08/2001	29	Week 4	Week 4	33.00	No	3.00	4.00	No	50.00	
					02/20/2001	41	Week 6	Week 6	20.00	Yes	2.00	3.00	Yes		
					03/07/2001	56	Week 8	Week 8	27.00	Yes	2.00	3.00	Yes	50.00	12.00
208	21	Citalopram	Children	12/13/2000	12/06/2000		Screening		52.00						
				02/06/2001	12/13/2000		Baseline		50.00			4.00		45.00	24.00
					12/20/2000	8	Week 1	Week 1	40.00	No	3.00	4.00	No		
					12/27/2000	15	Week 2	Week 2	38.00	No	2.00	3.00	Yes		
					01/10/2001	29	Week 4	Week 4	31.00	No	2.00	3.00	Yes	50.00	
					01/24/2001	43	Week 6	Week 6	30.00	No	2.00	3.00	Yes		
					02/07/2001	57	Week 8	Week 8	28.00	Yes	2.00	3.00	Yes	55.00	13.00
209	22	Placebo	Children	10/11/2000	10/02/2000		Screening		55.00						
				11/26/2000	10/11/2000		Baseline		57.00			5.00		52.00	25.00
					10/19/2000	9	Week 1	Week 1	44.00	No	3.00	4.00	No		
					10/24/2000	14	Week 2	Week 2	31.00	No	2.00	3.00	Yes		
					11/07/2000	28	Week 4	Week 4	38.00	No	2.00	3.00	Yes	60.00	
					11/27/2000	48	Week 8	Week 6	36.00	No	2.00	3.00	Yes	70.00	22.00
210	22	Placebo	Children	10/13/2000	10/06/2000		Screening		43.00						
				12/07/2000	10/13/2000		Baseline		45.00			4.00		65.00	25.00
					10/18/2000	6	Week 1	Week 1	30.00	No	3.00	4.00	No		
					10/27/2000	15	Week 2	Week 2	36.00	No	3.00	4.00	No		
					11/10/2000	29	Week 4	Week 4	33.00	No	3.00	4.00	No	55.00	
					11/21/2000	40	Week 6	Week 6	34.00	No	3.00	4.00	No		
					12/08/2000	57	Week 8	Week 8	38.00	No	3.00	4.00	No	65.00	21.00
211&	22	Citalopram	Children		10/03/2000		Screening		60.00						
					10/17/2000		Baseline		59.00			5.00		48.00	30.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit CRF	Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
212	22	Citalopram	Children	10/23/2000	10/16/2000		Screening		71.00						
				12/19/2000	10/23/2000		Baseline		66.00			5.00		48.00	33.00
					10/30/2000	8	Week 1	Week 1	53.00	No	3.00	5.00	No		
					11/06/2000	15	Week 2	Week 2	44.00	No	2.00	4.00	Yes		
					11/20/2000	29	Week 4	Week 4	37.00	No	2.00	3.00	Yes	65.00	
					12/04/2000	43	Week 6	Week 6	44.00	No	3.00	4.00	No		
					12/20/2000	59	Week 8	Week 8	51.00	No	3.00	4.00	No	52.00	26.00
213	22	Citalopram	Children	11/01/2000	10/25/2000		Screening		67.00						
				12/24/2000	11/01/2000		Baseline		58.00			5.00		45.00	27.00
					11/08/2000	8	Week 1	Week 1	42.00	No	3.00	4.00	No		
					11/15/2000	15	Week 2	Week 2	28.00	Yes	2.00	3.00	Yes		
					11/29/2000	29	Week 4	Week 4	24.00	Yes	2.00	2.00	Yes	70.00	
					12/15/2000	45	Week 6	Week 6	49.00	No	3.00	4.00	No		
214	22	Placebo	Children	11/10/2000	11/02/2000		Screening		56.00						
				01/14/2001	11/10/2000		Baseline		55.00			5.00		52.00	27.00
					11/17/2000	8	Week 1	Week 1	39.00	No	3.00	4.00	No		
					11/27/2000	18	Week 2	Week 2	31.00	No	3.00	4.00	No		
					12/15/2000	36	Week 4	Week 6	30.00	No	3.00	3.00	No	80.00	
					12/28/2000	49	Week 6	Week 8	21.00	Yes	1.00	1.00	Yes		
					01/15/2001	67	Week 8	Week 8	45.00	No	3.00	4.00	No	58.00	29.00
215	22	Placebo	Children	11/13/2000	11/06/2000		Screening		55.00						
				01/16/2001	11/13/2000		Baseline		61.00			4.00		52.00	30.00
					11/21/2000	9	Week 1	Week 1	55.00	No	4.00	4.00	No		
					11/28/2000	16	Week 2	Week 2	49.00	No	4.00	4.00	No		
					12/11/2000	29	Week 4	Week 4	47.00	No	4.00	4.00	No	55.00	
					12/27/2000	45	Week 6	Week 6	45.00	No	4.00	4.00	No		
					01/17/2001	66	Week 8	Week 8	47.00	No	4.00	4.00	No	59.00	28.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
216	22	Citalopram	Children	11/15/2000	11/06/2000		Screening		63.00						
				01/09/2001	11/15/2000		Baseline		65.00			5.00		55.00	34.00
					11/21/2000	7	Week 1	Week 1	36.00	No	2.00	4.00	Yes		
					11/29/2000	15	Week 2	Week 2	22.00	Yes	1.00	1.00	Yes		
					12/13/2000	29	Week 4	Week 4	20.00	Yes	1.00	1.00	Yes	85.00	
					12/27/2000	43	Week 6	Week 6	17.00	Yes	1.00	1.00	Yes		
					01/10/2001	57	Week 8	Week 8	18.00	Yes	1.00	1.00	Yes	91.00	9.00
217	05	Citalopram	Children	11/15/2000	11/01/2000		Screening		50.00						
				12/05/2000	11/15/2000		Baseline		49.00			4.00		46.00	28.00
					11/21/2000	7	Week 1	Week 1	43.00	No	4.00	4.00	No		
					11/29/2000	15	Week 2	Week 2	44.00	No	4.00	4.00	No		
					12/06/2000	22	Week 8	Week 4	56.00	No	5.00	4.00	No	42.00	23.00
221	19	Citalopram	Children	11/14/2000	11/06/2000		Screening		56.00						
				01/08/2001	11/14/2000		Baseline		56.00			4.00		50.00	28.00
					11/21/2000	8	Week 1	Week 1	48.00	No	3.00	4.00	No		
					11/28/2000	15	Week 2	Week 2	47.00	No	4.00	4.00	No		
					12/12/2000	29	Week 4	Week 4	35.00	No	3.00	3.00	No	70.00	
					12/27/2000	44	Week 6	Week 6	25.00	Yes	2.00	2.00	Yes		
					01/09/2001	57	Week 8	Week 8	18.00	Yes	1.00	1.00	Yes	90.00	9.00
222	19	Placebo	Children	11/16/2000	11/09/2000		Screening		69.00						
				01/10/2001	11/16/2000		Baseline		69.00			4.00		55.00	30.00
					11/21/2000	6	Week 1	Week 1	70.00	No	4.00	4.00	No		
					11/28/2000	13	Week 2	Week 2	69.00	No	4.00	4.00	No		
					12/14/2000	29	Week 4	Week 4	62.00	No	4.00	4.00	No	57.00	
					12/26/2000	41	Week 6	Week 6	56.00	No	4.00	4.00	No		
					01/11/2001	57	Week 8	Week 8	62.00	No	4.00	4.00	No	57.00	30.00
223	19	Citalopram	Children	11/25/2000	11/16/2000		Screening		58.00						

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit CRF	Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
223	19	Citalopram	Children	01/16/2001	11/24/2000		Baseline		58.00			4.00		41.00	32.00
					11/30/2000	6	Week 1	Week 1	55.00	No	4.00	4.00	No		
					12/07/2000	13	Week 2	Week 2	39.00	No	3.00	4.00	No		
					12/21/2000	27	Week 4	Week 4	39.00	No	3.00	4.00	No	65.00	
					01/04/2001	41	Week 6	Week 6	35.00	No	3.00	3.00	No		
					01/17/2001	54	Week 8	Week 8	31.00	No	3.00	3.00	No	75.00	15.00
224	19	Placebo	Children	12/12/2000	12/07/2000		Screening		61.00						
				02/07/2001	12/12/2000		Baseline		61.00			5.00		45.00	29.00
					12/21/2000	10	Week 1	Week 1	58.00	No	4.00	4.00	No		
					12/28/2000	17	Week 2	Week 2	52.00	No	3.00	4.00	No		
					01/09/2001	29	Week 4	Week 4	52.00	No	4.00	4.00	No	47.00	
					01/23/2001	43	Week 6	Week 6	50.00	No	4.00	4.00	No		
					02/08/2001	59	Week 8	Week 8	52.00	No	4.00	4.00	No	50.00	31.00
225	14	Placebo	Children	11/27/2000	11/16/2000		Screening		40.00						
				01/21/2001	11/27/2000		Baseline		40.00			4.00		60.00	20.00
					12/04/2000	8	Week 1	Week 1	40.00	No	4.00	4.00	No		
					12/15/2000	19	Week 2	Week 2	33.00	No	3.00	3.00	No		
					12/26/2000	30	Week 4	Week 4	34.00	No	3.00	3.00	No	80.00	
					01/08/2001	43	Week 6	Week 6	35.00	No	3.00	3.00	No		
					01/22/2001	57	Week 8	Week 8	29.00	No	2.00	3.00	Yes	80.00	15.00
226	14	Citalopram	Children	12/17/2000	12/07/2000		Screening		46.00						
				02/16/2001	12/14/2000		Baseline		57.00			4.00		60.00	30.00
					12/21/2000	5	Week 1	Week 1	53.00	No	4.00	4.00	No		
					01/02/2001	17	Week 2	Week 2	46.00	No	3.00	3.00	No		
					01/18/2001	33	Week 4	Week 4	60.00	No	4.00	4.00	No	60.00	
					02/01/2001	47	Week 6	Week 6	32.00	No	3.00	3.00	No		
					02/16/2001	62	Week 8	Week 8	50.00	No	3.00	4.00	No	65.00	23.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit CRF	Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
227	14	Placebo	Children	01/18/2001	01/11/2001		Screening		69.00						
				03/14/2001	01/18/2001		Baseline		57.00			4.00		60.00	29.00
					01/26/2001	9	Week 1	Week 1	51.00	No	4.00	4.00	No		
					01/31/2001	14	Week 2	Week 2	47.00	No	3.00	3.00	No		
					02/15/2001	29	Week 4	Week 4	50.00	No	3.00	4.00	No	65.00	
					02/28/2001	42	Week 6	Week 6	43.00	No	3.00	3.00	No		
					03/15/2001	57	Week 8	Week 8	44.00	No	3.00	4.00	No	70.00	18.00
229	22	Citalopram	Children	11/15/2000	11/06/2000		Screening		51.00						
				12/11/2000	11/15/2000		Baseline		53.00			4.00		58.00	23.00
					11/21/2000	7	Week 1	Week 1	32.00	No	2.00	3.00	Yes		
					11/29/2000	15	Week 2	Week 2	33.00	No	2.00	3.00	Yes		
					12/13/2000	29	Week 8	Week 4	29.00	No	2.00	3.00	Yes	50.00	25.00
230	22	Citalopram	Children	12/05/2000	11/27/2000		Screening		55.00						
				02/06/2001	12/05/2000		Baseline		55.00			4.00		65.00	28.00
					12/12/2000	8	Week 1	Week 1	57.00	No	4.00	4.00	No		
					12/19/2000	15	Week 2	Week 2	37.00	No	2.00	3.00	Yes		
					01/04/2001	31	Week 4	Week 4	45.00	No	3.00	4.00	No	68.00	
					01/23/2001	50	Week 6	Week 8	45.00	No	3.00	4.00	No		
					02/07/2001	65	Week 8	Week 8	48.00	No	3.00	4.00	No	68.00	29.00
231	22	Placebo	Children	12/06/2000	11/29/2000		Screening		62.00						
				01/23/2001	12/06/2000		Baseline		61.00			5.00		45.00	31.00
					12/18/2000	13	Week 1	Week 2	59.00	No	4.00	5.00	No		
					12/27/2000	22	Week 2	Week 4	51.00	No	3.00	4.00	No		
					01/08/2001	34	Week 4	Week 4	45.00	No	3.00	4.00	No	42.00	
					01/24/2001	50	Week 6	Week 8	52.00	No	3.00	4.00	No		
232	22	Placebo	Children	12/07/2000	11/29/2000		Screening		53.00						
				02/03/2001	12/07/2000		Baseline		53.00			4.00		58.00	34.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
232	22	Placebo	Children		12/14/2000	8	Week 1	Week 1	34.00	No	2.00	3.00	Yes		
					12/21/2000	15	Week 2	Week 2	25.00	Yes	2.00	2.00	Yes		
					01/03/2001	28	Week 4	Week 4	22.00	Yes	1.00	2.00	Yes	82.00	
					01/15/2001	40	Week 6	Week 6	20.00	Yes	1.00	1.00	Yes		
					02/05/2001	61	Week 8	Week 8	20.00	Yes	1.00	1.00	Yes	86.00	21.00
237	19	Placebo	Children	12/14/2000	12/07/2000		Screening		59.00						
				02/21/2001	12/14/2000		Baseline		59.00			4.00		41.00	33.00
					12/21/2000	8	Week 1	Week 1	56.00	No	4.00	4.00	No		
					01/02/2001	20	Week 2	Week 2	51.00	No	3.00	4.00	No		
					01/18/2001	36	Week 4	Week 6	34.00	No	3.00	3.00	No	50.00	
					02/01/2001	50	Week 6	Week 8	38.00	No	3.00	3.00	No		
					02/22/2001	71	Week 8	Week 8	28.00	Yes	2.00	2.00	Yes	80.00	18.00
238	19	Citalopram	Children	12/14/2000	12/07/2000		Screening		55.00						
				02/07/2001	12/14/2000		Baseline		47.00			4.00		41.00	20.00
					12/19/2000	6	Week 1	Week 1	39.00	No	3.00	4.00	No		
					12/28/2000	15	Week 2	Week 2	21.00	Yes	2.00	2.00	Yes		
					01/10/2001	28	Week 4	Week 4	21.00	Yes	1.00	1.00	Yes	85.00	
					01/30/2001	48	Week 6	Week 6	17.00	Yes	1.00	1.00	Yes		
					02/08/2001	57	Week 8	Week 8	17.00	Yes	1.00	1.00	Yes	90.00	9.00
239	19	Citalopram	Children	01/02/2001	12/21/2000		Screening		78.00						
				01/29/2001	01/02/2001		Baseline		82.00			5.00		41.00	39.00
					01/09/2001	8	Week 1	Week 1	41.00	No	3.00	4.00	No		
					01/16/2001	15	Week 2	Week 2	71.00	No	3.00	4.00	No		
					01/30/2001	29	Week 4	Week 4	59.00	No	3.00	4.00	No	45.00	
240	19	Placebo	Children	01/30/2001	01/23/2001		Screening		78.00						
				03/26/2001	01/30/2001		Baseline		77.00			5.00		45.00	31.00
					02/06/2001	8	Week 1	Week 1	73.00	No	4.00	5.00	No		

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
240	19	Placebo	Children		02/13/2001	15	Week 2	Week 2	68.00	No	4.00	5.00	No		
					02/27/2001	29	Week 4	Week 4	57.00	No	3.00	4.00	No	55.00	
					03/15/2001	45	Week 6	Week 6	33.00	No	2.00	3.00	Yes		
					03/27/2001	57	Week 8	Week 8	31.00	No	2.00	2.00	Yes	71.00	13.00
241	19	Citalopram	Children	02/13/2001	02/05/2001		Screening		60.00						
				04/09/2001	02/13/2001		Baseline		61.00			4.00		51.00	26.00
					02/20/2001	8	Week 1	Week 1	60.00	No	4.00	4.00	No		
					02/27/2001	15	Week 2	Week 2	55.00	No	4.00	4.00	No		
					03/13/2001	29	Week 4	Week 4	38.00	No	3.00	3.00	No	70.00	
					03/27/2001	43	Week 6	Week 6	53.00	No	4.00	4.00	No		
					04/10/2001	57	Week 8	Week 8	53.00	No	4.00	4.00	No	61.00	26.00
501	14	Citalopram	Adolescents	03/10/2000	02/23/2000		Screening		44.00						
				05/08/2000	03/10/2000		Baseline		51.00			5.00		50.00	22.00
					03/16/2000	7	Week 1	Week 1	30.00	No	3.00	3.00	No		
					03/23/2000	14	Week 2	Week 2	27.00	Yes	3.00	3.00	No		
					04/06/2000	28	Week 4	Week 4	42.00	No	3.00	3.00	No	50.00	
					04/20/2000	42	Week 6	Week 6	36.00	No	3.00	3.00	No		
					05/09/2000	61	Week 8	Week 8	29.00	No	2.00	3.00	Yes	85.00	15.00
502	14	Citalopram	Adolescents	07/07/2000	06/29/2000		Screening		52.00						
				09/06/2000	07/07/2000		Baseline		41.00			4.00		60.00	21.00
					07/13/2000	7	Week 1	Week 1	33.00	No	4.00	4.00	No		
					07/24/2000	18	Week 2	Week 2	24.00	Yes	3.00	3.00	No		
					08/10/2000	35	Week 4	Week 4	21.00	Yes	2.00	2.00	Yes	85.00	
					08/25/2000	50	Week 6	Week 8	36.00	No	3.00	3.00	No		
					09/07/2000	63	Week 8	Week 8	29.00	No	2.00	2.00	Yes	90.00	13.00
503	14	Placebo	Adolescents	07/14/2000	07/10/2000		Screening		62.00						
				07/30/2000	07/14/2000		Baseline		45.00			4.00		60.00	23.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
503	14	Placebo	Adolescents		07/24/2000	11	Week 1	Week 2	36.00	No	4.00	4.00	No		
					07/31/2000	18	Week 2	Week 2	32.00	No	4.00	4.00	No		
504	14	Placebo	Adolescents	08/04/2000	07/20/2000		Screening		59.00						
				09/21/2000	08/04/2000		Baseline		42.00			4.00		60.00	17.00
					08/09/2000	6	Week 1	Week 1	48.00	No	5.00	5.00	No		
					08/14/2000	11	Week 2	Week 2	48.00	No	5.00	5.00	No		
					08/25/2000	22	Week 4	Week 4	53.00	No	5.00	5.00	No	50.00	
					09/08/2000	36	Week 6	Week 6	50.00	No	5.00	5.00	No		
					09/22/2000	50	Week 8	Week 8	49.00	No	5.00	5.00	No	50.00	22.00
505&	02	Citalopram	Adolescents		02/03/2000		Screening		92.00						
					02/10/2000		Baseline		52.00			4.00		65.00	35.00
506	02	Citalopram	Adolescents	02/22/2000	02/14/2000		Screening		88.00						
				04/23/2000	02/21/2000		Baseline		79.00			5.00		45.00	40.00
					03/01/2000	9	Week 1	Week 1	60.00	No	3.00	5.00	No		
					03/06/2000	14	Week 2	Week 2	64.00	No	3.00	5.00	No		
					03/20/2000	28	Week 4	Week 4	35.00	No	2.00	3.00	Yes	60.00	
					04/03/2000	42	Week 6	Week 6	74.00	No	4.00	5.00	No		
					04/24/2000	63	Week 8	Week 8	84.00	No	4.00	5.00	No	40.00	35.00
507	02	Placebo	Adolescents	02/29/2000	02/23/2000		Screening		54.00						
				03/28/2000	02/29/2000		Baseline		55.00			4.00		65.00	21.00
					03/07/2000	8	Week 1	Week 1	41.00	No	3.00	4.00	No		
					03/14/2000	15	Week 2	Week 2	40.00	No	3.00	4.00	No		
					03/28/2000	29	Week 4	Week 4	35.00	No	2.00	3.00	Yes	70.00	
					04/11/2000	43	Week 8	Week 6	49.00	No	2.00	3.00	Yes	75.00	18.00
508	02	Placebo	Adolescents	03/16/2000	03/02/2000		Screening		63.00						
				05/10/2000	03/16/2000		Baseline		71.00			5.00		55.00	36.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
508	02	Placebo	Adolescents		03/23/2000	8	Week 1	Week 1	61.00	No	3.00	5.00	No		
					03/28/2000	13	Week 2	Week 2	59.00	No	3.00	5.00	No		
					04/11/2000	27	Week 4	Week 4	61.00	No	3.00	5.00	No	55.00	
					04/27/2000	43	Week 6	Week 6	58.00	No	3.00	5.00	No		
					05/11/2000	57	Week 8	Week 8	73.00	No	5.00	5.00	No	50.00	29.00
509	07	Placebo	Adolescents	02/29/2000	02/22/2000		Screening		68.00						
				04/09/2000	02/29/2000		Baseline		67.00			4.00		48.00	38.00
					03/08/2000	9	Week 1	Week 1	59.00	No	3.00	4.00	No		
					03/14/2000	15	Week 2	Week 2	57.00	No	3.00	4.00	No		
					03/28/2000	29	Week 4	Week 4	58.00	No	3.00	4.00	No	51.00	
					04/11/2000	43	Week 6	Week 6	64.00	No	4.00	4.00	No		
					04/25/2000	57	Week 8	Week 8	49.00	No	2.00	3.00	Yes	55.00	33.00
510	07	Citalopram	Adolescents	03/21/2000	03/14/2000		Screening		64.00						
				05/16/2000	03/21/2000		Baseline		46.00			4.00		50.00	21.00
					03/28/2000	8	Week 1	Week 1	33.00	No	2.00	3.00	Yes		
					04/04/2000	15	Week 2	Week 2	26.00	Yes	3.00	3.00	No		
					04/18/2000	29	Week 4	Week 4	44.00	No	5.00	4.00	No	45.00	
					05/03/2000	44	Week 6	Week 6	31.00	No	3.00	4.00	No		
					05/17/2000	58	Week 8	Week 8	28.00	Yes	2.00	4.00	Yes	83.00	17.00
511	07	Placebo	Adolescents	04/12/2000	03/29/2000		Screening		73.00						
				06/07/2000	04/12/2000		Baseline		56.00			4.00		65.00	27.00
					04/19/2000	8	Week 1	Week 1	52.00	No	3.00	4.00	No		
					04/26/2000	15	Week 2	Week 2	38.00	No	3.00	3.00	No		
					05/10/2000	29	Week 4	Week 4	35.00	No	2.00	4.00	Yes	50.00	
					05/24/2000	43	Week 6	Week 6	42.00	No	3.00	4.00	No		
					06/07/2000	57	Week 8	Week 8	33.00	No	3.00	3.00	No	63.00	19.00
512	07	Citalopram	Adolescents	04/26/2000	04/19/2000		Screening		51.00						

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
512	07	Citalopram	Adolescents	06/20/2000	04/26/2000		Baseline		42.00			4.00		60.00	25.00
					05/02/2000	7	Week 1	Week 1	33.00	No	3.00	4.00	No		
					05/11/2000	16	Week 2	Week 2	29.00	No	3.00	4.00	No		
					05/25/2000	30	Week 4	Week 4	29.00	No	2.00	2.00	Yes	90.00	
					06/07/2000	43	Week 6	Week 6	23.00	Yes	1.00	1.00	Yes		
					06/21/2000	57	Week 8	Week 8	24.00	Yes	1.00	1.00	Yes	86.00	11.00
513	16	Citalopram	Adolescents	02/10/2000	02/03/2000		Screening		80.00						
				04/04/2000	02/09/2000		Baseline		63.00			4.00		55.00	30.00
					02/16/2000	7	Week 1	Week 1	61.00	No	4.00	4.00	No		
					02/23/2000	14	Week 2	Week 2	54.00	No	3.00	4.00	No		
					03/09/2000	29	Week 4	Week 4	55.00	No	3.00	4.00	No	58.00	
					03/23/2000	43	Week 6	Week 6	30.00	No	3.00	3.00	No		
					04/06/2000	57	Week 8	Week 8	55.00	No	3.00	4.00	No	60.00	29.00
514	16	Placebo	Adolescents	02/25/2000	02/15/2000		Screening		94.00						
				04/03/2000	02/25/2000		Baseline		92.00			6.00		42.00	36.00
					03/03/2000	8	Week 1	Week 1	67.00	No	4.00	6.00	No		
					03/07/2000	12	Week 2	Week 2	82.00	No	4.00	6.00	No		
					03/21/2000	26	Week 4	Week 4	72.00	No	3.00	6.00	No	45.00	
					04/04/2000	40	Week 6	Week 6	77.00	No	4.00	6.00	No		
515	16	Citalopram	Adolescents	04/28/2000	04/21/2000		Screening		69.00						
				06/22/2000	04/28/2000		Baseline		69.00			4.00		50.00	30.00
					05/02/2000	5	Week 1	Week 1	63.00	No	3.00	4.00	No		
					05/09/2000	12	Week 2	Week 2	47.00	No	3.00	4.00	No		
					05/23/2000	26	Week 4	Week 4	42.00	No	2.00	3.00	Yes	55.00	
					06/06/2000	40	Week 6	Week 6	32.00	No	2.00	3.00	Yes		
					06/23/2000	57	Week 8	Week 8	26.00	Yes	2.00	3.00	Yes	65.00	18.00
516	16	Placebo	Adolescents	07/07/2000	06/27/2000		Screening		68.00						

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit CRF	Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
516	16	Placebo	Adolescents	08/28/2000	07/06/2000		Baseline		71.00			4.00		55.00	32.00
					07/11/2000	5	Week 1	Week 1	47.00	No	2.00	4.00	Yes		
					07/18/2000	12	Week 2	Week 2	46.00	No	3.00	4.00	No		
					08/01/2000	26	Week 4	Week 4	42.00	No	3.00	4.00	No	55.00	
					08/15/2000	40	Week 6	Week 6	40.00	No	3.00	4.00	No		
					08/29/2000	54	Week 8	Week 8	44.00	No	3.00	4.00	No	55.00	23.00
517	13	Placebo	Adolescents	08/22/2000	08/15/2000		Screening		57.00						
				10/17/2000	08/22/2000		Baseline		55.00			4.00		55.00	25.00
					08/28/2000	7	Week 1	Week 1	49.00	No	4.00	4.00	No		
					09/05/2000	15	Week 2	Week 2	51.00	No	4.00	4.00	No		
					09/19/2000	29	Week 4	Week 4	54.00	No	4.00	4.00	No	55.00	
					10/04/2000	44	Week 6	Week 6	50.00	No	4.00	4.00	No		
					10/18/2000	58	Week 8	Week 8	51.00	No	4.00	4.00	No	55.00	28.00
518	13	Citalopram	Adolescents	09/22/2000	09/12/2000		Screening		61.00						
				10/04/2000	09/22/2000		Baseline		62.00			4.00		61.00	31.00
					09/28/2000	7	Week 1	Week 1	59.00	No	4.00	4.00	No		
					10/05/2000	14	Week 2	Week 2	57.00	No	4.00	4.00	No		
519	13	Placebo	Adolescents	10/10/2000	10/03/2000		Screening		54.00						
				11/20/2000	10/10/2000		Baseline		54.00			4.00		55.00	20.00
					10/17/2000	8	Week 1	Week 1	56.00	No	4.00	4.00	No		
					10/24/2000	15	Week 2	Week 2	55.00	No	4.00	4.00	No		
					11/07/2000	29	Week 4	Week 4	53.00	No	4.00	4.00	No	55.00	
					11/21/2000	43	Week 8	Week 6	64.00	No	5.00	5.00	No	50.00	32.00
520	13	Citalopram	Children	10/30/2000	10/24/2000		Screening		53.00						
				12/24/2000	10/30/2000		Baseline		55.00			4.00		45.00	27.00
					11/07/2000	9	Week 1	Week 1	51.00	No	4.00	4.00	No		
					11/14/2000	16	Week 2	Week 2	45.00	No	3.00	4.00	No		

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
520	13	Citalopram	Children		11/28/2000	30	Week 4	Week 4	44.00	No	3.00	4.00	No	55.00	
					12/12/2000	44	Week 6	Week 6	38.00	No	3.00	4.00	No		
					12/26/2000	58	Week 8	Week 8	30.00	No	2.00	3.00	Yes	62.00	19.00
521	09	Placebo	Adolescents	09/01/2000	08/14/2000		Screening		64.81						
				10/25/2000	09/01/2000		Baseline		54.00			4.00		51.00	31.00
					09/07/2000	7	Week 1	Week 1	43.00	No	3.00	4.00	No		
					09/15/2000	15	Week 2	Week 2	35.00	No	2.00	3.00	Yes		
					09/28/2000	28	Week 4	Week 4	35.00	No	2.00	3.00	Yes	60.00	
					10/13/2000	43	Week 6	Week 6	46.00	No	3.00	4.00	No		
					10/26/2000	56	Week 8	Week 8	58.00	No	4.00	4.00	No	60.00	29.00
522	09	Citalopram	Adolescents	11/22/2000	11/16/2000		Screening		48.00						
				01/21/2001	11/22/2000		Baseline		42.00			4.00		55.00	23.00
					11/30/2000	9	Week 1	Week 1	19.00	Yes	1.00	1.00	Yes		
					12/08/2000	17	Week 2	Week 2	19.00	Yes	1.00	1.00	Yes		
					12/22/2000	31	Week 4	Week 4	18.00	Yes	1.00	1.00	Yes	81.00	
					01/08/2001	48	Week 6	Week 6	18.00	Yes	1.00	1.00	Yes		
					01/22/2001	62	Week 8	Week 8	17.00	Yes	1.00	1.00	Yes	85.00	11.00
525	01	Citalopram	Adolescents	03/10/2000	02/23/2000		Screening		63.00						
				05/04/2000	03/10/2000		Baseline		45.00			4.00		60.00	26.00
					03/17/2000	8	Week 1	Week 1	45.00	No	4.00	4.00	No		
					03/24/2000	15	Week 2	Week 2	45.00	No	4.00	4.00	No		
					04/07/2000	29	Week 4	Week 4	39.00	No	3.00	4.00	No	65.00	
					04/18/2000	40	Week 6	Week 6	31.00	No	2.00	3.00	Yes		
					05/05/2000	57	Week 8	Week 8	29.00	No	2.00	3.00	Yes	78.00	20.00
526	01	Placebo	Adolescents	05/03/2000	04/26/2000		Screening		64.00						
				06/27/2000	05/03/2000		Baseline		52.00			5.00		62.00	29.00
					05/10/2000	8	Week 1	Week 1	46.00	No	3.00	4.00	No		

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
526	01	Placebo	Adolescents		05/17/2000	15	Week 2	Week 2	38.00	No	2.00	4.00	Yes		
					05/31/2000	29	Week 4	Week 4	33.00	No	2.00	3.00	Yes	78.00	
					06/14/2000	43	Week 6	Week 6	34.00	No	2.00	3.00	Yes		
					06/28/2000	57	Week 8	Week 8	21.00	Yes	1.00	2.00	Yes	85.00	11.00
527	01	Placebo	Adolescents	05/30/2000	05/22/2000		Screening		64.00						
				07/25/2000	05/30/2000		Baseline		61.00			5.00		55.00	35.00
					06/05/2000	7	Week 1	Week 1	57.00	No	4.00	5.00	No		
					06/15/2000	17	Week 2	Week 2	41.00	No	2.00	4.00	Yes		
					06/26/2000	28	Week 4	Week 4	36.00	No	2.00	4.00	Yes	68.00	
					07/10/2000	42	Week 6	Week 6	31.00	No	2.00	3.00	Yes		
					07/26/2000	58	Week 8	Week 8	27.00	Yes	2.00	2.00	Yes	78.00	18.00
528	01	Citalopram	Adolescents	07/07/2000	06/28/2000		Screening		60.00						
				08/29/2000	07/07/2000		Baseline		54.00			5.00		60.00	31.00
					07/12/2000	6	Week 1	Week 1	47.00	No	3.00	4.00	No		
					07/19/2000	13	Week 2	Week 2	43.00	No	3.00	4.00	No		
					08/04/2000	29	Week 4	Week 4	40.00	No	2.00	4.00	Yes	68.00	
					08/16/2000	41	Week 6	Week 6	35.00	No	2.00	3.00	Yes		
					08/30/2000	55	Week 8	Week 8	36.00	No	2.00	3.00	Yes	72.00	18.00
533	06	Placebo	Adolescents	05/31/2000	05/22/2000		Screening		75.00						
				07/26/2000	05/30/2000		Baseline		55.00			4.00		40.00	30.00
					06/06/2000	7	Week 1	Week 1	54.00	No	3.00	4.00	No		
					06/14/2000	15	Week 2	Week 2	36.00	No	2.00	4.00	Yes		
					06/29/2000	30	Week 4	Week 4	49.00	No	3.00	3.00	No	59.00	
					07/12/2000	43	Week 6	Week 6	58.00	No	4.00	4.00	No		
					07/26/2000	57	Week 8	Week 8	41.00	No	2.00	3.00	Yes	60.00	22.00
534	06	Citalopram	Adolescents	07/01/2000	06/23/2000		Screening		81.00						
				07/31/2000	06/30/2000		Baseline		66.00			4.00		55.00	39.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit CRF	Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
534	06	Citalopram	Adolescents		07/11/2000	11	Week 1	Week 2	61.00	No	4.00	4.00	No		
					07/17/2000	17	Week 2	Week 2	56.00	No	3.00	4.00	No		
					07/31/2000	31	Week 8	Week 4	56.00	No	4.00	4.00	No	54.00	32.00
535	06	Citalopram	Adolescents	07/18/2000	07/06/2000		Screening		59.00						
				09/21/2000	07/17/2000		Baseline		56.00			4.00		41.00	27.00
					07/27/2000	10	Week 1	Week 1	52.00	No	3.00	4.00	No		
					08/01/2000	15	Week 2	Week 2	40.00	No	2.00	3.00	Yes		
					08/14/2000	28	Week 4	Week 4	41.00	No	2.00	3.00	Yes	61.00	
					08/31/2000	45	Week 6	Week 6	39.00	No	2.00	3.00	Yes		
					09/19/2000	64	Week 8	Week 8	30.00	No	1.00	2.00	Yes	70.00	17.00
536	06	Placebo	Adolescents	08/24/2000	08/16/2000		Screening		57.00						
				10/18/2000	08/24/2000		Baseline		49.00			4.00		55.00	31.00
					08/31/2000	8	Week 1	Week 1	46.00	No	3.00	4.00	No		
					09/07/2000	15	Week 2	Week 2	46.00	No	3.00	4.00	No		
					09/21/2000	29	Week 4	Week 4	50.00	No	4.00	4.00	No	55.00	
					10/05/2000	43	Week 6	Week 6	49.00	No	3.00	4.00	No		
					10/19/2000	57	Week 8	Week 8	40.00	No	3.00	3.00	No	60.00	24.00
537	18	Citalopram	Adolescents	04/15/2000	04/05/2000		Screening		61.00						
				06/13/2000	04/14/2000		Baseline		56.00			4.00		44.00	26.00
					04/21/2000	7	Week 1	Week 1	44.00	No	3.00	4.00	No		
					04/28/2000	14	Week 2	Week 2	45.00	No	3.00	4.00	No		
					05/10/2000	26	Week 4	Week 4	36.00	No	2.00	3.00	Yes	60.00	
					05/26/2000	42	Week 6	Week 6	36.00	No	2.00	3.00	Yes		
					06/13/2000	60	Week 8	Week 8	26.00	Yes	1.00	1.00	Yes	73.00	14.00
538	18	Placebo	Adolescents	04/25/2000	04/19/2000		Screening		66.00						
				06/06/2000	04/24/2000		Baseline		45.00			4.00		53.00	24.00
					05/01/2000	7	Week 1	Week 1	39.00	No	3.00	4.00	No		

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
538	18	Placebo	Adolescents		05/08/2000	14	Week 2	Week 2	38.00	No	3.00	3.00	No		
					05/22/2000	28	Week 4	Week 4	41.00	No	2.00	3.00	Yes	61.00	
					06/06/2000	43	Week 8	Week 6	24.00	Yes	1.00	1.00	Yes	72.00	14.00
539	18	Citalopram	Adolescents	05/11/2000	05/03/2000		Screening		78.00						
				07/10/2000	05/11/2000		Baseline		67.00			5.00		52.00	33.00
					05/19/2000	9	Week 1	Week 1	37.00	No	2.00	4.00	Yes		
					05/26/2000	16	Week 2	Week 2	39.00	No	3.00	4.00	No		
					06/09/2000	30	Week 4	Week 4	35.00	No	3.00	4.00	No	54.00	
					06/23/2000	44	Week 6	Week 6	24.00	Yes	2.00	2.00	Yes		
					07/10/2000	61	Week 8	Week 8	32.00	No	2.00	3.00	Yes	63.00	12.00
540	18	Placebo	Adolescents	05/20/2000	05/10/2000		Screening		71.00						
				07/14/2000	05/19/2000		Baseline		43.00			4.00		48.00	21.00
					05/26/2000	7	Week 1	Week 1	40.00	No	3.00	4.00	No		
					06/01/2000	13	Week 2	Week 2	34.00	No	3.00	4.00	No		
					06/16/2000	28	Week 4	Week 4	32.00	No	2.00	3.00	Yes	52.00	
					06/29/2000	41	Week 6	Week 6	38.00	No	3.00	3.00	No		
					07/14/2000	56	Week 8	Week 8	35.00	No	2.00	3.00	Yes	58.00	26.00
541	12	Citalopram	Adolescents	05/06/2000	04/20/2000		Screening		79.00						
				07/06/2000	05/04/2000		Baseline		79.00			4.00		60.00	39.00
					05/11/2000	6	Week 1	Week 1	70.00	No	3.00	4.00	No		
					05/19/2000	14	Week 2	Week 2	48.00	No	2.00	4.00	Yes		
					06/05/2000	31	Week 4	Week 4	35.00	No	2.00	3.00	Yes	70.00	
					06/19/2000	45	Week 6	Week 6	29.00	No	2.00	2.00	Yes		
					07/06/2000	62	Week 8	Week 8	25.00	Yes	1.00	1.00	Yes	75.00	22.00
542	12	Placebo	Adolescents	08/03/2000	07/25/2000		Screening		68.00						
				10/06/2000	08/02/2000		Baseline		61.00			6.00		45.00	36.00
					08/09/2000	7	Week 1	Week 1	46.00	No	3.00	5.00	No		

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
542	12	Placebo	Adolescents		08/18/2000	16	Week 2	Week 2	44.00	No	3.00	5.00	No		
					09/06/2000	35	Week 4	Week 4	31.00	No	2.00	4.00	Yes	61.00	
					09/20/2000	49	Week 6	Week 8	46.00	No	3.00	4.00	No		
					10/04/2000	63	Week 8	Week 8	38.00	No	2.00	3.00	Yes	60.00	26.00
545	10	Placebo	Adolescents	11/14/2000	11/06/2000		Screening		59.00						
				01/08/2001	11/13/2000		Baseline		44.00			4.00		53.00	26.00
					11/20/2000	7	Week 1	Week 1	37.00	No	3.00	3.00	No		
					11/27/2000	14	Week 2	Week 2	24.00	Yes	2.00	2.00	Yes		
					12/11/2000	28	Week 4	Week 4	29.00	No	2.00	2.00	Yes	60.00	
					12/22/2000	39	Week 6	Week 6	32.00	No	2.00	3.00	Yes		
					01/08/2001	56	Week 8	Week 8	33.00	No	2.00	3.00	Yes	63.00	20.00
546	10	Citalopram	Adolescents	12/05/2000	11/27/2000		Screening		65.00						
				01/29/2001	12/04/2000		Baseline		57.00			5.00		40.00	33.00
					12/11/2000	7	Week 1	Week 1	48.00	No	3.00	5.00	No		
					12/18/2000	14	Week 2	Week 2	41.00	No	3.00	5.00	No		
					01/02/2001	29	Week 4	Week 4	41.00	No	3.00	5.00	No	45.00	
					01/15/2001	42	Week 6	Week 6	38.00	No	3.00	4.00	No		
					01/29/2001	56	Week 8	Week 8	40.00	No	3.00	4.00	No	45.00	30.00
547	10	Placebo	Adolescents	12/28/2000	12/20/2000		Screening		72.00						
				02/19/2001	12/28/2000		Baseline		44.00			4.00		51.00	23.00
					01/05/2001	9	Week 1	Week 1	42.00	No	4.00	4.00	No		
					01/11/2001	15	Week 2	Week 2	37.00	No	3.00	4.00	No		
					01/24/2001	28	Week 4	Week 4	39.00	No	4.00	4.00	No	51.00	
					02/07/2001	42	Week 6	Week 6	46.00	No	4.00	4.00	No		
					02/20/2001	55	Week 8	Week 8	47.00	No	4.00	4.00	No	51.00	25.00
549	03	Placebo	Adolescents	04/07/2000	03/31/2000		Screening		80.00						
				06/07/2000	04/07/2000		Baseline		79.00			5.00		60.00	40.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
549	03	Placebo	Adolescents		04/14/2000	8	Week 1	Week 1	71.00	No	3.00	5.00	No		
					04/21/2000	15	Week 2	Week 2	51.00	No	2.00	4.00	Yes		
					05/05/2000	29	Week 4	Week 4	57.00	No	3.00	4.00	No	61.00	
					05/19/2000	43	Week 6	Week 6	43.00	No	2.00	3.00	Yes		
					06/07/2000	62	Week 8	Week 8	24.00	Yes	2.00	2.00	Yes	85.00	17.00
550	03	Placebo	Adolescents	05/11/2000	05/05/2000		Screening		57.00						
				06/20/2000	05/11/2000		Baseline		63.00			4.00		50.00	30.00
					05/17/2000	7	Week 1	Week 1	66.00	No	4.00	4.00	No		
					05/24/2000	14	Week 2	Week 2	45.00	No	3.00	4.00	No		
					06/07/2000	28	Week 4	Week 4	65.00	No	4.00	4.00	No	60.00	
					06/21/2000	42	Week 8	Week 6	65.00	No	5.00	5.00	No	50.00	31.00
553	08	Citalopram	Adolescents	07/20/2000	07/13/2000		Screening		66.00						
				09/24/2000	07/20/2000		Baseline		53.00			5.00		45.00	30.00
					07/27/2000	8	Week 1	Week 1	44.00	No	2.00	4.00	Yes		
					08/03/2000	15	Week 2	Week 2	42.00	No	2.00	4.00	Yes		
					08/23/2000	35	Week 4	Week 4	56.00	No	4.00	5.00	No	45.00	
					09/05/2000	48	Week 6	Week 6	43.00	No	3.00	4.00	No		
					09/25/2000	68	Week 8	Week 8	47.00	No	4.00	5.00	No	55.00	25.00
554	08	Placebo	Adolescents	08/08/2000	08/01/2000		Screening		68.00						
				10/09/2000	08/08/2000		Baseline		57.00			5.00		40.00	33.00
					08/22/2000	15	Week 2	Week 2	52.00	No	3.00	5.00	No		
					09/05/2000	29	Week 4	Week 4	42.00	No	2.00	4.00	Yes	70.00	
					09/19/2000	43	Week 6	Week 6	58.00	No	3.00	5.00	No		
					10/10/2000	64	Week 8	Week 8	31.00	No	1.00	2.00	Yes	85.00	16.00
555	08	Placebo	Adolescents	12/14/2000	12/08/2000		Screening		67.00						
				02/08/2001	12/14/2000		Baseline		66.00			5.00		40.00	33.00
					12/22/2000	9	Week 1	Week 1	56.00	No	2.00	4.00	Yes		

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
555	08	Placebo	Adolescents		12/27/2000	14	Week 2	Week 2	27.00	Yes	2.00	2.00	Yes		
					01/11/2001	29	Week 4	Week 4	31.00	No	2.00	3.00	Yes	70.00	
					01/24/2001	42	Week 6	Week 6	32.00	No	3.00	3.00	No		
					02/09/2001	58	Week 8	Week 8	21.00	Yes	2.00	1.00	Yes	80.00	12.00
557	19	Placebo	Adolescents	03/22/2000	03/15/2000		Screening		67.00						
				04/04/2000	03/22/2000		Baseline		69.00			4.00		45.00	29.00
					03/29/2000	8	Week 1	Week 1	74.00	No	4.00	4.00	No		
					04/12/2000	22	Week 8	Week 4	78.00	No	4.00	4.00	No	55.00	31.00
558	19	Citalopram	Adolescents	03/23/2000	03/16/2000		Screening		75.00						
				05/21/2000	03/23/2000		Baseline		78.00			4.00		50.00	35.00
					03/30/2000	8	Week 1	Week 1	74.00	No	4.00	4.00	No		
					04/06/2000	15	Week 2	Week 2	61.00	No	3.00	4.00	No		
					04/24/2000	33	Week 4	Week 4	70.00	No	4.00	4.00	No	50.00	
					05/08/2000	47	Week 6	Week 6	62.00	No	3.00	4.00	No		
					05/22/2000	61	Week 8	Week 8	20.00	Yes	1.00	1.00	Yes	80.00	9.00
559	19	Citalopram	Adolescents	03/24/2000	03/14/2000		Screening		77.00						
				05/17/2000	03/24/2000		Baseline		77.00			4.00		51.00	28.00
					03/30/2000	7	Week 1	Week 1	70.00	No	4.00	4.00	No		
					04/06/2000	14	Week 2	Week 2	65.00	No	4.00	4.00	No		
					04/20/2000	28	Week 4	Week 4	55.00	No	4.00	4.00	No	60.00	
					05/04/2000	42	Week 6	Week 6	36.00	No	2.00	3.00	Yes		
					05/18/2000	56	Week 8	Week 8	27.00	Yes	2.00	2.00	Yes	80.00	13.00
560	19	Placebo	Adolescents	03/27/2000	03/20/2000		Screening		74.00						
				05/21/2000	03/27/2000		Baseline		76.00			4.00		50.00	31.00
					04/03/2000	8	Week 1	Week 1	75.00	No	4.00	4.00	No		
					04/10/2000	15	Week 2	Week 2	75.00	No	4.00	4.00	No		
					04/24/2000	29	Week 4	Week 4	75.00	No	4.00	4.00	No	55.00	

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	____Visit Name_____ CRF	DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
560	19	Placebo	Adolescents		05/08/2000	43	Week 6	Week 6	79.00	No	4.00	4.00	No		
					05/22/2000	57	Week 8	Week 8	69.00	No	4.00	4.00	No	55.00	33.00
561	07	Citalopram	Adolescents	04/26/2000	04/12/2000		Screening		45.00						
				05/17/2000	04/26/2000		Baseline		42.00			4.00		50.00	21.00
					05/03/2000	8	Week 1	Week 1	31.00	No	3.00	4.00	No		
					05/11/2000	16	Week 2	Week 2	21.00	Yes	2.00	4.00	Yes		
					05/25/2000	30	Week 8	Week 4	26.00	Yes	3.00	3.00	No	73.00	17.00
565	02	Citalopram	Adolescents	03/17/2000	03/03/2000		Screening		48.00						
				05/11/2000	03/17/2000		Baseline		52.00			4.00		50.00	31.00
					03/24/2000	8	Week 1	Week 1	28.00	Yes	2.00	3.00	Yes		
					03/30/2000	14	Week 2	Week 2	31.00	No	2.00	3.00	Yes		
					04/14/2000	29	Week 4	Week 4	49.00	No	3.00	4.00	No	50.00	
					05/02/2000	47	Week 6	Week 6	50.00	No	4.00	4.00	No		
					05/12/2000	57	Week 8	Week 8	39.00	No	3.00	3.00	No	50.00	23.00
573	05	Placebo	Adolescents	05/12/2000	05/05/2000		Screening		70.00						
				07/13/2000	05/12/2000		Baseline		61.00			5.00		43.00	26.00
					05/19/2000	8	Week 1	Week 1	49.00	No	3.00	4.00	No		
					05/26/2000	15	Week 2	Week 2	43.00	No	3.00	4.00	No		
					06/09/2000	29	Week 4	Week 4	41.00	No	2.00	4.00	Yes	48.00	
					06/27/2000	47	Week 6	Week 6	27.00	Yes	2.00	2.00	Yes		
					07/14/2000	64	Week 8	Week 8	25.00	Yes	2.00	2.00	Yes	85.00	11.00
574	05	Placebo	Adolescents	05/24/2000	05/18/2000		Screening		72.00						
				05/30/2000	05/24/2000		Baseline		68.00			5.00		38.00	34.00
					05/31/2000	8	Week 8	Week 1	82.00	No	6.00	6.00	No	40.00	44.00
575	05	Citalopram	Adolescents	05/31/2000	05/22/2000		Screening		74.00						
				07/31/2000	05/31/2000		Baseline		65.00			5.00		47.00	29.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit CRF	Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
575	05	Citalopram	Adolescents		06/09/2000	10	Week 1	Week 1	56.00	No	3.00	4.00	No		
					06/19/2000	20	Week 2	Week 2	33.00	No	2.00	3.00	Yes		
					06/28/2000	29	Week 4	Week 4	26.00	Yes	2.00	2.00	Yes	70.00	
					07/12/2000	43	Week 6	Week 6	24.00	Yes	2.00	2.00	Yes		
					08/01/2000	63	Week 8	Week 8	22.00	Yes	2.00	2.00	Yes	80.00	10.00
576	05	Citalopram	Adolescents	06/12/2000	06/05/2000		Screening		68.00						
				08/06/2000	06/12/2000		Baseline		50.00			4.00		48.00	25.00
					06/19/2000	8	Week 1	Week 1	36.00	No	2.00	2.00	Yes		
					06/26/2000	15	Week 2	Week 2	28.00	Yes	2.00	3.00	Yes		
					07/10/2000	29	Week 4	Week 4	39.00	No	3.00	4.00	No	59.00	
					07/24/2000	43	Week 6	Week 6	28.00	Yes	1.00	2.00	Yes		
					08/07/2000	57	Week 8	Week 8	26.00	Yes	1.00	2.00	Yes	75.00	12.00
577	19	Citalopram	Adolescents	04/04/2000	03/28/2000		Screening		70.00						
				05/29/2000	04/04/2000		Baseline		70.00			4.00		50.00	27.00
					04/11/2000	8	Week 1	Week 1	46.00	No	4.00	4.00	No		
					04/18/2000	15	Week 2	Week 2	41.00	No	3.00	3.00	No		
					05/02/2000	29	Week 4	Week 4	42.00	No	3.00	3.00	No	60.00	
					05/16/2000	43	Week 6	Week 6	38.00	No	3.00	3.00	No		
					05/30/2000	57	Week 8	Week 8	52.00	No	4.00	4.00	No	55.00	27.00
578	19	Placebo	Adolescents	04/04/2000	03/28/2000		Screening		71.00						
				05/29/2000	04/04/2000		Baseline		71.00			4.00		50.00	37.00
					04/11/2000	8	Week 1	Week 1	60.00	No	3.00	4.00	No		
					04/18/2000	15	Week 2	Week 2	44.00	No	3.00	4.00	No		
					05/02/2000	29	Week 4	Week 4	61.00	No	3.00	4.00	No	55.00	
					05/18/2000	45	Week 6	Week 6	40.00	No	2.00	3.00	Yes		
					05/30/2000	57	Week 8	Week 8	36.00	No	3.00	3.00	No	75.00	18.00
579	19	Citalopram	Adolescents	05/05/2000	04/27/2000		Screening		71.00						

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit CRF	Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
579	19	Citalopram	Adolescents	06/20/2000	05/04/2000		Baseline		72.00			4.00		45.00	30.00
					05/11/2000	7	Week 1	Week 1	45.00	No	3.00	3.00	No		
					05/18/2000	14	Week 2	Week 2	40.00	No	3.00	3.00	No		
					06/01/2000	28	Week 4	Week 4	35.00	No	3.00	3.00	No	70.00	
					06/13/2000	40	Week 6	Week 6	28.00	Yes	2.00	2.00	Yes		
					06/21/2000	48	Week 8	Week 6	25.00	Yes	2.00	2.00	Yes	80.00	12.00
580	19	Placebo	Adolescents	05/30/2000	05/23/2000		Screening		57.00						
				07/24/2000	05/30/2000		Baseline		58.00			4.00		55.00	24.00
					06/06/2000	8	Week 1	Week 1	38.00	No	3.00	3.00	No		
					06/13/2000	15	Week 2	Week 2	27.00	Yes	2.00	2.00	Yes		
					06/27/2000	29	Week 4	Week 4	19.00	Yes	1.00	1.00	Yes	90.00	
					07/11/2000	43	Week 6	Week 6	23.00	Yes	1.00	1.00	Yes		
					07/25/2000	57	Week 8	Week 8	25.00	Yes	1.00	1.00	Yes	76.00	14.00
585	18	Placebo	Adolescents	06/01/2000	05/26/2000		Screening		53.00						
				07/25/2000	06/01/2000		Baseline		42.00			4.00		58.00	17.00
					06/09/2000	9	Week 1	Week 1	39.00	No	3.00	4.00	No		
					06/16/2000	16	Week 2	Week 2	28.00	Yes	3.00	3.00	No		
					06/29/2000	29	Week 4	Week 4	33.00	No	3.00	3.00	No	58.00	
					07/14/2000	44	Week 6	Week 6	19.00	Yes	2.00	2.00	Yes		
					07/26/2000	56	Week 8	Week 8	24.00	Yes	1.00	1.00	Yes	64.00	12.00
586	18	Citalopram	Adolescents	12/12/2000	12/04/2000		Screening		61.00						
				01/31/2001	12/12/2000		Baseline		57.00			4.00		45.00	32.00
					12/20/2000	9	Week 1	Week 1	49.00	No	3.00	4.00	No		
					12/27/2000	16	Week 2	Week 2	44.00	No	3.00	4.00	No		
					01/11/2001	31	Week 4	Week 4	64.00	No	5.00	4.00	No	45.00	
					01/25/2001	45	Week 6	Week 6	40.00	No	3.00	4.00	No		
					02/07/2001	58	Week 8	Week 8	46.00	No	3.00	4.00	No	48.00	27.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit CRF	Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
587	18	Citalopram	Adolescents	05/24/2000	04/20/2000		Screening		60.00						
				07/19/2000	05/23/2000		Baseline		49.00			4.00		51.00	23.00
					06/02/2000	10	Week 1	Week 1	40.00	No	3.00	3.00	No		
					06/12/2000	20	Week 2	Week 2	34.00	No	2.00	3.00	Yes		
					06/30/2000	38	Week 4	Week 6	27.00	Yes	2.00	2.00	Yes	66.00	
					07/06/2000	44	Week 6	Week 6	21.00	Yes	1.00	1.00	Yes		
					07/19/2000	57	Week 8	Week 8	22.00	Yes	1.00	1.00	Yes	75.00	14.00
588	18	Placebo	Adolescents	06/01/2000	05/25/2000		Screening		86.00						
				07/27/2000	05/31/2000		Baseline		79.00			5.00		35.00	33.00
					06/08/2000	8	Week 1	Week 1	73.00	No	3.00	4.00	No		
					06/15/2000	15	Week 2	Week 2	61.00	No	2.00	4.00	Yes		
					06/29/2000	29	Week 4	Week 4	70.00	No	4.00	4.00	No	45.00	
					07/13/2000	43	Week 6	Week 6	43.00	No	2.00	3.00	Yes		
					07/27/2000	57	Week 8	Week 8	56.00	No	3.00	4.00	No	55.00	29.00
589	20	Placebo	Adolescents	05/31/2000	05/24/2000		Screening		53.00						
				07/23/2000	05/31/2000		Baseline		53.00			4.00		50.00	28.00
					06/07/2000	8	Week 1	Week 1	53.00	No	4.00	4.00	No		
					06/12/2000	13	Week 2	Week 2	53.00	No	4.00	4.00	No		
					06/26/2000	27	Week 4	Week 4	40.00	No	3.00	4.00	No	55.00	
					07/10/2000	41	Week 6	Week 6	27.00	Yes	2.00	3.00	Yes		
					07/24/2000	55	Week 8	Week 8	17.00	Yes	1.00	1.00	Yes	95.00	9.00
590	20	Citalopram	Adolescents	06/13/2000	06/07/2000		Screening		48.00						
				08/07/2000	06/13/2000		Baseline		50.00			5.00		30.00	32.00
					06/21/2000	9	Week 1	Week 1	47.00	No	4.00	5.00	No		
					06/27/2000	15	Week 2	Week 2	47.00	No	4.00	5.00	No		
					07/13/2000	31	Week 4	Week 4	34.00	No	3.00	4.00	No	55.00	
					07/25/2000	43	Week 6	Week 6	35.00	No	3.00	4.00	No		
					08/08/2000	57	Week 8	Week 8	34.00	No	3.00	4.00	No	60.00	21.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit CRF	Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
591	20	Placebo	Adolescents	06/27/2000	06/21/2000		Screening		60.00						
				08/20/2000	06/27/2000		Baseline		58.00			4.00		50.00	22.00
					07/05/2000	9	Week 1	Week 1	51.00	No	3.00	4.00	No		
					07/10/2000	14	Week 2	Week 2	49.00	No	3.00	4.00	No		
					07/24/2000	28	Week 4	Week 4	49.00	No	3.00	4.00	No	55.00	
					08/07/2000	42	Week 6	Week 6	47.00	No	3.00	4.00	No		
					08/21/2000	56	Week 8	Week 8	48.00	No	3.00	4.00	No	60.00	20.00
592	20	Citalopram	Adolescents	06/28/2000	06/19/2000		Screening		41.00						
				08/20/2000	06/28/2000		Baseline		41.00			4.00		50.00	26.00
					07/05/2000	8	Week 1	Week 1	23.00	Yes	2.00	3.00	Yes		
					07/10/2000	13	Week 2	Week 2	19.00	Yes	2.00	2.00	Yes		
					07/24/2000	27	Week 4	Week 4	17.00	Yes	1.00	1.00	Yes	95.00	
					08/07/2000	41	Week 6	Week 6	17.00	Yes	1.00	1.00	Yes		
					08/21/2000	55	Week 8	Week 8	17.00	Yes	1.00	1.00	Yes	95.00	9.00
593	11	Placebo	Adolescents	09/08/2000	08/14/2000		Screening		76.00						
				11/02/2000	09/08/2000		Baseline		74.00			4.00		55.00	43.00
					09/14/2000	7	Week 1	Week 1	68.00	No	4.00	4.00	No		
					09/22/2000	15	Week 2	Week 2	60.00	No	4.00	4.00	No		
					10/03/2000	26	Week 4	Week 4	59.00	No	4.00	4.00	No	55.00	
					10/19/2000	42	Week 6	Week 6	57.00	No	5.00	4.00	No		
					11/03/2000	57	Week 8	Week 8	71.00	No	4.00	4.00	No	55.00	39.00
594	11	Citalopram	Adolescents	09/08/2000	08/24/2000		Screening		73.00						
				11/03/2000	09/08/2000		Baseline		59.00			4.00		55.00	25.00
					09/18/2000	11	Week 1	Week 2	58.00	No	3.00	4.00	No		
					09/28/2000	21	Week 2	Week 2	41.00	No	2.00	4.00	Yes		
					10/10/2000	33	Week 4	Week 4	48.00	No	2.00	4.00	Yes	60.00	
					10/20/2000	43	Week 6	Week 6	40.00	No	2.00	4.00	Yes		
					11/03/2000	57	Week 8	Week 8	39.00	No	2.00	4.00	Yes	62.00	16.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit CRF	Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
595	11	Citalopram	Adolescents	09/25/2000	09/13/2000		Screening		58.00						
				11/19/2000	09/25/2000		Baseline		60.00			4.00		51.00	39.00
					10/02/2000	8	Week 1	Week 1	62.00	No	4.00	4.00	No		
					10/11/2000	17	Week 2	Week 2	64.00	No	4.00	4.00	No		
					10/23/2000	29	Week 4	Week 4	48.00	No	3.00	4.00	No	58.00	
					11/06/2000	43	Week 6	Week 6	50.00	No	3.00	4.00	No		
					11/20/2000	57	Week 8	Week 8	43.00	No	4.00	4.00	No	51.00	18.00
597	15	Citalopram	Adolescents	07/06/2000	06/29/2000		Screening		55.00						
				09/04/2000	07/06/2000		Baseline		52.00			4.00		55.00	28.00
					07/14/2000	9	Week 1	Week 1	47.00	No	3.00	4.00	No		
					07/19/2000	14	Week 2	Week 2	45.00	No	5.00	4.00	No		
					07/27/2000	22	Week 4	Week 4	43.00	No	2.00	3.00	Yes	60.00	
					09/18/2000	75	Week 8	Week 8	30.00	No	2.00	3.00	Yes	65.00	18.00
598	15	Citalopram	Adolescents	07/06/2000	06/28/2000		Screening		75.00						
				08/23/2000	07/06/2000		Baseline		57.00			5.00		45.00	33.00
					07/13/2000	8	Week 1	Week 1	57.00	No	5.00	5.00	No		
					07/21/2000	16	Week 2	Week 2	43.00	No	3.00	4.00	No		
					07/28/2000	23	Week 4	Week 4	40.00	No	2.00	3.00	Yes	55.00	
					08/10/2000	36	Week 6	Week 6	40.00	No	2.00	4.00	Yes		
					08/24/2000	50	Week 8	Week 8	52.00	No	3.00	4.00	No	50.00	29.00
599	15	Placebo	Adolescents	08/31/2000	08/22/2000		Screening		53.00						
				10/18/2000	08/31/2000		Baseline		49.00			4.00		55.00	29.00
					09/06/2000	7	Week 1	Week 1	50.00	No	3.00	4.00	No		
					09/11/2000	12	Week 2	Week 2	43.00	No	3.00	4.00	No		
					09/25/2000	26	Week 4	Week 4	48.00	No	3.00	4.00	No	55.00	
					10/09/2000	40	Week 6	Week 6	39.00	No	3.00	4.00	No		
					10/19/2000	50	Week 8	Week 8	35.00	No	3.00	4.00	No	65.00	24.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit CRF	Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
605	20	Citalopram	Adolescents	07/28/2000	07/21/2000		Screening		63.00						
				09/20/2000	07/28/2000		Baseline		69.00			5.00		75.00	36.00
					08/02/2000	6	Week 1	Week 1	50.00	No	3.00	4.00	No		
					08/09/2000	13	Week 2	Week 2	48.00	No	3.00	4.00	No		
					08/24/2000	28	Week 4	Week 4	46.00	No	3.00	5.00	No	75.00	
					09/07/2000	42	Week 6	Week 6	39.00	No	3.00	4.00	No		
					09/21/2000	56	Week 8	Week 8	32.00	No	3.00	4.00	No	80.00	16.00
606	20	Placebo	Adolescents	08/08/2000	08/02/2000		Screening		55.00						
				10/05/2000	08/08/2000		Baseline		55.00			4.00		60.00	27.00
					08/15/2000	8	Week 1	Week 1	50.00	No	3.00	4.00	No		
					08/22/2000	15	Week 2	Week 2	45.00	No	3.00	4.00	No		
					09/07/2000	31	Week 4	Week 4	37.00	No	3.00	4.00	No	72.00	
					09/21/2000	45	Week 6	Week 6	25.00	Yes	2.00	3.00	Yes		
					10/05/2000	59	Week 8	Week 8	29.00	No	2.00	3.00	Yes	88.00	13.00
607	20	Citalopram	Adolescents	08/07/2000	07/31/2000		Screening		47.00						
				10/01/2000	08/07/2000		Baseline		50.00			4.00		55.00	32.00
					08/14/2000	8	Week 1	Week 1	47.00	No	4.00	4.00	No		
					08/21/2000	15	Week 2	Week 2	38.00	No	3.00	3.00	No		
					09/05/2000	30	Week 4	Week 4	35.00	No	3.00	3.00	No	65.00	
					09/18/2000	43	Week 6	Week 6	33.00	No	3.00	3.00	No		
					10/02/2000	57	Week 8	Week 8	27.00	Yes	2.00	2.00	Yes	80.00	16.00
608	20	Placebo	Adolescents	08/16/2000	08/09/2000		Screening		57.00						
				08/28/2000	08/16/2000		Baseline		40.00			4.00		60.00	20.00
					08/24/2000	9	Week 1	Week 1	33.00	No	3.00	4.00	No		
					09/06/2000	22	Week 8	Week 4	30.00	No	3.00	3.00	No	76.00	13.00
609	05	Citalopram	Adolescents	06/30/2000	06/22/2000		Screening		53.00						
				08/31/2000	06/29/2000		Baseline		50.00			4.00		48.00	23.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	____Visit CRF	Name_____ DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
609	05	Citalopram	Adolescents		07/11/2000	12	Week 1	Week 2	38.00	No	3.00	4.00	No		
					07/20/2000	21	Week 2	Week 2	35.00	No	2.00	3.00	Yes		
					08/03/2000	35	Week 4	Week 4	33.00	No	2.00	3.00	Yes	62.00	
					08/14/2000	46	Week 6	Week 6	26.00	Yes	2.00	3.00	Yes		
					08/31/2000	63	Week 8	Week 8	24.00	Yes	2.00	2.00	Yes	70.00	16.00
610	05	Placebo	Adolescents	08/21/2000	08/14/2000		Screening		68.00						
				10/16/2000	08/21/2000		Baseline		69.00			5.00		46.00	33.00
					08/28/2000	8	Week 1	Week 1	70.00	No	4.00	5.00	No		
					09/05/2000	16	Week 2	Week 2	52.00	No	3.00	4.00	No		
					09/18/2000	29	Week 4	Week 4	42.00	No	3.00	4.00	No	54.00	
					10/02/2000	43	Week 6	Week 6	43.00	No	3.00	4.00	No		
					10/19/2000	60	Week 8	Week 8	44.00	No	3.00	4.00	No	57.00	23.00
611	05	Placebo	Adolescents	09/26/2000	09/21/2000		Screening		76.00						
				11/26/2000	09/26/2000		Baseline		56.00			4.00		62.00	34.00
					10/02/2000	7	Week 1	Week 1	65.00	No	4.00	4.00	No		
					10/09/2000	14	Week 2	Week 2	61.00	No	3.00	4.00	No		
					10/23/2000	28	Week 4	Week 4	63.00	No	4.00	4.00	No	42.00	
					11/06/2000	42	Week 6	Week 6	41.00	No	2.00	3.00	Yes		
					11/27/2000	63	Week 8	Week 8	35.00	No	2.00	3.00	Yes	58.00	22.00
617	21	Citalopram	Adolescents	09/27/2000	09/21/2000		Screening		56.00						
				11/28/2000	09/27/2000		Baseline		56.00			4.00		48.00	30.00
					10/04/2000	8	Week 1	Week 1	59.00	No	4.00	4.00	No		
					10/11/2000	15	Week 2	Week 2	54.00	No	4.00	4.00	No		
					10/25/2000	29	Week 4	Week 4	51.00	No	4.00	4.00	No	48.00	
					11/08/2000	43	Week 6	Week 6	44.00	No	4.00	4.00	No		
					11/29/2000	64	Week 8	Week 8	52.00	No	4.00	4.00	No	48.00	24.00
618	21	Placebo	Adolescents	10/19/2000	10/12/2000		Screening		59.00						

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
618	21	Placebo	Adolescents	12/11/2000	10/19/2000		Baseline		56.00			4.00		45.00	26.00
					10/26/2000	8	Week 1	Week 1	49.00	No	4.00	4.00	No		
					10/31/2000	13	Week 2	Week 2	50.00	No	4.00	4.00	No		
					11/14/2000	27	Week 4	Week 4	53.00	No	4.00	4.00	No	50.00	
					11/28/2000	41	Week 6	Week 6	52.00	No	4.00	4.00	No		
					12/12/2000	55	Week 8	Week 8	49.00	No	4.00	4.00	No	50.00	26.00
619	21	Placebo	Adolescents	11/08/2000	11/01/2000		Screening		54.00						
				11/28/2000	11/08/2000		Baseline		52.00			4.00		45.00	27.00
					11/15/2000	8	Week 1	Week 1	50.00	No	4.00	4.00	No		
					11/22/2000	15	Week 2	Week 2	47.00	No	4.00	4.00	No		
					12/06/2000	29	Week 8	Week 4	53.00	No	4.00	4.00	No	45.00	
625	22	Placebo	Adolescents	09/10/2000	08/31/2000		Screening		72.00						
				11/01/2000	09/06/2000		Baseline		72.00			5.00		50.00	31.00
					09/14/2000	5	Week 1	Week 1	71.00	No	4.00	5.00	No		
					09/21/2000	12	Week 2	Week 2	68.00	No	4.00	5.00	No		
					10/05/2000	26	Week 4	Week 4	73.00	No	4.00	5.00	No	42.00	
					10/17/2000	38	Week 6	Week 6	70.00	No	4.00	5.00	No		
					11/02/2000	54	Week 8	Week 8	69.00	No	4.00	5.00	No	46.00	31.00
626	22	Citalopram	Adolescents	09/13/2000	09/06/2000		Screening		63.00						
				10/29/2000	09/13/2000		Baseline		62.00			5.00		55.00	29.00
					09/20/2000	8	Week 1	Week 1	74.00	No	5.00	5.00	No		
					09/27/2000	15	Week 2	Week 2	67.00	No	3.00	5.00	No		
					10/16/2000	34	Week 4	Week 4	46.00	No	3.00	4.00	No	51.00	
					10/30/2000	48	Week 6	Week 6	19.00	Yes	1.00	1.00	Yes		
627	22	Placebo	Adolescents	09/28/2000	09/21/2000		Screening		62.00						
				11/21/2000	09/28/2000		Baseline		62.00			5.00		52.00	34.00
					10/05/2000	8	Week 1	Week 1	54.00	No	3.00	5.00	No		

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
627	22	Placebo	Adolescents		10/12/2000	15	Week 2	Week 2	51.00	No	3.00	5.00	No		
					10/24/2000	27	Week 4	Week 4	48.00	No	3.00	4.00	No	53.00	
					11/07/2000	41	Week 6	Week 6	30.00	No	2.00	3.00	Yes		
					11/21/2000	55	Week 8	Week 8	29.00	No	2.00	3.00	Yes	72.00	17.00
628	22	Citalopram	Adolescents	10/16/2000	10/05/2000		Screening		61.00						
				11/12/2000	10/16/2000		Baseline		62.00			5.00		52.00	33.00
					10/23/2000	8	Week 1	Week 1	33.00	No	3.00	4.00	No		
					10/30/2000	15	Week 2	Week 2	30.00	No	3.00	4.00	No		
					11/13/2000	29	Week 8	Week 4	27.00	Yes	3.00	4.00	No	70.00	21.00
629	01	Citalopram	Adolescents	09/28/2000	09/11/2000		Screening		59.00						
				11/26/2000	09/28/2000		Baseline		56.00			5.00		60.00	30.00
					10/05/2000	8	Week 1	Week 1	40.00	No	2.00	4.00	Yes		
					10/12/2000	15	Week 2	Week 2	32.00	No	2.00	3.00	Yes		
					10/26/2000	29	Week 4	Week 4	27.00	Yes	2.00	3.00	Yes	80.00	
					11/07/2000	41	Week 6	Week 6	26.00	Yes	2.00	3.00	Yes		
					11/27/2000	61	Week 8	Week 8	30.00	No	1.00	2.00	Yes	80.00	18.00
637	14	Placebo	Adolescents	12/27/2000	12/18/2000		Screening		55.00						
				02/21/2001	12/27/2000		Baseline		51.00			4.00		65.00	26.00
					01/03/2001	8	Week 1	Week 1	46.00	No	4.00	4.00	No		
					01/10/2001	15	Week 2	Week 2	42.00	No	3.00	3.00	No		
					01/25/2001	30	Week 4	Week 4	40.00	No	3.00	3.00	No	75.00	
					02/08/2001	44	Week 6	Week 6	44.00	No	4.00	4.00	No		
					02/22/2001	58	Week 8	Week 8	36.00	No	3.00	3.00	No	75.00	17.00
638	14	Citalopram	Adolescents	10/26/2000	10/20/2000		Screening		44.00						
				10/27/2000	10/26/2000		Baseline		41.00			4.00		65.00	22.00
					11/02/2000	8	Week 8	Week 1	30.00	No	3.00	3.00	No	75.00	14.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.

Listing 8
Efficacy Parameters

Patient Number	Center Number	Treatment Group	Age Group	Start(Stop) Date of Double-Blind Medication	Date of Assessment	Study Day	Visit Name CRF	Visit Name DERIVED	CDRS-R Total Score	CRDS-R Responder	CGI-I	CGI-S	CGI Responder	CGAS	K-SADS-P Depression Module
639	14	Placebo	Adolescents	10/26/2000	10/18/2000		Screening		42.00						
				12/21/2000	10/26/2000		Baseline		41.00			4.00		60.00	26.00
					11/02/2000	8	Week 1	Week 1	33.00	No	3.00	3.00	No		
					11/09/2000	15	Week 2	Week 2	29.00	No	3.00	3.00	No		
					11/20/2000	26	Week 4	Week 4	37.00	No	3.00	3.00	No	75.00	
					12/06/2000	42	Week 6	Week 6	24.00	Yes	2.00	3.00	Yes		
					12/21/2000	57	Week 8	Week 8	19.00	Yes	1.00	1.00	Yes	90.00	11.00
640	14	Citalopram	Adolescents	11/02/2000	10/25/2000		Screening		58.00						
				11/15/2000	11/02/2000		Baseline		54.00			5.00		70.00	31.00
					11/09/2000	8	Week 1	Week 1	51.00	No	4.00	5.00	No		
					11/16/2000	15	Week 2	Week 2	45.00	No	3.00	4.00	No		
645	19	Citalopram	Adolescents	11/16/2000	11/07/2000		Screening		71.00						
				12/26/2000	11/15/2000		Baseline		71.00			5.00		45.00	28.00
					11/22/2000	7	Week 1	Week 1	61.00	No	4.00	5.00	No		
					11/29/2000	14	Week 2	Week 2	53.00	No	3.00	4.00	No		
					12/13/2000	28	Week 4	Week 4	48.00	No	3.00	4.00	No	55.00	
					12/26/2000	41	Week 6	Week 6	52.00	No	3.00	4.00	No		
646	19	Placebo	Adolescents	12/12/2000	12/06/2000		Screening		63.00						
				02/14/2001	12/12/2000		Baseline		63.00			5.00		35.00	32.00
					12/20/2000	9	Week 1	Week 1	61.00	No	4.00	5.00	No		
					12/27/2000	16	Week 2	Week 2	50.00	No	3.00	4.00	No		
					01/11/2001	31	Week 4	Week 4	47.00	No	3.00	4.00	No	40.00	
					01/25/2001	45	Week 6	Week 6	43.00	No	3.00	4.00	No		
					02/16/2001	67	Week 8	Week 8	46.00	No	3.00	4.00	No	65.00	29.00

& = Patient not included in the ITT Population.
Note: CDRS-R responder is defined by CDRS-R total score <= 28. CGI-I repsponder is defined buy a CGI-I rating of 1 or 2
Study day = Date of assessment - Start date of double-blind medication + 1.
DERIVED Visit Name: Derived week number using time windows.
CRF visit week 8 = visit of week 8 or early termination.
Report generated by program: /sasprog/cit/citmd18/programs/listings/leff1.sas.